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 Abstract  
 
In current times, the aquaculture industry has been faced with the dramatic on-set of 
various viral diseases specifically infectious pancreatic necrosis virus (IPNV) in 
Atlantic salmon (Salmo salar). In order for the industry to persevere through and 
successfully meet a consistently growing demand, substantial measures need to be 
taken. The process of vaccination is known to reduce incidence of disease in addition 
to reducing intensity of infection as well. Even though vaccination has gradually 
become an essential part of disease control, there are still some challenges that need 
to be faced head on. Maintenance of antigen viability, incorporation of antigen in an 
appropriate delivery system and process of antigen delivery require further 
understanding as limited research has been reported on the development of oral 
delivery systems as far as vaccination in aquaculture is concerned.   
This thesis explored three fundamental elements of oral drug delivery development; 
optimisation of microbead fabrication techniques, characterisation of microbeads 
through their unique mechanical and dissolution properties and finally the analysis of 
immune response following consumption of orally delivered antigen.  
The first objective of this thesis was to demonstrate the potential of electrospraying 
(ES) and aerodynamically assisted jetting (AAJ) as fabrication methodologies for 
advanced orally deliverable systems. Micron-ranged delivery systems have previously 
been utilized for the long-term delivery of active biological compounds. However 
conventional methodologies pose significant challenges, particularly poor sample 
repeatability, lack of homogeneity and poor control, among other drawbacks. This 
thesis reports ES and AAJ as possessing the ability to produce highly monodisperse, 
porous and reproducible polymeric microbeads at low cost. Operational maps obtained 
through an extensive sizing study established that ES possessed the ability to produce 
microbeads ranging from 250 – 2500 µm while AAJ produced beads ranging from 25 
– 60 µm. The sizes of microbeads were seen to be primarily controlled through the 
fine tuning of process and solution parameters.  
Since these polymeric microbeads offer protection of the active pharmaceutical 
ingredients (API), their own stability is crucial in order to achieve optimal 
performance. Effects of polymer concentration, type of cross-linking agent and 
fabrication methodologies on the mechanical stability of microbeads were studied. 
Polymeric microbeads also offer the imperative feature of safeguarding an API 
through proteolytic enzymes and harsh pH encountered in the digestive tract of fish. 
This prospect was studied by looking into the release characteristics of microbeads, 
using a model API and fabricated microbeads using various types of alginate. 
Microbead release kinetics were addressed through a custom tailored in vitro 
dissolution test representative of the environmental conditions faced by A. salmon.   
To achieve the final objective of this thesis, A. salmon was exposed to a dose of viral 
antigen by using orally administered microbeads with encapsulated antigen. ELISA 
analysis indicated that at least some exposed fish had higher level of IgM antibodies 
targeting the specific IPNV antigen used for immunization. These results were also 
complemented by qPCR profiling in the head kidney, also including those encoding 
important immune transcription factors. Both treatments, with and without viral 
antigen showed an effect on a number of genes in head kidney. The most distinct 
expression profiles in the group of fish exposed to the viral antigen were seen at day 
21 post exposure while at day 57 gene expression in both groups looked more similar. 
STAT6, IL17A, Tbet and TCRy were found to be regulated at time points selected in 
this study. 
The work presented in this thesis involves several stages in the process of development 
and optimization of the oral vaccine delivery system for an IPNV antigen in A. salmon. 
The system allows easy incorporation in fish feeds, however, it is not clear if the 
observed activation of the immune response will end up being protective against the 
disease. The hope is that the activation of the immune response by the studied antigen 
delivery system can be further optimized and tested in a challenge trial with live IPNV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Impact Statement 
 
Presently, aquaculture contributes towards 50% of the global seafood supply. Current 
reports suggest a substantially consistent increase in aquaculture demand. In order to 
meet this proposed demand, aquaculture production will have to almost double in the 
next ten years. The critical impediment standing in the way of achieving this goal is 
the startling ten-fold increase in the onset of viral diseases in fish farming operations. 
Disease prevention in aquaculture is usually handled through vaccination. Although 
vaccination through injection is highly effective, it is an arduous task especially during 
some of the later lifecycle stages, also being both time consuming and labour intensive. 
Oral delivery systems for vaccination have not been thoroughly explored yet as far as 
aquaculture is concerned.  
This research puts forward two novel fabrication methodologies for the generation of 
oral drug delivery mechanisms; Electrospraying and Aerodynamically assisted jetting. 
The fabricated delivery mechanisms take the form of polymeric beads. The polymer 
acts as a superficial layer that surrounds a vaccine candidate protecting it from 
degradation. These methodologies have been rendered successful in producing 
perfectly spherical and monodispersed beads, capable of offering protection to 
sensitive biological compounds while the choice of polymer used can also offer 
biodegradability hence reducing any possible side-effects following consumption. 
Their micro/nano size range allows for them to be vacuum packed into fish feed 
pellets, so while farmed fish is being routinely fed it can also be vaccinated 
simultaneously.  
 
These systems in combination with appropriate vaccine candidates present an 
immensely exciting prospect as far as curbing the rate of viral diseases is concerned. 
A decrease in disease onset is exceptionally advantageous for the aquaculture industry 
as it not only contributes to the improvement of the industry’s economic sustainability 
but also enhances end product quality. Furthermore, these novel fabrication techniques 
possess the ability to generate delivery systems that can be of use across a wide range 
of disciplines such as materials science, the food industry, regenerative medicine as 
well as tissue engineering.    
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nintr intrinsic viscosity 
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1. Introduction  
 
1.1 Background and motivation 
Being one of the fastest growing food production industries in the world, aquaculture 
plays a vital role in many countries by contributing to an increased income, improved 
nutrition and employment opportunities (Kannadhason et al., 2011). Aquaculture now 
provides approximately 50% of the global seafood supply. A recent newsletter 
published in 2015 by FAO (Food and agriculture association of the United Nations) 
suggests that aquaculture production should double by 2030 to meet the world’s 
growing demands. Along with this development, however, there has also been a 
dramatic ten-fold increase in the incidence of viral diseases affecting in particular 
salmon farming operations (Norwegian Veterinary Institute., 2012). Diseases such as 
Infectious Pancreatic Necrosis (IPN) (Chen et al., 2014), Pancreas disease (PD) 
(Aunsmo et al., 2010) and Salmon Rickettsial Septicemia (SRS) (Cusack et al., 2002) 
are the most contagious diseases affecting salmon hence costing the fish farming 
industry millions annually. These diseases have a vast range of significant impacts 
namely; increased mortality, reduced final weight, increased transmission in wild 
stocks and finally, lower product quality. 
Since disinfection is difficult to accomplish and pathogenic microorganisms can be 
transmitted through water more easily due to the increased number and density of fish 
in culture, disease prevention can become an issue when it comes to fish culture. 
Disease prevention established through stimulation of the immune system i.e. 
vaccination has now become a significant part of the development of the aquaculture 
industry (Gudding and Muiswinkel, 2013). Currently, the most common preventative 
method in use for vaccination is through injection. Although, it is both time consuming 
and labour intensive, vaccination by injection remains highly effective. However, the 
efficacy of these vaccines tends to decline after a year in sea water. This is only made 
worse by the fact that re-vaccinating fish by injection is not an easy task (Ruma, 2006). 
When salmon is in freshwater, its handling is easier, therefore, vaccination through 
injection takes place during this phase. However, when salmon is moved to seawater 
it becomes almost impossible to inject due to the great increase in salmon size as well 
as density present in each sea cage. A viable option for immunisation then is to 
incorporate a viral antigen into industrially available fish feed, so that A. salmon 
population develops protective immunity against IPN through diet.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2 Thesis objective 
Over the years, research has delved into the development of oral vaccination in 
aquaculture but some hindering factors still remain, namely, encapsulation and 
protection of vaccine in the feed itself. Ultrasonic agitation and high speed mixing are 
perhaps the most common encapsulation methods being used currently. Even though 
these methodologies are able to produce a high yield of samples, these samples lack 
monodispersity. This stops the salmon population from receiving an equally 
distributed dose of vaccine. 
As a response to the industrial need for novel encapsulation techniques that offer 
protection to sensitive biological compounds, this research aims to look into the 
encapsulation of specific vaccine candidates into an FDA (Food and Drug 
Administration) approved polymer through Electrospraying (ES) and 
Aerodynamically assisted jetting (AAJ), to be orally delivered via fish feed. This will 
allow the feed itself to be consumed, leaving behind the polymer to degrade inside the 
salmon’s digestive tract without causing side-effects, while the vaccine itself passes 
intact into the blood stream, and further to immune organs where it initiates the 
development of adaptive immune responses. 
Since the size and dissolution rates of particles play a paramount role in tuning 
adaptive immunity (Rice-Ficht et al., 2010), the short term objective is to assess and 
optimise the encapsulation methodologies; ES and AAJ for their ability to generate 
oral drug delivery systems capable of being incorporated within fish feed pellets. This 
means that when delivering a vast range of vaccine antigen candidates, encapsulated 
vaccine needs to have the ability to withstand acidic and proteolytic degradation along 
with shear mechanical forces. This will be achieved by determining their optimal size 
distribution, morphology, dissolution characteristics and mechanical stability. The 
long term objective of this research project is the assessment of encapsulation 
efficiency of these drug delivery systems and antigen uptake. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3 Summary of contribution 
The recognition of electrospraying and aerodynamically assisted jetting as novel 
fabrication methodologies for the production of alginate beads that can act as 
successful oral drug delivery mechanisms in aquaculture, puts forward a highly 
attractive prospect. These orally deliverable systems combined with specific vaccine 
candidates will not only help curb the rate of viral diseases affecting aquaculture but 
also improve the economic sustainability of the salmon farming industry by helping 
reduce mortality rates while also increasing product quality. Subsequently, these drug 
delivery systems can also be of use across various disciplines such as regenerative 
medicine and materials science. 
 
 
 
 
 
 
 
 
 
 
 
1.4 Thesis Outline 
This thesis is composed of 7 chapters, where the first chapter highlights the current 
obstacles faced by the aquaculture industry – the need for vaccination through oral 
delivery, specifically in Atlantic Salmon. 
Chapter 2 consists of the literature review. It focuses on the significance of vaccination 
in aquaculture, the use of polymeric microbeads as drug delivery systems and drug 
encapsulation methodologies with an emphasis on electrospraying and 
aerodynamically assisted jetting. 
Chapter 3 proceeds with a description of the materials that were used during the 
experimental procedures of this work. The production and optimization techniques, 
dissolution and mechanical testing protocols along with the IPNV trial specifications 
are detailed here.  
The next three chapters contain the fundamental findings of this thesis. Chapter 4 looks 
into the fabrication, optimisation and characterisation of microbeads produced through 
electrospraying and aerodynamically assisted jetting. Factors such as the effect of 
governing process parameters as well as polymer characteristics were investigated. 
Furthermore, operational maps of microbead sizes were also produced and the 
mechanical properties of these microbeads were studied.   
Chapter 5 investigates dissolution characteristics, employing both visual observation 
techniques as well as in vitro tests. Through microscopic observation, the effect of 
polymer concentration, cross-linking agent as well as fabrication methodologies was 
reported. Following which the encapsulation efficiencies and release profiles of 
microbeads - fabricated using five leading alginate types in industry currently - were 
assessed. To further our understanding of these characteristics, their viscosities and 
molecular weights were also determined. 
Chapter 6 delved into the biological effects of the encapsulated IPNV antigen into 
microbeads produced using aerodynamically assisted jetting; qPCR profiling of 
immune genes’ expression was assessed at three time points, and was complemented 
with ELISA measurement in plasma of antibodies generated specifically against the 
used IPNV antigen. Measurement of biological responses at the molecular level can 
point out which specific treatments favour the most prominent immune response in 
the host, thus providing the basis for further refinement of the encapsulation technique.  
Chapter 7 offers an overview and summary of the primary objectives established 
through the duration of this research, along with suggestions for further work.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 1-1: Overview of the primary objectives established through the duration of this work, in sequential order
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 2. Literature review  
 
 
Overview 
In order to preserve sustainable aquaculture, disease prevention and control are 
critical. Even though fish are the most primitive organisms to possess an adaptive 
immune system, it remains undifferentiated and less complex as compared to 
mammals. A fundamental difference between immune system of fish and that of 
higher vertebrates is that fish are poikilothermic, which means they adapt their body 
temperature to that of their surroundings. This is why their immune response is directly 
dependent upon the temperature of their aquatic environment. Hence, when an 
infectious agent is introduced, the response of the immune system will depend on 
whether it has experienced that specific infectious agent previously or not. Depending 
on the type of infectious agent, aspects of both innate and adaptive immunity will play 
their role in countering it (Ruma Guidelines 2006). 
Vaccination is a method used for prevention of infectious diseases by increasing 
specific immunity (Ruma Guidelines 2006). Vaccines help produce immunity in the 
body, which provides protection against infection. It does so by introducing an antigen 
e.g. chemicals, viruses or bacteria to the body which then alerts the immune system to 
produce antibodies that have the ability to fight off that specific antigen. Antibody 
producing cells known as B lymphocytes will remain sensitised and ready to counter 
attack should the same agent enter the body again. However, before vaccines can be 
 successfully commercialised factors such as the production of effective and cheap 
antigens as well as adjuvants need to be taken care of, too. 
In 1942, Duff published the first report highlighting disease prevention through the 
use of vaccines by presenting results showing protection against Aeromonas 
salmonicida in trout through immunisation (Duff 1942). However, it was only until 
the seventies that vaccines became commercially available to use in the aquaculture 
industry. The first vaccine licensed in aquaculture was to prevent ‘yersiniosis’ in 
salmonid fish in 1976, USA (Gudding and Van Muiswinkel 2013). In the eighties, a 
disease first known as ‘Hitra disease’ (Egidius, Wiik et al. 1986) had a serious effect 
on salmonid aquaculture in Norway. Since then most of Atlantic salmon as well as 
rainbow trout have been successfully vaccinated in Norway, originally through 
immersion but currently via injection. 
The three most viable routes for the application of vaccines in aquaculture are; 
injection, immersion and oral. Application via the injection route is tedious and time 
consuming. Injecting vaccines may also induce stress-related effects such as 
immunosuppression, injection/handling related mortalities and reduction in feed 
uptake. Injection may also not be a practical choice for fish that are transported to 
open-sea cages for final grow-out, as they may require additional injections or booster 
vaccinations to sustain the heightened protective status all through the farming period. 
This can result in a significant loss of fish due to infection just before marketing, which 
can prove disastrous for fish farmers who have devoted significant time as well as 
resources (Caruffo, Maturana et al. 2016). However, the injection method remains 
highly suitable for fish of high unit value in order to counter the cost of this procedure. 
 The size of the fish also limits the use of this delivery method. For example, due to the 
small size of ‘fry’, its safe handling becomes an issue (Ruma Guidelines 2006). On 
the other hand, the volume of vaccine needed for injection is relatively lower and each 
fish is vaccinated with the accurate dose required. Professional vaccination teams or 
machines are normally used in industrial salmonid farming (Sommerset, Krossoy et 
al. 2005). However, most importantly antigen protection is commonly highest with 
injection-vaccination (Embregts and Forlenza 2016) .  
Immersion vaccination is a safe and easy method which is less stress inducing as 
compared to injection. The process starts with dipping fish in a hyperosmotic salt 
solution for a short time (in order to enhance the uptake of antigen) followed by 
immersion in antigen solution (Nakanishi and Ototake 1997). The main advantage of 
the immersion technique is that a large number of fish can be vaccinated at the same 
time. However, this method is limited to only small fish and is impractical for larger 
sized fish in tanks or sea cages. This technique is also labour intensive along with 
being costly as both tanks and specialised equipment is required.  
Due to the disadvantages associated with the immersion and injection techniques, a 
more practical approach was developed. Oral vaccination represents a massive 
advantage in aquaculture health management as it can be used for virtually any fish 
size. Not only is oral vaccination inexpensive and simple, it is also stress free. But in 
order to be deemed successful, oral vaccine delivery technology needs to address 
challenges such as shelf storage stability and prevention of leaching from feed upon 
contact with water (Caruffo, Maturana et al. 2016). 
Other factors such as the adhering and persisting on the gut mucosal tissues, 
overcoming degradation in low and harsh pH digestive environment as well as 
 adequately eliciting innate and systemic immune responses also prove challenging for 
this method. However, these issues can be taken care of through the adoption of a 
viable vaccine encapsulation approach. Once the vaccine is encapsulated, the capsule 
itself tends to degrade in the lower gut, which in turn maximises the amount of antigen 
which reaches the intestine where it is eventually absorbed into the blood stream 
(Dunn 1989). It should be noted however that this method of delivery would also only 
be feasible for fish that are fed an artificial diet. 
Over the years, several approaches to protect the antigen have been employed, such as 
entrapping in alginate beads (Maurice, Nussinovitch et al. 2004) or liposomes (Irie, 
Watarai et al. 2005), and neutralisation of gastric secretions or application of biofilm 
vaccines (Azad, Shankar et al. 2000). Currently, more than 40 million fish are orally 
vaccinated against ISA (Infectious salmon anemia) and SRS (Salmon rickettsial 
syndrome) annually, in Chile alone and due to the success of oral vaccination demand 
for more programmes is growing (Caruffo, Maturana et al. 2016). 
 
 
 
 
 
 
 
 
  
2.1 Polymeric particles as drug delivery mechanisms 
Drug delivery is a process where a pharmaceutical compound/drug is administered in 
order to achieve a therapeutic effect in humans or animals (Ward and Georgiou 2011). 
Though, achieving successful controlled drug delivery is not an easily accomplishable 
task. Environmental or enzymatic degradation, failure to cross the biological barrier 
and non-specific toxicity are just some of the crucial obstacles standing in the way of 
drug delivery success. 
In the paradigm of tissue engineering, polymers have extensively been used as 
biomaterials for the development of scaffolds within which biological compounds can 
be incorporated (Dhandayuthapani, Yoshida et al. 2011) and used as delivery 
mechanisms. The polymer helps give the scaffold an appropriate three-dimensional 
structure so as to provide ample mechanical stability during the process of drug 
delivery (Morch, Donati et al. 2006). Polymeric scaffolds have gained intensive 
attention due to the rare properties they possess; biodegradation, mechanical strength, 
high surface to volume ratio and high porosity with small pore size. Furthermore, 
naturally occurring polymers such as polysaccharides (collagen, gelatin, actin, 
alginate), proteins (cellulose, dextran, chitin) or polynucleotides (DNA, RNA) 
(Yannas 2004) tend to have even better interactions with cells as they enhance cell 
performance, as compared to synthetic polymers (Dhandayuthapani, Yoshida et al. 
2011). 
The most significant qualities hydrogels possess are low levels of toxicity and 
biocompatibility (Bhattarai, Gunn et al. 2010). The three-dimensional structure of 
 tissues and other macromolecular based components in the body can also be mirrored 
in the gel (Elisseeff 2008). Hydrogels are formed when the polymer chains are cross-
linked (either through covalent or non-covalent bonds), this means that hydrogels can 
simply be divided into two types; physical and chemical. Physical hydrogels are held 
together either by hydrophobic interactions, chain entanglements or electrostatic 
forces whereas chemical hydrogels will be connected through more permanent 
covalent bonds. Such a type of bond is characterised by shared pairs of electrons 
between atoms (Paleos 2012).  Even though hydrogels have a high water content and 
water absorbing affinity, they demonstrate swelling instead of dissolving once present 
in an aqueous environment. This is attributed to the critical crosslinks present in the 
structure of the hydrogel (Hamidi, Azadi et al. 2008).  
Considerable interest in hydrogels began after pioneering work was carried out on 
cross-linked HEMA (2-hydroxyethyl methacrylate) hydrogels in 1960 (Dreifus, 
Herben et al. 1960). Later, (Lim and Sun 1980) exhibited successful application of 
calcium alginate microcapsules for cell encapsulation. Since then, the use of polymeric 
hydrogel particles has gained rapid attention in the biomedical field particularly bio 
sensing, targeting and especially drug delivery. The interstitial spaces present in 
hydrogel structures provide a highly attractive prospect for the storage of a vast variety 
of biological compounds or drugs (Elisseeff 2008). Moreover, the high water content 
present in the hydrogel network provides a suitable environment for the diffusion of 
nutrients and oxygen as well as other empirical molecules that are critical for cell 
growth as well as proliferation (Canepa, Imperiale et al. 2017).  
(Zhang, Ermann et al. 2015) studied an inflammation targeting hydrogel for local drug 
delivery in inflammatory bowel disease. It was reported that the inflammation 
targeting hydrogel preferentially adhered to mucosa from inflamed lesions as 
 compared to histologically normal sites. Hence, concluding that hydrogels act as a 
promising approach for targeted enema-based therapies specifically for patients with 
colonic inflammatory bowel disease.  
PLGA (polylactic-co-glycolic acid) - PEG (polyethylene glycol) - PLGA copolymer 
hydrogels were assessed for sustained drug delivery in the ear (Feng, Ward et al. 
2014). These copolymer hydrogels did not show any toxicity and also provided 
sustained release, which could also be controlled by using further additives for inner 
ear applications. Alginate hydrogels were investigated for the repair of the peripheral 
and central nerve systems. It was reported that alginate hydrogels introduced into the 
spinal cord parenchyma did not give rise to major inflammatory responses while also 
directing axonal regrowth (Prang, Muller et al. 2006).  
 
2.1.1 Significance of particle size for delivery systems 
Nanoparticles are solid particles ranging from 1 to 1000 nm in size while 
microparticles range from 1 to 1000 µm (Kreuter 1996) in size. Researchers are in 
agreement that where vaccine delivery is concerned, it is the size of the particles 
containing the antigen that is crucial to their adjuvant activities (Oyewumi, Kumar et 
al. 2010). However, conflicting data has been presented over time regarding the ideal 
size range of particle-based adjuvants depending on their resultant immune responses.  
The success of carrier particles posing as drug delivery mechanisms by being taken up 
through target cells depends upon their size; particles ranging from 20 to 200 nm are 
taken up by endocytosis while those falling in the range of 500 nm to 5 microns are 
usually taken up through the process of phagocytosis (Coelho, Ferreira et al. 2010). 
 Since specific cells only have a certain size range for particles that they will tend to 
successfully take up the biggest advantage of polymeric particles is their ability to 
adapt in order to suit specific needs.  
 The popularity of particles being used as drug delivery mechanisms is simply due to 
two main advantages such carriers have to offer; adjustable drug release rates and drug 
protection (Nidhi, Rashid et al. 2016). Polymeric micro-particles act as reservoir 
systems since they are able to protect proteins from harsh environments thus boosting 
long term biological activity. They also allow for release rate control of the specific 
encapsulated drug anywhere from hours to months, while providing easy 
administration (Yang, Chung et al. 2000). These biodegradable particles are also of 
particular interest because of their high dissolution rates which in turn enhance drug 
bioavailability (Noyes and Whitney 1897, Horter and Dressman 2001). Therefore, 
possessing the ability to solubilise a concentrated drug while improving both drug 
stability and bioavailability. Coupled with the use of biodegradable and biocompatible 
polymers, they can help reduce the risk of toxicity and other such detrimental side 
effects. 
Over the years, several studies have shown that not only the shape (Barua, Yoo et al. 
2013), but also the size (Shang, Nienhaus et al. 2014) and surface functionalisation 
(Saha, Kim et al. 2013) of particles play critical roles where internalisation by cells is 
concerned. For example, Frohlich (2012) found out that nanoparticles with a cationic 
surface charge show higher cellular uptake and greater cytotoxicity in non-phagocytic 
cells whereas anionic nanoparticles showed more cytotoxicity towards phagocytic 
cells. This preference will indubitably affect the selectivity of these particles for drug 
delivery.  
 Even though smaller sized particles are more successful when it comes to permeating 
biological barriers, and hence are ideal as targeted delivery systems, but as far as 
vaccine delivery is concerned, microparticles are deemed more suitable. A primary 
reason being that the drug can be sustained for a longer time due to their decreased 
surface area therefore lowering the chance of abrupt drug release (Sinha, Bansal et al. 
2004). However, when it comes to vaccine delivery there is no clear answer as to what 
is the ideal particle size range which produces the strongest and most long-standing 
immune response (Xiang, Scholzen et al. 2006). Another significant factor to note here 
is that their size might dictate the type of immune response induced. Research has 
shown that microparticles promote humoral immune responses while nanoparticles 
give rise to cellular immune responses instead (Caputo, Brocca-Cofano et al. 2008). 
Yadav and Mote (2008) observed that Domperidone was released from starch 
microspheres in a sustained release manner. These microspheres were fabricated 
through emulsification and ranged from 22 – 103 microns in size and were used for 
the treatment of various kinds of emesis through intranasal administration. (Gawde 
and Agrawal 2012) prepared chitosan microspheres of Deflazacort for colon targeting, 
average bead size ranged from 1 – 1000 micron. (Savale 2016) presented the 
encapsulation of Aceclofenac (an anti-inflammatory drug used for the treatment of 
osteoarthiritis) in ethyl cellulose microbeads. Sustained release activity was noted.  
Perhaps it can be said that employing a mixture of particles covering specific size 
ranges favouring either a strong humoral or cellular response can help produce the 
most desirable of an immune response that is well-balanced (Oyewumi, Kumar et al. 
2010). 
 
 2.1.2 Vaccine entrapment/encapsulation in microbeads  
Due to the use of micro and nano particles as successful vaccine delivery tools they 
have garnered rapid attention commercially. Vaccination acts as an effective measure 
to not only treat but also prevent diseases. This is achieved through the activation of 
innate defences and the consequent development of the adaptive immune responses in 
order to combat intruding pathogens (Oyewumi, Kumar et al. 2010).   
Ideally, the immune system should be presented with antigens at the precise location 
and the appropriate time. However, some antigens tend to exhibit weak 
immunogenicity. The inclusion of an immune adjuvant helps overcome this by 
enhancing the immune response (Scheerlinck and Greenwood 2008). An immunologic 
adjuvant is a substance that acts to accelerate, prolong and intensify antigen-specific 
immune responses (Lowrie and Whalen 2000).  
The entrapment/encapsulation of an antigen inside the polymer works like so: once 
the mixture is subjected to a cross-linking agent, a gel-like polymeric matrix is 
produced. Following this, the antigen becomes entrapped inside the matrix. This gives 
rise to a particle that contains an antigen, which is now safely protected by an outer 
layer of cross-linked polymer matrix as seen in figure 2 - 1. The antigen itself 
covalently bonds to the polymer carrier. It is this covalent bonding that helps prevent 
rapid release of the entrapped antigen. Therefore, once the crosslinking takes place, 
the particle with antigen/adjuvant acts as one single macromolecule that allows for 
ease of purification. Increased levels of purity are essential to analyse the prime 
mechanism of action with regards to immunogenic activation (Rijcken and Holthuis., 
2016).   
 Previous research states that uptake of an antigen by antigen presenting cells (APCs) 
is preferred in particulate form rather than its soluble state. The particulate nature of 
the antigen delivery system can greatly affect activation of the immune response. Once 
the response has been induced, the specific type of immune response will then be 
dependent upon the chemical composition of the vaccine consumed (Storni, Kundig 
et al. 2005) 
 
 
 
 
 
 
 
 
 
Figure 2-1: Shows vaccine entrapped in a polymeric microbead and the same 
mirobead later being vaccum packed into the crevices present in feed pellets 
 
Not only do particles enhance immune response through stimulating antigen uptake, 
an antigen-loaded degradable particle will also act as a storage reservoir for the 
antigen. It will slowly help release the antigen in order to prolong antigen availability 
(Rice-Ficht, Arenas-Gamboa et al. 2010). Particulate vaccines also have the ability to 
cross-present antigens which is critical because cross-presentation contributes to the 
activation of CD8 T-cell responses against viral infections (Jain, Yap et al. 2005). 
Furthermore, cross-presentation is also required for the induction of cytotoxic 
immunity.    
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 2.1.3 Role of oral vaccines in aquaculture  
As previously mentioned, vaccination regimes are developed for various species 
consisting of a combination of injection, immersion and oral, in order to ensure 
protection throughout the entire production cycle (Embregts and Forlenza 2016).  
Olesen and Jorgensen 1986 reported that antibody responses in salmonids are not 
always correlated with protection. Subsequently, Bootland, Dobos, and Stevenson 
1990 reported that inactivated vaccines were in fact capable of reducing mortality but 
substantial evidence was still not put forward that suggested infection prevention. 
Much improvement has occurred in more recent times. De las Heras, Saint-Jean, and 
Perez-Prieto (2010) vaccinated rainbow trout and brown trout orally with 
microparticles containing DNA of VP2 protein of the infectious pancreatic necrosis 
virus (IPNV). The vaccine was reported to have induced innate immune responses by 
raising IFN expression more than ten-fold relative to fish vaccinated using an empty 
plasmid. It was reported that protection against IPNV was high with a 15% mortality 
rate for brown trout and 15 – 20% for rainbow trout. 
Mucosal membranes make up the core barrier between the internal tissues and 
invading pathogens. Since injury at these sites normally result in the onset of infection, 
induction of an immune response at mucosal sites becomes a logical strategy for 
allowing specific immunity against viral microorganisms (Tobar, Jerez et al. 2011). 
With respect to fish welfare, it is now certain that the mucosal route of vaccination 
particularly oral is an ideal mechanism for vaccine delivery (Embregts and Forlenza 
2016).   
 There are several reasons why the gut is the most attractive route for antigen delivery 
in fish. Not only is it a simpler way of administering antigens, the level of stress 
decreases considerably, a vast range of fish with different size ranges can be 
vaccinated with no associated side effects (Mutoloki, Munang'andu et al. 2015). 
However there are still very few oral vaccines registered for the purpose of treatment 
in the aquaculture industry. Out of the seventeen commercial vaccines available in 
2014, only 2 were oral preparations (Dhar, Manna et al. 2014).   
Oral vaccines that are currently commercially available for salmonid species include 
those against Infectious pancreatic virus (IPN), Piscirickettsia salmonis (P. salmonis) 
and infectious salmon anaemia virus (ISAV), for rainbow trout against IPN, Y. ruckeri, 
P. salmonis and for rainbow trout and sea bass against V. anguillarum (Embregts and 
Forlenza 2016). Leading regions where oral vaccination for fish is routinely practised 
are Norway, Chile and Scotland (Brudeseth, Wiulsrod et al. 2013).   
The oral route taken by the encapsulated polymer-vaccine matrix works like so; the 
polymer possesses the ability to protect the microbe/antigen or plasmid encoding 
antigen, while transporting it through the digestive tract. It then diffuses through the 
gut mucus layer and reaches the enterocyte surface. From there, the polymer 
(especially alginate) can be actively taken up by antigen-sampling cells and deliver 
the microbe/antigen or DNA plasmid. Enteric pathogens are likely to possess the 
innate ability to activate local mucosal responses whereas DNA plasmids encoding 
antigen of interest can enter the nucleus, triggering antigen expression in the host cell, 
comparable to what happens during a viral infection. The substantial success of DNA 
vaccines in fish can be attributed to the aforementioned latter mechanism (Lorenzen 
and LaPatra 2005).   
 The potential of nano and/or microparticles for oral antigen delivery has been explored 
in various species of fish, utilising a variety of polymers. Even though, oral delivery 
in fish is highly preferred, lack of efficacy has been its main limitation. However, there 
is research present, which presents positive levels of uptake in the end gut, an 
increased specific antibody production and enhanced protection through the use of 
carrier particles (Gudding and Van Muiswinkel 2013).   
In the world of aquaculture supporting evidence has been acquired for the use of 
polymeric micro-particles as oral drug delivery systems. Joosten, Tiemersma et al. 
(1997) were one of the first to assess the ability of antigen encapsulated micro-particles 
as oral vaccination for fish against Vibrio anguillarum. Their results indicated that 
antigen encapsulated alginate microparticles evoked systemic memory and induced 
mucosal immune responses in fish. 
Also, it was observed that vaccinated carriers of IPNV were less able to spread the 
disease as compared to unvaccinated carriers (de las Heras, Saint-Jean et al. 2010). In 
a catfish study, (Thinh, Kuo et al. 2009) concluded that repeated oral boosting offers 
an attractive method to maintain immunity. Other significant results for orally 
administered vaccines in various aquaculture species have been summarised in figure 
2 - 2.  
 
  
Author/Year 
 
Vaccine/Antigen/Adjuvant 
 
Encapsulation 
methodology 
 
Size 
 
Polymer 
 
Application 
(Joosten et al. 1997) Vibrio anguillarum bacterin  
using Artemia nauplii as the 
antigen carrier 
Bioencapsulation 1 – 20 μm Alginate Vaccination of juvenile carp 
and gilthead seabream 
(Maurice at al 2004) A-layer protein (At-R) and At-
MTS as antigen 
Mixing Microspheres 
(unspecified) 
Alginate Immunisation of goldfish 
(Ramos, Relucio, and 
Torres-Villanueva 
2005) 
 
Β-galactosidase DNA-vaccine Coacervation Nanospheres 
(unspecified) 
Chitosan DNA immunisation for 
transient gene expression in 
tilapia 
(Rajeshkumar et al. 
2009) 
DNA construct containing 
VP28 gene of WSSV 
Mixing Nanoparticles 
(unspecified) 
Chitosan Immunisation of  Penaeus 
monodon (black tiger shrimp) 
against WSSV (white spot 
syndrome virus) 
(de las Heras, Saint-
Jean, and Perez-
Prieto 2010) 
IPNV DNA-vaccine Emulsification Microspheres 
(unspecified) 
Alginate Vaccination of brown trout 
and rainbow trout 
(Ballesteros et al. 
2012) 
VP2 IPNV DNA-vaccination Emulsification Microspheres 
(unspecified) 
Alginate Vaccination of 
Oncorhynchus mykiss 
(rainbow trout) 
(Chen et al. 2014) Infectious pancreatic necrosis 
vaccine  
Electrospraying Microparticles 
(unspecified) 
Alginate Vaccination of Atlantic 
salmon  
 
Figure 2-2: Summary of previous research carried out where vaccines were orally administered in aquaculture 
 2.1.4 Vaccine types in aquaculture  
 As previously mentioned, fish are known to be the most primitive vertebrates that 
possess a developed immune system along with an adaptive immune response.  It is 
this adaptive immune response, which leads to the expansion of B-lymphocytes – a 
population of antibody producing cells.  B-lymphocytes produce antibodies, which are 
specialised proteins that have the ability to specifically bind to sites available on the 
antigen.  Since the immune response is a complicated process that not only stimulates 
immune functions, homeostasis maintains memory of the infection and is also 
responsible for restoring functions that were perhaps lost during infection. The 
thymus, spleen, blood tissue and anterior (head) kidney are the major lymphoid organs 
of the fish. The head-kidney in particular is exclusive to teleost fish, consisting of 
cytokine producing lymphoid and endocrine cells (Geven and Klaren 2017).   
Currently, in the aquaculture industry the most common virus vaccines are either based 
on inactivated viruses, recombinant subunit proteins or live attenuated vaccines. As 
far as inactivated vaccines are concerned, inactivating agents are normally used to 
connect pathogen proteins that combine with cellular receptors and block nucleic acid 
replication. However, a disadvantage of this type of vaccine is that toxic reactions may 
be caused by immune enhancing adjuvants and also a decreased level of 
immunogenicity due to denaturation of proteins and systemic reactions (USDA 2014). 
It is also important to note that inactivated viral vaccines are not quite efficacious 
unless delivered through injection. Cost-effectiveness also becomes an issue for 
inactivated viral vaccines as relatively high doses are required to achieve protection 
(Sommerset, Krossoy et al. 2005).   
 On the other hand, live viral vaccines are prepared from one or more viruses. The 
pathogens are attenuated with heat, serial passage in cell culture, culture under 
abnormal conditions or even genetic manipulation (Desmettre and Martinod 1997).  
Live viral vaccines have produced positive results in terms of efficacy and protection 
(Ronen, Perelberg et al. 2003). They also offer the advantage of good antigen 
presentation as the organism is growing in the host and delivery can be offered through 
various routes. The major drawbacks of this type of vaccine however are the safety 
issues that come with its usage. Hazards include virulence in immune-compromised 
vaccinates, residual virulence or reversion to virulence (USDA 2014).    
Where salmonid farming is concerned, commercial vaccines are available for the 
majority of common viral diseases. For example, IPNV caused by the birnavirus has 
both types of vaccines available (based on inactivated cell culture-propagated virus or 
recombinant structural proteins). Mainly, IPNV vaccines exist as polyvalent oil-
adjuvanted vaccines however. The IPNV antigen is mixed with one or more bacterins 
which appears to enhance the efficacy as compared to monovalent IPNV vaccines 
(Sommerset, Krossoy et al. 2005). 
 It should be noted that mucosal tolerance is driven by high local levels of anti-
inflammatory cytokine expression that help sustain the generation and maintenance of 
tolerogenic regulatory T cells and dendritic cells (Weiner, da Cunha et al. 2011). 
Hence, for the development of oral vaccination in veterinary species, potent mucosal 
adjuvants along with targeted delivery strategies are being used. (Neutra and 
Kozlowski 2006) found that the use of live attenuated vaccine administered along with 
strong adjuvants show immense capacity to facilitate the induction of mucosal 
responses. (Zhang, Sun et al. 2008) produced an attenuated vaccine against E.tarda – 
a marine and freshwater pathogen – and was shown to be efficacious as well as safe 
 in Japanese flounder through injection, immersion and also oral delivery. Marana et al 
(2017) set out to test the efficacy of experimental subunit vaccines against A. 
salmonicida infection in rainbow trout. A significant immune response was seen in 
fish that were immunised using the subunit vaccines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2.2 Atlantic Salmon (Salmo salar L.) 
Among all the commercially cultivated species, Atlantic salmon (Salmo salar) is the 
highest per fish and total value fish species that is cultivated at an industrial scale 
(Dhar, Manna, and Thomas Allnutt 2014). Commercial farming of Atlantic salmon 
began in Norway in the late 1960s. Production gradually spread over the next three 
decades towards north-western Europe as well as Chile, currently standing at over 2.3 
million tonnes of production worldwide as highlighted in figure 2-3 (FAO 2012). Due 
to advancement in diets, feeding, management and also genetic selection, there has 
been a continuous increase in their growth rate (Webster and Lim., 2002). According 
to the Norwegian Seafood Council the export value of salmon stood at an all-time high 
of NOK65.5b in 2016, cementing its position as one of the most significant species in 
the fish farming industry (Lokka., 2013).   
 
 
 
Figure 2-3: A. Production of salmonids (in tonnes) as reported by the FAO for the 
time period spanning 1950 – 2010 (FAO., 2012), B. A.Salmon production by country 
highlighting Norway and Chile to be the lead suppliers worldwide 2005 – 2017 
(GOAL., 2016) with production of almost 1.4 million and 0.6 million tonnes, 
respectively 
 Salmon farming requires both freshwater as well as seawater operations. It starts by 
the roe/fish eggs being fertilised in fresh water, they hatch approximately after 60 days. 
Soon after hatching the salmon fry develops a sac on its stomach, which it uses to feed 
itself. 4 - 6 weeks after hatching the salmon fry becomes ready to eat feed and is 
transferred to freshwater tanks. After remaining in the freshwater tanks for 10 – 16 
months, the salmon is moved to net pens in the sea to undergo smoltification which 
enables the salmon to live in saltwater. Smoltification is a series of physiological 
changes where juvenile salmonid fish adapt from living in fresh water to sea water.  
 
 
 
Figure 2-4: Highlights the salmon farming process in its entirety - from roe to market. 
Images acquired and modified from Aquaculture in Norway, 2011 
 
Norwegian seawater temperatures can range from below 4℃ in winter to above 18℃ 
during the summer (Aldrin et al. 2013). After being in net pens for 14 – 22 months, 
the fish reaches a mature state where it weighs at an average of 4 – 6 kg and is ready 
to be processed (Norwegian Seafood Federation FHL and the Norwegian Seafood 
Council NSC., 2011).  
 
 2.2.1 Ontogeny 
Till today there is only limited information present regarding Atlantic salmon 
gastrointestinal tract development. The functional development however of the 
digestive organs from hatch following the start of feeding has been known to follow 
the order; liver and pancreas followed by mouth and rectum then the oesophagus and 
intestine and finally the stomach and pyloric caeca (Sahlmann et al. 2015). Reports 
have suggested that digestive functions are detected as early as 7 dph (days post hatch). 
Moreover, Sahlmann’s (2015) research also indicates that A.Salmon fry digestive 
functions are ready for the digestion of external feed much before the yolk sac is even 
internalised into the abdominal cavity. The newly hatched fry however has a yolk sac 
present in the stomach, which produces necessary nutrients until the digestive tract is 
fully functional, and equipped to take in exogenous food.   
Atlantic salmon is indigenously carnivorous and is placed in the salmonid family in 
the teleost (ray-finned fish) division phylogenetically. It is to be noted that the teleost 
gastrointestinal system is different from that of mammals. The teleost tract displays a 
varying topography through the intestinal length, the number of pyloric caeca and the 
extent of looping (Kapoor, Smit, and Verighina 1975). Due to this, a general division 
of headgut, foregut, midgut and hindgut is used even if distinguishing between the 
precise borders of the regions is difficult (Harder 1975). The fore-gut consists of the 
mouth, oesophagus and stomach. The pyloric caeca and mid intestine are part of the 
mid-gut while the hind-gut consists of the distal intestine all the way to the rectum 
(Madsen et al. 2011).  
 
  
  
Figure 2-5: Shows before and after images of a dissected A.Salmon. The second image 
shows the gastrointestinal tract displaced from the body cavity of a hemorratic 
salmon. This condition is attributed to the stress caused due to the living conditions 
present in a tank. As this fish is not completely healthy, this image shows a larger than 
normal intestine, more mucus, increased number of red lines on both the intestine and 
the fins and also more defined capillaries with filaments as compared to a healthy 
sample. This dissected sample has an overall larger capillary network due to swelling 
and haemorrhage. Dissection of sample shown took place at EWOS, Chile 
 
According to histological studies, mucus cells are present throughout the full length 
of the stomach (Sahlmann et al. 2015). Food is transported from the stomach – where 
digestion begins - into the midgut through the pylorus. The effectiveness of digestive 
enzymes present in the stomach is mainly controlled by two main factors; pH and 
temperature. A.Salmon has an adequate complement of digestive enzymes – proteases, 
lipases and glucosidases out of which pepsinogen and trypsinogen are key. These 
enzymes are secreted in the pyloric caeca and small intestine, both areas where nutrient 
absorption takes place. Since the pancreas is a diffuse organ in Atlantic salmon, it is 
 responsible for the synthesis of precursors of the main digestive enzymes necessary 
for luminal digestion (FAO 2017).  
 
 
Figure 2-6: A closer look into the intestinal tract of Atlantic salmon divided into; 
pyloric caeca (PC), mid intestine (MI) and distal intestine (DI) as visible. Dissection 
of sample shown took place at EWOS, Chile 
  
The intestine is a straight linear tube and the longest portion of the digestive tract as 
shown in figure 2-5. The proximal intestine is equipped with the pyloric caeca, which 
are blind-ended finger-like projections (FAO 2017). The pyloric caeca increases the 
mucosal surface area which in turn increases the digestive capacity too. Majority of 
digestion as well as absorption of nutrients takes place in this region, which is why 
this region’s functional development can signify the level of development of the 
functional digestive system. Histological studies show that pancreatic tissue is present 
in the mesenterium adjacent to the pyloric caeca.  
Usually, the distinguishing factor between distal and proximal intestine is the presence 
of mucosal folds in the former region (Sahlmann et al. 2015). Both are however lined 
by a simple layer of epithelium. The nervous system is rendered responsible for the 
regulation of the digestive function, secretion of digestive enzymes and the absorption 
of nutrients. While the distal intestine is in charge of osmoregulation and also the site 
 where electrolyte secretion takes place (FAO 2017). It has been reported that both the 
posterior and anterior intestine is important for the uptake of IPN virus. Live as well 
as inactivated IPNV has been reported to have been taken up by enterocytes present 
in the intestine through receptor-mediated mechanism (Chen, 2015).  
The stomach of teleosts is presumed to be similar to mammals in that NaCl and H2CO3 
react to produce NaHCO3 and HCl. Along with acid and enzymes the stomach wall is 
also responsible for secreting mucus so as to keep the stomach from being digested. 
The midgut happens to be mildly alkaline as it contains not just enzymes but also bile. 
For teleosts such as rainbow trout research by (Bucking and Wood 2009) suggested 
that the average gastric pH of 2.7 increases to 4.9 as it goes from a state of being 
starved to fed. After the proteins are processed in the stomach, they are moved into 
the pyoloric caeca. It was reported that an average pH of 8.2 through the entire 
intestinal section before intake of feed, once the feeding state is over the pH decreases 
to around 7.5 in the proximal and mid intestine and remains unchanged in the distal 
section of the intestine.   
Even though the proteolytic environment in the foregut and midgut is harsh, there are 
still some proteins that make their way to the distal intestine for absorption. Peptides 
which happen to be large in size or even antigens for oral delivery of vaccines have 
been reported to be absorbed in the distal intestine region (Dalla Valle et al. 2008).   
 
2.2.2 Immune response following oral vaccination  
Studies looking into host response to virus infections suggest that teleost fish and 
mammals are similar where vital mechanisms of both innate and adaptive immune 
 responses against viruses are concerned (Workenhe et al. 2010). A.Salmon’s immune 
system possesses both non-specific (innate) immunity and acquired immune functions 
(adaptive/humoral and cell-mediated immunity) to tackle and eradicate invading 
pathogens. A satisfying response from an oral vaccine employed to aquatic species 
would be the successful induction of both humoral and mucosal antibody response.  
Their first line of defence against foreign agents is mucus and skin, which contain 
immune-reactive molecules such as Ig (immunoglobulin). The biochemical 
composition of mucus in salmonid species has been found to contain molecules which 
are involved in immune response such as lysozyme, proteases, alkaline phosphatase 
etc. Moreover, antimicrobial peptides present in fish mucus have also been shown to 
inhibit viral replication (Collet 2014).   
Non-specific humoral molecules in fish include transferrin, lectins and lytic enzymes 
while non-specific cells of the immune system include neutrophils, cytotoxic cells and 
macrophages. The activation of macrophages occurs through cytokines and beta-
glycan, both of which help destroy invading foreign agents. In many cases, the innate 
immune system of salmonids will help limit viral replication until an adaptive response 
can be reinforced.  
On the other hand, adaptive immunity in fish consists of both humoral and cell 
mediated responses. Adaptive immunity is associated with T and B cell activation 
which is followed by an immune response to specific pathogens (Hu and Pasare 2013). 
Immune responses characterised by cytokines, T-cell receptors, immunoglobulins and 
histocompatibility complex molecules (HSC) are displayed.  If administered correctly, 
oral vaccination induces the production of cytokines that help regulate and also 
enhance the cellular response (Ruma 2006).    
 Once the oral vaccine has survived the gastric environment, it will also have to put up 
against attacks by proteases or nucleases. After which they have to penetrate through 
the thick mucus to finally reach the epithelial barrier. The vaccine will then be in 
contact with the apical epithelium, where it will be taken up and delivered to the basal 
side. It will then be processed by the lamina propria, innate immune cells and 
specifically APC’s (antigen presenting cells) (Embergts and Forlenza., 2016).   
After the APC’s process the ingested antigens, their fragments are presented to T cells 
specially CD4+ T cells. These CD4+ T cells play a significant role in immune 
protection by helping B cells produce antibodies, induce macrophages, employ 
eosinophils, neutrophils and basophils at the infection site. Moreover, through the 
production of cytokines they are also able to coordinate a whole array of immune 
responses (Zhu and Paul., 2008) as shown in figure 2-6.   
Depending on the pattern of signals received by CD4+ T cells during their initial 
interaction with the antigen, they can differentiate into either of these populations; 
Th1, Th2, Th17 and also induced regulatory Treg cells. Th1 cells play a significant 
role for immunity towards intracellular microorganisms while Th2 cells for immunity 
to extracellular pathogens. It has been noted that the abnormal activation of Th1 cells 
led to autoimmune diseases whereas Th2 cells are held responsible for inflammatory 
diseases (Zhu and Paul., 2008). Th1 response induces the cell-mediated immune 
system while Th2 will induce humoral immunity (Collet., 2014).  
Other than the Th1 and Th2 response pathways, there is a third mechanism too – Th3 
– that occurs when Th1 and Th2 cytokines are balanced in order to prevent any 
inflammatory cell-mediated reactions, this mechanism is usually witnessed in the 
 mucosal tissue (Strober and Coffman 1997). Th3 cells happen to be an offset of Treg 
cells. The Th3 mechanism still remains unexplored for the most part.  
Another novel T cell effector subset are Th17 cells. The induction of the Th17 pathway 
promotes autoimmunity and is highly pro-inflammatory characterised by quick 
induction of neutrophils (Skugor et al. 2008). Th17 cells are known to mediate immune 
responses against extracellular bacteria (Weaver et al. 2006).   
 
 
 
 
Figure 2-6: Possible pathways taken by antigens following processing by APC’s 
followed by their target cells. Th1 cells produce the cellular immune response while 
Th2 cells produce the humoral immune response. Major effectors of cellular immunity 
are macrophages and cytotoxic T cells. Humoral immunity effector cells happen to be 
basophils, eosinophils and B cells. Th3 cells help balance the Th1 and Th2 response. 
Treg cells are induced by the immune system in order to self-limit its response. On the 
other hand, the induction of Th17 pathway leads to autoimmunity. 
  
Transcription factors happen to be quite significantly involved in cytokine production 
upon stimulation. It should be noted that Th0 cells are activated and matured into 
effector Th1 cells against virus, intracellular bacteria and protozoa. This 
differentiation into Th1 cells is activated by IL-12 and IFN- γ cytokines (Wang and 
Husain 2014). Research concludes that T-bet and STAT4 are the transcription factors 
that control this rate of transcription (Whitmire 2014). (Sun et al. 2011) also suggested 
that IFN possesses the ability to offer protection to cells from IPNV infection either 
directly or indirectly through the production of type II IFN. T-bet on the other hand 
works as the Th1 master regulator and is up-regulated during Th1 differentiation. 
STAT1 also acts as a primary transducer of IFN- γ signalling plays an important role 
in the IFNy induction of T-bet (Lighvani et al. 2001).   
There is also evidence to suggest the involvement of IFN in in vivo viral infections of 
fish. (Herath et al. 2012) found that Atlantic salmon infected by salmonid alphavirus 
had a potent IFN response in the head kidney as early as three days post infection. 
Moreover, IFN and IFN related genes are induced in the liver and head kidney of 
A.Salmon following ISAV infection (LeBlanc et al. 2012).   
Parasitic infections are known to drive Th2 immune responses which happen to be 
characterised by production of IL-4 and IL-13, which in turn are capable of mediating 
elimination of multicellular parasites (Skugor et al. 2008). 
Where the humoral response is concerned, T cells develop into effector T cells against 
pathogenic extracellular microorganisms. While the transcription is controlled by 
STAT6 and GATA-3 transcription factors, the development itself is activated by 
Interleukin (IL)-4 and IL-10.  IL-17 is a pro-inflammatory cytokine that not only 
contributes to the pathology of various autoimmune conditions but also plays a 
 significant role in the clearance of extracellular bacteria. IL-17 is produced by T helper 
cells called Th17 (Moisan et al. 2007) thus far six IL-17 family ligands (IL-17A-F) 
and five receptors (IL-17RA-IL-17RD and SEF) have been identified (Shen and 
Gaffen 2008). Amongst these, CD4+ T helper cells have been shown to primarily 
secrete IL-17A.   
Once an infection is eliminated, induction is suppressed and proliferation of effector 
T cells takes place. This takes place due to Treg cells and happens to be a significant 
feature of the immune system. (Li and Flavell 2008) state that TGF-β and IL-6 
cytokines help trigger the production of Treg cells which are responsible for limiting 
inflammatory responses while also preventing autoimmunity as described in further 
detail in section 2.2.3.  
The rate of transcription is dealt by FoxP3 and STAT5 (Chen et al. 2003; Hori, 
Nomura, and Sakaguchi 2003). GATA-3 is known as the master regulator of Th2 and 
helps counteract proinflammatory responses (Takizawa et al. 2011). FoxP3 happens 
to be a T cell-specific transcription factor that plays a vital role in Treg cell 
development. Continous FoxP3 expression is needed to maintain the suppressive 
activity of Treg cells (Williams and Rudensky 2007). FoxP3 is highly expressed in the 
thymus however regulated expression can be seen in the head kidney, liver and spleen 
also (Zhang et al. 2011). 
Th3 cells are a subset of Treg cells, even though Th3 cells are considered to be non-
specific, their response is linked with microbial antigens (Weiner et al. 2011). With 
the influence of IL-10 and TGF- β, Treg cells can differentiate from Th0 cells therefore 
it can be concluded that these two cytokines are essentially apt markers for Th3 
 response (Sonmez et al. 2004). Previous research (Castro-Sanchez and Martin-Villa 
2013) has also proposed that orally ingested antigens can commence the Th3 response.    
B cells are one of the major effector cells of humoral immunity that are altered into 
antibodies or immunoglobulins (Ig). The three main Ig isotypes found in salmonids 
are: IgM, IgD and IgT which are determined by the heavy chain of the molecule µ, δ 
and τ respectively. Research carried out in 2011 (Tadiso, Lie, and Hordvik 2011) 
found out that in A.Salmon, the quantity of µ transcripts was 200 times that of δ while 
τ transcripts were 20 times more than δ. IgM is the major systemic antibody in teleost 
fish specially salmonids, whereas IgT and IgD are specialised to mucosal immune 
responses (Hordvik 2015).  
 
2.2.3 Immune tolerance 
Immunological tolerance is the non-reactivity of a body towards something that would 
normally be expected to elicit an immunological response. Even though immune 
suppression is a very significant factor that impacts oral vaccine efficiency, very few 
studies have looked into this phenomenon especially in aquaculture.  
Research carried out by (Abad et al. 1987) reported that immune tolerance was seen 
to decrease specific antibody production against antigens in A.Salmon. In mammals, 
T cells control the differentiation and function of Tregs and are associated with 
immune tolerance. FOXP3 was also characterised in A.Salmon and its highest level 
of expression was observed in the thymus (Zhang et al. 2011). Furthermore, (Aas et 
al. 2017) found that the inter-branchial lymphoid tissue (ILT) present in A.Salmon, 
plays a significant role in immune tolerance as high levels of the transcription factor 
 FOXP3 were seen along with regulatory T cells (Tregs). It was also shown that 
mechanisms of central tolerance as found in mammals are also present in the thymus 
of A.Salmon. Therefore, identification of transcripts such as FOXP3, which is a 
marker for Tregs proves their involvement in maintaining tolerance in the ILT.    
2.2.4 Current prevalent diseases   
Infectious diseases pose a constant risk to industrial farming where a high density of 
farms and organisms within each farm are present (Aldrin et al. 2013). The substantial 
increase in aquaculture operations over the years has opened a new window for the 
transmission of aquatic viruses (Crane and Hyatt 2011). Due to the innate resistance 
present in wild populations of fish, periodic outbreaks of viral diseases have resulted 
in catastrophic losses hence threatening the long-term sustainability of the aquaculture 
industry (Dhar, Manna, and Thomas Allnutt 2014).  
Some of the significant viral pathogens of finfish have been known since early 20th 
century – aquabirnaviruses and infectious hematopoietic necrosis virus – while some 
have been discovered more recently – betanodaviruses. Aquabirnavirus is perhaps the 
largest and most distinct of the three genera that make up the Birnaviridae family. 
Examples of members belonging to the Aquabirnavirus family include the infectious 
pancreatic necrosis virus and yellowtail ascites virus. Aquabirnavirus particles are 
non-enveloped icosahedrons that contain a genome consisting of two segments: A and 
B, of dsRNA.  
Segment A encodes a polyprotein that is separated post-translationally in order to form 
three viral proteins; VP2, VP3 and VP4. While segment B on the other hand encodes 
VP1 which is an RNA-dependent RNA polymerase (Crane and Hyatt 2011). 
 Betanodavirus on the other hand is one of the two genera making up the Nodaviridae 
family. Viral nervous necrosis is one of the biggest diseases caused by this etiological 
agent. This virus infects a vast range of host species, approximately 40 marine species 
and freshwater fish worldwide (Munday, Kwang, and Moody 2002).   
The main causative agents of infectious diseases in aquaculture include bacteria – 
54.9%, viruses – 22.6%, parasites – 19.4% and fungi – 3.1% (Taksdal et al. 2007). 
Even though bacterial diseases tend to be more prevalent in fish farming, it is the viral 
diseases that are more difficult to control mainly due to challenges in development of 
effective viral vaccines, natural resistance in wild populations of fish, lack of anti-viral 
therapeutics and a high susceptibility of fish during early stages of their life cycle 
(Dhar, Manna, and Thomas Allnutt 2014).  
A few of the main viral diseases impacting Atlantic salmon are listed in figure 2-7. 
 
 
 
 
 
 
 
 
 
 
 Name of viral disease Causal agent Prevalence 
Heart and skeletal muscle 
inflammation (HSMI) 
Piscine reovirus 
(suspected) 
Norway, Scotland 
Cadiomyopathy syndrome 
(CMS) 
Piscine myocarditis 
virus 
Norway, Scotland 
Infectious salmon anaemia (ISA) Infectious salmon  
anaemia virus  
Norway, Scotland, 
Canada, UK, USA, 
Chile 
 
Pancreatic disease (PD) 
 
Salmon alphavirus  Europe  
Infectious pancreatic necrosis 
(IPN) 
Infectious 
pancreatic  
necrosis virus 
Europe, USA, 
Canada, India, 
Japan  
 
Figure 2-7: Viral diseases prevalent in the Atlantic salmon population, their causal 
agents and their regions of prevalence (Dhar, Manna, and Thomas Allnutt 2014) 
 
ISA was first detected in Chile in 1999 (Munir and Kibenge 2004). The estimated loss 
of salmon due to ISA from 2007 to 2011 was approximately US $1.0 billion. One of 
the major reasons contributing to such a devastating outbreak was the failure to 
vaccinate fish against ISA (Dhar, Manna, and Thomas Allnutt 2014). HSMI was also 
initially diagnosed in 1999, and there has been an annual increase in the number of 
outbreaks recorded. Affected fish exhibit anaemia and abnormal swimming behaviour. 
Atlantic salmon are commonly affected around 5 to 9 months after transfer to sea, even 
though mortality is variable, morbidity has been recorded to be very high (Kongtorp 
et al. 2004).  
On the other hand, CMS is a recently identified disease and its aetiology currently 
remains uncertain. It primarily affects adult salmon after sea transfer. Fish suffering 
 from CMS may unexpectedly die without any clinical signs of disease and is usually 
diagnosed through histopathology, with severe inflammation and degeneration of the 
spongy part of the myocardium and similar changes in the atrium (Haugland et al. 
2011). PD is caused by the highly contagious salmonid alphavirus, it is a disease that 
causes excessive damage to the exocrine pancreatic tissue combined with chronic 
myositis. The levels of PD associated mortalities during natural outbreaks have ranged 
from negligible up to 63% (Taksdal et al. 2007). On the other hand, IPN can cause up 
to 100% mortality in young salmonids if in its acute form, and it is highly likely that 
viral, environmental and host factor will only add to the severity of the outbreak 
(Snieszko 1975).   
 
2.2.5 Infectious pancreatic necrosis virus (IPNV) 
IPNV is a highly contagious disease that causes high mortality in juvenile salmonids. 
During the 1940’s in North America this disease was first reported as catarrhal enteritis 
mainly affecting fingerlings (McGonigle 1941). However, it was not until 1960 that 
the virus was first isolated and characterised (Wolf et al. 1960). Currently, the virus 
has a worldwide distribution and has been isolated from more than 32 fish species, 4 
crustacean species and 11 molluscs (DFO 2017). IPNV is a prototype member of the 
Aquabirnavirus in the Birnavridae family. It is an un-enveloped bi-segmented double 
stranded RNA virus.  
As seen in figure 2-8, the two segments: A and B, contain ORFs (open reading frames). 
Segment A consists of two ORFs – the translatable part of DNA/RNA sequence. ORF1 
encodes a VP5 protein, which has an anti-apoptopic effect while ORF2 consists of a 
 polyprotein which cleaves to produce three gene products: VP1, VP2 and VP3. VP2 
is the major capsid protein, which is assumed to be a critical carrier of the virulence 
properties of IPN virus (Song et al. 2005). VP2 also plays a critical role where virus 
entry is concerned as it is responsible for receptor recognition  (Bruslind and Reno 
2000). VP3 is a minor structural protein with specific neutralising epitopes and 
VP4/NS is a non-structural protein with protease activity. On the other hand, segment 
B consists of one ORF which encodes VP1 – RNA dependent RNA polymerase which 
is involved in viral RNA synthesis (Dobos., 1995).  
 
 
 
 
Figure 2-8: A schematic representation of the IPNV virion and the segmented linear 
dsRA genome. The capsid itself is around 70 nm in diameter, consisting of 260 trimers 
of VP2 that are situated radially along the capsid. Image acquired and modified from 
Taghavian et al, 2013 
 
The virus can replicate in various types of continuous cell lines from teleost fishes at 
temperatures below 24°C. This virus has the ability to replicate in the cytoplasm. It 
 takes approximately 16 – 20 hours at 22°C for a single cycle of replication to take 
place, resulting in a characteristic cytopathic effect (CPE) (Dobos 1995).    
The disease can be horizontally transmitted directly from fish to fish or vertically from 
the broodstock (Ruma., 2006). Infections mainly occur during the freshwater or fry 
first-feeding stages. However, with the expansion of aquaculture over time, IPNV 
outbreaks are now commonly witnessed in postmolts, too. Infected fish that overcome 
IPN remain asymptomatic carriers, these carrier fish are perhaps the key mechanism 
through which the virus is maintained and replicated in hematopoietic tissues 
(Holopainen et al. 2017).   
IPNV remains one of the most economically critical viral pathogens of Atlantic 
salmon. In 2015, this viral agent was responsible for 30% of disease diagnoses 
reported by Chilean salmon farming centres (Manriquez et al. 2017).  
A deeper understanding of the interferons (IFNs) and their path of action against 
viruses is imperative in order to develop new strategies to control this virus (Larsen et 
al. 2004).  
 
 
 
 
 
 
 
 
 
 
 
 2.3 Drug encapsulation methodologies 
Various techniques have been identified for the production of polymeric nano and 
micro-particles over time. The most popular ones are based around the emulsion 
technique. In this process, specific therapeutic molecules are dissolved into a polymer 
solution and then emulsified to form micro-droplets that are then dried in order to 
remove the solvent. However, it is important to note that the use of solvents can cause 
denaturation of protein-based drugs hence giving rise to variability in encapsulation 
efficiencies and also loading capacities (Yang et al. 2000). The use of high shearing 
forces in this methodology can also contribute to the degradation of a sensitive antigen 
(Baras et al. 2000). Another major drawback of the emulsion technique is its 
production of inhomogeneous particles, which leads to their lack of reproducibility 
thus limiting their clinical use as monodispersity in terms of size of a sample is a 
critical factor as it gives better control of drug release profiles and bioavailability of 
the loaded drug (Valo et al. 2009).  
Spray drying is another commonly used encapsulation method. It involves the 
atomization of liquid feed in order to form solid particles. However, this method uses 
high temperatures and therefore cannot be used for temperature sensitive compounds 
and mono-dispersity is again an issue (Murillo et al. 2002). Also, other physical 
stresses such as organic solvents, emulsion conditions and aqueous/organic interface 
can produce structural changes to the protein which can then contribute to loss of 
enzymatic activity (Baras et al. 2000). Similarly, for spray congealing, the drug being 
encapsulated needs to be stable at the temperature required to melt the matrix material. 
This method is also not favourable for viscous molten mixtures since it may cause 
clogging in the feed tube or atomiser (Oh et al. 2014). 
 Microfluidic techniques have also been used to fabricate microbeads. Such techniques 
offer simplicity and make use of robust devices however most reported microfluidic 
approaches involve emulsification hence possessing the disadvantages that come 
along with batch-wise emulsification techniques. Microfluidic devices have also 
reported to show low productivity unless a multichannel system is used (Kendall et al. 
2012).  
The development of various jetting processes has rapidly taken place over the last few 
years with electrospraying and aerodynamically assisted jetting leading as the main 
approaches that demonstrate versatile abilities in terms of fabricating an array of 
particle sizes using a range of materials – from nano and micro suspensions to 
biologically active cellular suspensions (Jayasinghe and Suter 2006). The flexibility, 
consistency and proficiency of producing micro or nanostructures with tailored shape, 
morphology and size make both these methodologies extremely promising especially 
in the pharmaceutical and biomedical fields. Both methodologies boost bioavailability 
of aqueous soluble drugs, offer control over drug release systems in order to deliver 
protein based drugs and also living cells along with producing targeted drug delivery 
systems. However, it should be noted that the multiple number of processing as well 
as formulation factors put forward some complexities (Nguyen, Clasen, and Van den 
Mooter 2016). These will need to be comprehended thoroughly for the success of 
encapsulated drug delivery systems.  
   
 2.3.1 Electrospraying (ES) 
Electrospraying has emerged as a technology that overcomes the limitations related to 
most micro-particle fabrication techniques specifically the emulsion method. In 1600, 
William Gilbert noted that when a droplet of water and a piece of amber were held 
closely to each other, the interaction between them formed a conical shaped droplet. 
In the early 20th century Zeleny (1914) exhibited the formation of fine droplets from 
a conical shaped meniscus under an electric stress. Interest in the electrospraying 
process was increased by the Nobel Prize winning work of (Fenn 2002) on mass 
spectroscopy for the detection of macromolecules. 
 
 
 
 
 
 
 
 
Figure 2-9: Schematic image showing the electrospraying set-up. A high voltage 
supply is connected to a ground electrode. A syringe loaded with the liquid polymer 
solution is fixed onto a programmable syringe pump (PHD 4400, HARVARD 
Apparatus Ltd., Edenbridge, UK), which is connected to a needle through silicon 
tubing. The polymer solution flows through the syringe towards the charged needle, 
which acts as an outlet for the solution, exposing it to electric stress once pushed out 
of the needle tip. The jet breaks down into droplets, which due to simple gravitational 
pull compile onto the collector plate placed directly under the needle. A magnetic 
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 stirrer is present underneath the collector plate so as to avoid cross-linking solution 
from remaining stagnant, which in turn helps against aggregation of droplets  
 
During the ES process, the liquid solution is pushed through a conducting needle as 
seen in figure 2-9. Once the liquid is pushed out of the charged needle it is exposed to 
an external electric field. The shear stress on the liquid surface due to the established 
electric field causes elongation of the jet. This jet then undergoes instabilities, which 
help disrupt the jet into charged droplets. 
The jet break-up can be caused by axisymmetric or lateral instabilities. Axisymmetric 
instabilities are known as ‘varicose’. With higher applied flow rates, the current 
flowing through the liquid will increase and with this the surface charge on the liquid 
will increase too. Lateral instabilities on the other hand are known as ‘kink’. With the 
increasing influence of these kink instabilities, the size distribution of the main 
droplets becomes wider (Hartman et al. 2000). 
There is however a limit present for the maximum charge allowed on the surface of a 
liquid, which is known as the Rayleigh limit. The Rayleigh limit being the magnitude 
of charge on a droplet which overcomes the surface tension of the droplet (Jaworek 
2007). In simple terms, there are two forces acting in opposite directions in the charged 
droplet; surface tension of the charged droplet which tries to maintain the droplet’s 
spherical shape and coulomb force of repulsion between the like charges on the surface 
due to which the droplet’s spherical shape may or may not be broken down.  
At the point where the surface tension can no longer retain the Coulomb force of 
repulsion, Coulomb fission will occur. Due to which the main/parent droplet will 
disintegrate into secondary/offspring droplets. Not only are the secondary droplets 
much smaller in size but also have a much higher charge to mass ratio (Banerjee and 
 Mazumdar 2012). Wang et al. (2012) concluded that Coulombic repulsion between 
induced charges is responsible for jet break-up. While, surface tension remains 
responsible for jet length. (Hartman et al. 2000) stated that charge in the liquid cone 
can be transported in two ways; through conduction in the liquid due to the electric 
fields or by charge convection. 
ES is governed by processing conditions such as flow rate, needle diameter, distance 
between the needle tip and ground electrode and the voltage applied (Enayati et al. 
2011) and also the properties of liquid solution itself such as its’ conductivity, density, 
viscosity, surface tension and relative permittivity. A balance between all these factors 
promotes jet stability. An increased stability of jet gives rise to the production of a 
more homogenous sample of droplets (Irvine et al. 2007). 
Once the liquid solution is accelerated at a specific flow rate, various morphologies 
can be observed exiting the needle. These are referred to as modes of jetting which are 
divided into two groups; the first comprising of modes where only fragments of liquid 
are ejected from the capillary i.e. dripping, spindle etc. The second group includes 
modes where a capillary in the form of a long and continuous jet is produced which 
eventually breaks off into droplets e.g. oscillating jet, multi-jet mode, cone-jet 
(Jaworek and Krupa 1999). 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 2-10: Illustrating liquid solution electrosprayed in the stable cone-jet mode 
 
Due to its steady operation, the cone-jet mode, as illustrated in figure 2-10, has become 
the most researched mode of operation (Yurteri, Hartman, and Marijnissen 2010). 
Also known as the Taylor cone - as it was discovered by Sir Geoffrey Taylor in 1964 
before the existence of electrospraying due to his interest in the behaviour of water in 
the presence of strong electric fields - this mode implies the formation of an almost 
conical shape of liquid at the meniscus, which is present at the needle tip.  
The cone jet mode can go through three different processes; the first process is the 
acceleration of the liquid in the liquid cone, this acceleration and consequently the 
shape of the liquid cone are a result of the force balance of surface tension, gravity, 
inertia, electric stresses in the liquid surface and viscous stresses. The second process 
of electrospraying atomization in the cone-jet mode is the break-up of the jet into 
droplets. The third process is the development of the spray once droplets have been 
produced. Electrical interaction between highly charged droplets with various sizes 
(and therefore different inertia) causes a size segregation effect. Small droplets will be 
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 found at the edge of the spray while the larger sizes will be found in the spray centre 
(Hartman et al. 1999).  
It is significant to know that the shape of the liquid cone is a result of the balance of 
liquid pressure, liquid surface tension, electric stresses in the liquid surface, gravity, 
the liquid viscosity and inertia. On the other hand, the size distribution however is 
dependent upon the diameter of the jet and on the break-up of this jet into droplets 
(Hartman et al. 1999).  
 
2.3.2 Aerodynamically assisted jetting (AAJ) 
AAJ on the other hand is a pressure driven technology based on pneumatic atomisation 
technology. The laminar accelerating gas stream helps shape the steady liquid filament 
that then ultimately breaks up into a spray. It is capable of handling concentrated nano-
suspensions for drop and placement of nanomaterials within droplet residues. Over 
time, various suspensions containing a vast array of nanomaterials – silicone, SiO2, 
fullerenes, quantum dots, etc – have been processed using this approach (Jayasinghe 
and Suter 2006). (Irvine et al. 2007) demonstrated the ability of AAJ to handle living 
primary organisms, namely; porcine vascular and rabbit aorta smooth muscle cells.  
Even though electrospraying has previously been shown to produce nanostructures 
from nanosuspensions, this approach relies heavily on the applied voltage, flow rate 
and suspension properties out of which the electrical conductivity and viscosity play 
an extremely significant role. As too high or too low a level can greatly hinder the 
generation of monodispersed droplets to form a jet.   
  
 
 
 
 
 
 
 
 
 
Figure 2-11: Schematic image depicting the aerodynamically assisted jetting set-up. 
The main set up remains the same as electrospraying except the pressure chamber is 
put in place of the charged needle. The syringe pump holds the polymer solution in 
place which travels towards the pressure chamber with the help of silicone tubing 
attached at the inlet present at the top of the pressure chamber. The solution exits the 
chamber from the outlet present at the bottom directly facing the collector plate   
 
In the AAJ set-up, compressed air is used as a gas stream. If the applied pressure 
velocity is adjusted so that the liquid-gas surface tension stresses are larger than the 
gas pressure fluctuations, then the liquid filament will end up breaking into a nearly 
mono dispersed spray. As highlighted in figure 2-12 pressure is applied over an exit 
orifice within a chamber (further details on pressure chamber discussed ahead in 
section 3.2.1.2) that contains a needle holding the flow of the medium. Meanwhile, 
the gas flow is accommodated by the second inlet on the wall of the chamber that gives 
rise to a differential pressure within the chamber with respect to the surrounding 
atmosphere. The fluid medium gets drawn out of the needle due to the resulting 
pressure differential through the exit orifice, which is centrally in line with the exit of 
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 the needle itself. The exit orifice is also counter sunk externally in order to let the jet 
have a smaller diameter as it passes through the exit orifice (Jayasinghe and Suter., 
2006).  
Therefore, the formation of a jet occurs which later undergoes Rayleigh’s instabilities 
along with surface tension effects which will then help initiate the generation of 
droplets as well as droplet residues as seen in figure 2-11.  
 
 
 
 
 
 
 
 
 
Figure 2-12: Demonstrates the effect of applied pressure on the liquid filament exiting 
the orifice of the pressure chamber and then eventually breaking up into droplets. The 
pressure chamber contains three different orifices; one where the syringe containing 
media connects via silicone tubing (at the top), the other connecting the pressure 
regulator (sideways) and lastly an exit orifice (at the bottom) 
 
This jetting methodology and the various jet break up regimes are governed by the 
rheological properties of the liquid medium in combination with the applied flow rate. 
The only varying factor coming into play is the applied pressure unlike the applied 
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 voltage in electrospraying. However, AAJ shares quite a few similarities with 
electrospraying in that they both have the ability to handle high viscosity suspensions 
containing a range of materials through which micro as well as nano structures can be 
generated. Another specific feature shared by both these technologies is their ability 
to switch from producing droplets to fibres with a simple change in the rheological 
properties of the liquid media being used (Jayasinghe and Sullivan 2006).  
 
2.3.4 Encapsulation of bioactives by ES and AAJ 
 
Many successful examples of bioactive compounds encapsulated within drug delivery 
mechanisms produced using these fabrication methodologies exist in literature today. 
(Martinez-Sanz, Lopez-Rubio, and Lagaron 2012) reported the successful 
encapsulation of whey protein concentrate in micro, submicro and nanocapsules 
through electrospraying. These capsules were also able to stabilise functional additives 
like antioxidant β-carotene making them suitable for applications in the food industry. 
Omega-3 fatty acid was encapsulated by (Torres-Giner et al. 2010) via electrospraying 
to offer protection from oxidative degradation. They reported that secondary oxidation 
products formed in encapsulated fatty acid were at a much lower level than the un-
encapsulated products. (Valo et al. 2009) encapsulated two model drugs namely; 
beclomethasone dipropionate and salbutamol sulfate in PLA nanoparticles through 
electrospraying. They reported successful drug entrapment in these fabricated 
spherical polymeric delivery vehicles.     
 When it comes to the encapsulation/entrapment of antigens specifically, Preis and 
Langer were the first to present the ideology of a polymer construct encapsulating a 
protein antigen in (Preis and Langer 1979). Since then various polymers such as 
PLGA, PLA have been widely used as antigen encapsulating polymeric delivery 
mechanisms. (Gallovic et al. 2016) used the coaxial electrospraying methodology to 
formulate a micro particulate-based subunit anthrax vaccine. This study concluded an 
increased protection against the highly virulent B. anthracis ames strain in mice. 
(Furtmann et al. 2017) the ability of the electrospraying technique to produce PLGA 
nanoparticles that act as peptide based vaccine carriers. Klaric (2014) demonstrated 
the ability of electrospraying to encapsulate the IPNV antigen within alginate 
microbeads. It was concluded that this fabrication methodology was non-damaging 
towards the antigen. 
AAJ has been known to not only safely handle biological materials but also produce 
encapsulated annular residue structures consisting of active primary cells 
(Arumuganathar et al. 2007). (Pakes, Jayasinghe, and Williams 2011) set out to 
examine the model eukaryotic Dictyostelium discoideum – a model for immune cell 
chemotaxis – under AAJ. It was concluded that the use of AAJ did not induce any 
stress to the cells neither did it affect cell development. Hence suggesting that the 
technique can be safely used in order to manipulate cells of this biological model. 
Furthermore, (Griessinger, Jayasinghe, and Bonnet 2012) also demonstrated the 
ability of AAJ to jet hematopoietic stem/progenitor cells directly while maintaining 
their viability. (Kwok et al. 2008) went one step further and combined both these 
fabrication methodologies to give rise to a hybrid bio-jetting approach. This was used 
to handle human embryonic kidney cells stably expressing eGFP (enhanced green 
fluorescent protein), it was found that post treatment these cells still remained viable.           
 3. Materials and methods  
 
3.1 Materials 
This chapter provides details of all the raw materials; chemicals and stock solutions, 
analytical instruments as well as the experimental methodologies/techniques used in 
this thesis.   
 
3.1.1 Polymer selection 
Alginate - an anionic, water soluble, linear polymer - is amongst one of the most 
versatile and readily available biopolymers at present as it has immense applications 
in the biomedical industry. Moreover, properties such as the alginate’s mechanical 
strength, biodegradability, gelation and cell affinity can be attuned through its 
chemical and physical modification (Venkatesan et al. 2015).   
The ability of alginates to protect the microbe and the plasmid while passing through 
the digestive tract and then diffuse through the gut mucus layer has been widely 
researched and supported. Following diffusion, alginate will reach the enterocyte 
surface. After the alginate comes in contact with the epithelium, the antigen sampling 
cells will take them up and deliver to the microbe or DNA plasmid. From thereon, 
DNA plasmids will enter the nucleus and trigger antigen expression in the host cell 
whereas enteric pathogens may possess the intrinsic ability to activate local mucosal 
responses (Embregts and Forlenza 2016).   
 Extensive research has supported the use of alginate microparticles as delivery 
vehicles for macromolecules such as proteins and DNA.  A diverse range of biological 
compounds such as vitamins, vaccines etc can be incorporated into alginate matrices 
(Wee and Gombotz 1998) to avoid damage from low pH and interaction with 
proteolytic enzymes present in the digestive tract. An advantage of loading 
biomolecules into alginate micro-particles is that it helps retain their three-dimensional 
structure. Mandal et al (2001) suggests that porous alginate micro particles have a 
faster release rate as well as a higher loading content as compared to non-porous 
micro-particles. 
Alginates are composed of homopolymeric regions; M (β-D-mannuronic acid) and G 
(α-l-guluronic acid) (MM- and GG- blocks) infused with segments of alternating  
heteropolymeric sequences; GM- or MG- block structures, making them true block 
copolymers (Grasdalen, Larsen, and Smidsrod 1981). It is the organism or tissue from 
which the alginates are isolated which dictate its molecular variability. The average 
molecular weight, the molecule-weight distribution of the polymer and the sequence 
of M and G residues dictates the physical properties of alginate (Ding et al., 2009).  
The capacity of alginate to gel under benign conditions makes it attractive for 
encapsulation (Peppas et al. 2006). Divalent cations such as chloride salts have the 
ability to bind preferentially to the G-blocks present in alginate, therefore forming a 
gel. When sodium alginate is placed into a calcium based ion, the sodium ion in the 
polymer ends up being replaced by the calcium ion - with each calcium ion being 
cross-linked with two moieties of polymer stands (Venkatesan et al. 2015) as shown 
in figure 3 – 1. 
 
  
Figure 3-1: Divalent ion binding site in G-blocks (Ca2+ in this case). Image acquired 
and modified from Venkatesan et al (2015) 
 
Once in solution, alginates tend to behave like flexible coils. They are however capable 
of forming ordered structures but only upon interaction with divalent metal ions. 
Therefore, divalent ions such as calcium, strontium and barium will bind to the G-
blocks present in the alginate structure, preferentially but co-operatively, hence, 
resulting in the formation of a gel. For example, one Ca2+ binds to the G units in two 
alginate chains, following an ‘egg-box model’ (Smidsrod 1973) as shown in figure 3 
- 2. The gelation tends to be instant and is an irreversible process.  
 
 
 
Figure 3-2: The ‘egg-box model’ for alginate gel formation with divalent cations 
 
 
 
 3.1.1.1 Sodium alginate  
 
Alginate is found in seaweed and extracted from brown algae through treatment with 
aqueous alkali solutions, usually NaOH. In order to precipitate alginate, the extract is 
then filtered and calcium chloride is mixed with the filtrate. Treating it with dilute 
hydrochloric acid will help turn the alginate salt into alginic acid if needed. Once 
purification has taken place, water soluble sodium alginate is produced.  Resilient gels 
tend to be formed when sodium alginate is in the presence of calcium and acid 
mediums.  
Sodium salt is the most commonly used water soluble form of alginate. Over time, 
sodium alginate has found various applications mainly for the encapsulation and 
immobilisation of a range of cells since they can maintain their viability even within 
the cross-linked gel (Trivedi et al. 2001). Due to this, sodium alginate is typically used 
in an array of topical and oral pharmaceutical formulations and has specifically been 
used for the aqueous microencapsulation of drugs (Motwani et al. 2008).   
Different grades of sodium alginate are commercially available and they all vary in 
their molecular weight, particle size and chemical composition (Liew et al. 2006). 
Sodium alginates are generally divided into two groups: M- and G- rich alginates. M-
rich alginates are made up of approximately 60% mannuronic acid and 40% guluronic 
acid while the G-rich alginates consist of around 37% mannuronic acid and 63% 
guluronic acid (Lawson., 2003). M-rich alginates consist of various types of Keltone, 
Kelcosol, Kelvis whereas Manugels fall under G-rich alginates (Liew et al. 2006).   
 
 Table 3-1: All sodium alginates are cold soluble gelling agents. Dry, free flowing 
powder form in nature and yellow to light brown in colour. All supplied and 
manufactured by FMC BioPolymer AS Norway. Reference: FMC Biopolymers – 
product specification 
 
 
The M:G ratio of these alginates is highlighted in the table below; 
Alginate Type M:G ratio 
Manugel GMB 37:63 
Manugel GHB 37:63 
Manugel DMB 37:63 
Scogin MV 61:39 
Scogin LD 
Protanal LF 10/60 FT 
61:39 
25:75 
Table 3-2: M:G ratios of different grades of alginates used in chapter five as provided 
by FMC Biopolymers 
 
Types of Alginate 
Manugel GHB/GMB/DMB 
 
All three types are generally used in fillings, 
structured foods and heat stable gels 
Scogin MV/LDH Scogin alginates are pre-eminent water retention 
agents and enhance rheology. Normally used as 
surface sizers and strengthen oil resistance, solvent 
handout possess greaseproof properties 
 
Protanal (10/60FT) 
 
Medical grade sodium alginate. Most common 
application is wound care 
 Figure 3-3 shows a visual representation of the types of alginates used in the 
encapsulation efficiency and in vitro dissolution tests. The particle sizes of all five 
types were not rendered quite significant simply because the samples were not used in 
powder form, rather as solutions.     
 
 
Figure 3-3: Shows 1g each of Manugel GHB, Manugel GMB, Manugel DMB, Scogin 
LDH and Scogin MV respectively. The free-flowing powders are solubilised in DI 
water to produce alginate solutions which are then used to fabricate particles to be 
used in optimisation and characterisation tests. As seen in the image Manugels tend 
to have granules that are off-white in colour whereas Scogin alginates tend to possess 
more yellowish-brown coloured granule. This difference in colour is dependent on 
their extraction source 
 
 
 
 
 
 
 
 
 
 
 
 3.1.2 Raw materials  
Name Description/Manufacturer  
DI water Analytic reagent grade, certified AR for analysis. Fisher 
Scientific, UK 
Protanal LF 10/60FT, Lot # GQ5501401, FMC Biopolymer, AS 
Norway 
CaCl2 Calcium chloride dehydrate, Mw 147.01, Lot # SLBB9179V 
SrCl2 Strontium chloride hexahydrate, Lot # 8253A, Sigma 
Aldrich, UK 
BaCl2 Barium chloride dehydrate ≥ 99%, Lot # MKBL4935V, 
Sigma Aldrich, UK 
KPH Potassium hydrogen Phthalate 99%, VWR, UK 
HCl Hydrochloric acid, 37%, VWR, UK 
Glycine Glycine ≥ 99%, Lot # SZBA357AV, Sigma Aldrich, UK 
NaOH Sodium hydroxide, flake, 98%, Lot # 10159374, Alfa Aesar, 
Fisher Scientific, UK 
Blue dextran Molecular weight 2,000,000, Sigma Aldrich, UK 
Manugel GHB Lot # G0600201, FMC Biopolymer, AS Norway 
Manugel GMB Lot # G1305601, FMC Biopolymer, AS Norway 
Manugel DMB 
MGLDMB 
 
Lot # G1011902, FMC Biopolymer, AS Norway 
Scogin MV Lot # G0903901, FMC Biopolymer, AS Norway 
 Scogin LDH Lot # G9207802, FMC Biopolymer, AS Norway 
TiO2 Titanium (IV) dioxide 99.0 – 100.5%, Mw 79.88 g/mol, 
VWR, UK 
Dye Blue Food colouring, Super Cook, UK 
96 well plate Multiwall cell culture plates, VWR, UK 
Plastic syringe Sterile, disposable syringe, 1 ml, 10ml and 60 ml. VWR, 
UK 
Needle Hypodermic needle 19G, 1.1 x 50mm/21G, 0.8 x 50mm 
Terumo, VWR, UK 
Silicone tubing Silicone rubber tubing, platinum cured 
Wall thickness: 0.8 mm, Inner diameter: 0.8 mm, Outer 
diameter: 2.4 mm 
Silex Ltd, UK 
Magnetic beads PTFE coated spin bars, egg-shaped and polygon shaped. 
Spinbar, Sigma-Aldrich, UK 
Filter  Cell strainer, 100 µm nylon, VWR, UK 
Eppendorf tubes  1.5 ml, Sigma Aldrich, UK 
 
Table 3-3: Raw materials used during the experimentation stage of this research, 
including their type, grade and manufacturer details 
 
 
 
 3.1.3 Stock solutions 
Name Description 
CaCl2 36.8g CaCl2 dissolved in DI H2O (1000ml)  
SrCl2 106g SrCl2 dissolved in DI H2O (100 ml) 
BaCl2 12g BaCl2 dissolved in DI H2O (100 ml) 
KPH 0.4M Potassium hydrogen phthalate (KPH) prepared 
by dissolving 81.69g KPH in DI H2O (1000 ml) 
HCl 0.4M Hydrochloric acid (HCl) prepared by dissolving 
33.33 ml in DI H2O (1000 ml) 
Buffer pH 3.0 Prepared by combining 0.4M KPH and 0.4M HCl 
(Hydrochloric acid). The resulting buffer is adjusted 
to pH 3.0 before replenishing with DI H2O to give a 
total volume of 1000ml 
Glycine 0.4M Glycine prepared by dissolving 30.03g in DI 
H2O (1000ml) 
NaOH 0.4M NaOH prepared by dissolving 16g in DI H2O 
(1000 ml)  
Buffer pH 8.6 Prepared by combining 500 ml of 0.4M Glycine with 
40 ml of 0.4M NaOH. After fine tuning the pH to 8.6, 
the generated buffer solution is diluted to a volume of 
2000 ml with DI H2O 
 NaHCO3 (saturated) 0.4M NaHCO3 mixed with DI H2O (1000 ml). Any 
undissolved NaHCO3 crystals were filtered off prior to 
use 
Blue Dextran (BD) 
solution  
1g BD (powdered form) in 20ml DI H2O 
Table 3-4: Stock solutions used during the experimental stage of this research 
 
 
3.1.4 Analytical Instruments  
Name Description 
Modular stereomicroscope MZ10 F, Leica microsystems 
Microtec stereomicroscope Infinity 1-1M, Lumenera, UK  
Magnetic stirrer  Magnetic hot plate stirrer, Stuart® 
Weighing scale  Plate size: 275mm x 225mm, Adam® CBK 
Bench scale 
Weighing scale  Precision scale, Mettler Toledo, UK 
High voltage DC unit FP-30. Glassman Europe Ltd, UK 
Texture Analyser XT Plus, Stable Micro Systems, 
Godalming, UK 
Dissolution tester DT 626 series, ERWEKA, Heusenstamm, 
Germany 
 Microplate reader Bio-tek Absorbance Platereader with Gen5 
Data collection and Analysis software 
qPCR LightCycler 490 system (Roche) using the 
SYBR green RT-PCR Kit (Qiagen), 
Norway 
ELISA plate reader GENios, XFLUOR4 Version: V4.40, Tecan 
Group Ltd, Switzerland  
Vacuum coater VC-6, No, 1870, Halvor Forbeng AS, 
Norway 
High performance disperser T-25 IKA  Werke GmbH & Co, Germany 
pH meter Oakton handheld pH meter. Oakton® 
instruments, Sigma Aldrich, UK 
Rheometer The Discovery Hybrid Rheometer series 3, 
TA Instruments, UK 
Table 3-5: Analytical instruments used during the experimental stage of this research 
 
 
 
 
 
 
 
 
 
 
 3.2 Experimental Methodologies  
 
3.2.1 Encapsulation Methodologies 
The two alginate bead fabrication and encapsulation methodologies employed were 
namely electrospraying and aerodynamically assisted jetting. 
 
3.2.1.1 Electrospraying  
 
For the electrospraying process, microbeads were produced using the horizontal 
electrospraying configuration comprising of a high voltage supply which had the 
potential of reaching up to 30 kV. A 10 ml syringe was fixed onto a programmable 
syringe pump cradle (PHD 4400, HARVARD apparatus Ltd., Edenbridge, UK) as 
shown in schematic figure 2-9. The inner diameter of the stainless steel needle used 
was 15 mm, this needle was placed just above a copper ground electrode (10 mm 
external diameter and 8 mm internal diameter) which is connected to the syringe 
through silicone tubing. The microbeads produced were collected on a petri dish 
containing 35 ml of CaCl2 (cross-linking solution). Each sample set was collected for 
50 seconds. The same experimental set-up and procedure was used for microbead 
production by electrospraying throughout. Only the process variables were altered 
which will be highlighted in tables where needed.   
In order to produce operational maps for alginate microbead sizes, a suitable polymer 
concentration needed to be determined first. This was assessed through 
experimentation where process variables highlighted in table 3 - 6 were used. 
 
 Process parameters 
Flow rate (ml/hr) 50 
Voltage (kV) 5 
Distance between electrode and collector (cm) 8 
Distance between needle tip and electrode (cm) 2 
Alginate concentration (%) 0.5, 1, 1.5, 2 
Table 3-6: Process variables used for experiment assessing the effect of polymer 
concentration on the size of electrosprayed microbeads 
 
3.2.1.1.1 Operational size maps  
Once an appropriate polymer concentration was selected, the operational maps for 
microbead sizes were then produced using process variables shown in table 3 - 7 
 
Process parameters  
Alginate concentration (%) 2 
Distance between electrode and collector (cm) 8 
Distance between needle tip and electrode 
(cm) 
2 
Molarity of cross linker (mol) 25 
Sample collection time (sec) 50 
Table 3-7: Process variables used for producing microbead size operational maps 
using Electrospraying. Flow rate and voltage were changed over a range of 10 – 60 
ml/hr and 0 – 12kV respectively 
 
 3.2.1.1.2 Mechanical Testing 
Alginate beads fabricated for mechanical testing were generated using the same 
parameters for the dissolution tests as seen in table 3 – 12, 3 – 13 and 3 – 14.    
 
3.2.1.2 Aerodynamically Assisted Jetting (AAJ) 
 
The Aerodynamically assisted jetting set-up consisted of a ‘pressure chamber’ which 
is a stainless steel container (DIN 1.4435). It consists of two inlets, one for compressed 
air and the other for a threaded needle and an exit orifice. The internal diameter of exit 
orifice is the same as the threaded needle i.e. 0.35 mm. Once the needle is fitted into 
the device, the distance between the needle tip and the exit orifice is 0.18 mm. The 
internal diameter of the chamber itself is 8.2 mm, while the height is 16.2 mm. Nozzle 
measurements are listed below in table 3-8.   
 
Nozzle measurements  Metric (mm) 
Top inlet diameter  8.5 
Side inlet diameter 6.2 
Needle length 4 
Needle thread  9.9 
Table 3-8: AAJ nozzle/pressure chamber measurements 
 
The threaded needle helps accommodate the media flow into the device and is fitted 
vertically at the top of the chamber. The second inlet present on the chamber is to let 
compressed air flow in, this inlet is perpendicular to the threaded needle inlet. A 
 precision regulator connects to the compressed air inlet present at the pressure 
chamber through a silicone tube. The main air supply has a controllable on/off switch 
and a manual tuner to adjust the pressure with a resolution of +/- 0.01 bar. Similar to 
the electrospraying procedure, each sample was collected in a petri dish containing 35 
ml of CaCl2 for 50 seconds each.  
Suitable polymer concentration for microbead fabrication using AAJ was chosen 
through an optimisation experiment for which there are process variables highlighted 
in table 3 - 9 below.  
 
Process parameters 
Flow rate (ml/hr) 60 
Pressure (bar) 0.03 
Distance between exit orifice and collector (cm) 10 
Alginate concentration (%) 0.5, 1, 1.5, 2 
Table 3-9: Process variables used for experiment assessing the effect of polymer 
concentration on the size of microbeads produced through AAJ 
 
3.2.1.2.1 Operational size maps 
Operational maps for microbeads produced using AAJ were then produced using 
variables highlighted in table 3 - 10. 
 
 
 Process parameters  
Alginate concentration w/v (%) 2 
Distance between exit orifice and collector (cm) 8 
Molarity of cross-linker (mol) 25 
Sample collection time (sec) 50 
Table 3-10: Process variables used for producing microbead size operational maps 
using AAJ. Flow rate and pressure was changed over a range of 10 – 60 ml/hr and 
0.1 – 1 bar respectively 
 
 
3.2.2 Characterisation 
3.2.2.1 Scanning electron microscopy (SEM) 
Feed pellet morphology was determined with the help of SEM images. These were 
taken using the Hitachi S-3400 PC-based pressure scanning electron microscope – 
with a magnification range of 5x to 300,000x. It allowed for the porous surface of the 
pellets to be examined and helped determine the range of pore sizes present.    
 
3.2.2.2 Environmental Scanning electron microscopy (ESEM) 
ESEM has the ability to analyse hydrated samples without causing any physical 
alteration to them (Stabentheiner, Zankel, and Polt 2010). The Philips XL30 ESEM 
was used to examine the external structure of alginate microbeads as they were only 
partially dried.  
 
 3.2.2.3 Transmission Electron microscopy (TEM) 
As the success or failure of TiO2 encapsulation was based upon the size of their 
particles, TEM was used to determine their size range. This was done using the 2x 
JOEL 1010 transmission electron microscope with digital image capture and 
magnification up to 660,000. 
 
3.2.3 Mechanical Testing 
The mechanical properties of microbeads were quantified using a Texture Analyser 
XT Plus (Stable Micro Systems, Godalming, UK) a schematic diagram for which can 
be seen in figure 3-4. This equipment has the ability to measure up to 50 kg in force 
and can also be used to measure a range of properties including adhesiveness, tensile 
strength, fracturability, viscoelasticity etc. 
 
 
Figure 3-4: Shows the TA.XT Plus Texture Analyser set-up including the texture 
exponent software version 6.0 for data recording, the probe used for compression 
testing; Perspex cylinder (diameter: 8mm), the platform where the test sample is 
 placed and the moving arm that pushes the load cell vertically once the compression 
test starts 
 
The base table is such that it provides easy and quick height adjustment in order to 
accommodate various sized samples. The selection of probe is dependent upon the 
type of test being carried out along with the surface area of the sample to be tested. 
Compression probes are usually cylindrical in shape. In order to maintain the applied 
compression forces it is important for the probe being used to have a larger area than 
that of the sample being tested (Test Cells Fixtures, Food Technology Corporation). 
The mechanical stability of samples was measured by compressing each individual 
microbead (n = 5 for each sampling point assessed). After a microbead was sized under 
an optical microscope, it was then placed on a plate and the probe was moved towards 
the microbead. The parameters highlighted in table 3 - 11 were set on the Analyser 
before starting the compression test; 
 
Process parameters 
Pretest speed (mm/s) 0.5 
Test speed (mm/s) 0.01 
Postest speed (mm/s) 2 
Trigger force (g) 2 
Compression (%) 60 
 
Table 3-11: Test parameters used for compression testing 
 3.2.5 Dissolution Testing  
These tests were divided into two sets; observational and in vitro. Evidently, the testing 
requirements and experimental methodologies for both differed from each other as 
described in sections 3.2.5.1 and 3.2.5.2 below.  
3.2.5.1 Dissolution – Observational 
Ten different alginate concentrations were produced; 0.2%, 0.4%, 0.6%, 0.8%, 1%, 
1.2%, 1.4%, 1.6%, 1.8% and 2%. Cross-linking solutions; CaCl2, SrCl2 and BaCl2 
were also produced at the same molarity i.e. 0.25 M. While the dissolving solution 
NaHCO3 was produced at a molarity of 1 M. 
Manual microbead production was carried out by simply loading the test solution into 
a 5 ml syringe (21G x 2/0.8 x 50mm). Microbeads produced through ES and AAJ for 
this test used the same set up as described in section 3.2.1.1 for ES and 3.2.1.2 for AAJ 
using the parameters in table 3 – 12 and 3 – 13 respectively.  
The experimental set-up for the fabrication procedure combining both ES and AAJ 
aims to combine both the electrospraying processes successfully. To achieve this, the 
applied voltage is connected to the pressure chamber, so now the liquid drawn out of 
the exit orifice is dependent upon two factors; applied pressure and applied voltage. 
Similar to the aforementioned experimental set-ups, a 10ml syringe is fixed onto a 
syringe pump and the pressure chamber is placed just above a copper ground electrode 
which is connected to the syringe through silicone tubing. The voltage supply is 
connected to the needle present on top of the pressure chamber. The precision 
regulator is connected to the compressed air inlet which is attached to the pressure 
 chamber. Once, the flow rate, voltage and pressure were set to the values listed in table 
3 - 14, microbeads were produced. 
 
Process parameters  
Flow rate (ml/hr) 50 
Voltage (kV) 2.5 
Distance between electrode and collector (cm) 8 
Distance between needle tip and electrode (cm) 2 
Alginate concentration (%) 0.6, 1, 1.6, 2 
Table 3-12: Process variables used for experiment assessing the effect of fabrication 
methodology on the dissolution rate of electrosprayed microbeads 
 
 
Process parameters 
Flow rate (ml/hr) 40 
Pressure (bar) 0.01 
Distance between exit orifice and collector (cm) 10 
Alginate concentration (%) 0.6, 1, 1.6, 2 
 
Table 3-13: Process variables used for experiment assessing the effect of fabrication 
methodology on the dissolution rate of microbeads produced through 
aerodynamically assisted jetting 
 
 
 
 
 
 
 Process parameters  
Flow rate (ml/hr) 40 
Voltage (kV) 2.5 
Pressure (bar) 8 
Distance between exit orifice and electrode (cm) 2 
Distance between electrode and collector (cm) 8 
Alginate concentration (%) 0.6, 1, 1.6, 2 
Table 3-14: Process variables used for experiment assessing the effect of fabrication 
methodology on the dissolution rate of microbeads produced through ES and AAJ in 
conjunction 
 
Once the microbeads were produced they were sized using an optical microscope 
(Leica MZ10F). The L4078 stage micrometre (1 mm scale, 0.01 mm sub-divisions, 
line width 2 µm, accuracy +/- 2 µm overall) was used as a simple and reliable means 
of precisely calibrating the optical microscope (Leica DFC280).  A single bead was 
then moved into a single well of a 24 well plate containing 1 ml NaHCO3 acting as the 
dissolving solution. The well plate was then placed under an optical microscope and 
images were taken at various time intervals while the process of dissolution was timed 
and recorded. Five replicates were carried out for each sample point being assessed. 
 
3.2.5.2 Dissolution – In vitro 
 
Dissolution tester ERWEKA DT 626 series (6x 1000ml semi-hemispherical bottomed 
glass vessel) in accordance with the USP 1 and 2 general method – rotating basket and 
paddle - was used. The apparatus consists of a metallic shaft attached to a rotating 
 cylindrical basket that is positioned in a cylindrical glass vessel, which holds the test 
media. According to FIP/AAPS guidelines to dissolution (2003) the volume capacity 
of the six vessels present in the dissolution tester is up to 1000 ml each. The six vessels 
themselves are placed in a rectangular glass water bath. The temperature probe helps 
regulate the temperature at which the test takes place as seen in schematic figure 3-5.  
Figure 3-6 shows a closer look of the mesh basket placed in the glass vessel while 
being attached to the shaft which helps move the rotating basket in a vertical direction 
before or after the test as well as rotating it during the test.  The mesh basket itself is 
made of stainless steel with 40 openings per linear inch of mesh. An opening at the 
top of the basket allows for the test sample to be placed inside. 
 
 
Figure 3-5: Schematic showing dissolution tester- frontal view. The ERWEKA DT 626 
series. Equipped with six test stations, with centering rings for the shafts, covers for 
each vessel along with a distance ball for height adjustment of the paddles 
 
  
Figure 3-6: A schematic representation of the USP rotating basket connected to a 
mettalic shaft that is placed in a semi-hemispherical glass vessel. Image on the right 
shows the 40 size mesh basket in which the test sample is placed 
 
For the in vitro dissolution tests, alginate beads were produced using 1.5 ml alginate 
solution for each vessel. Once bead fabrication took place, the beads were removed 
from the cross-linking solution – 25 ml CaCl2 - after 10 minutes of the last bead being 
formed. They were then washed with DI water thoroughly in order to remove any 
excess cross-linking solution. Meanwhile, it was made sure that the rotation speed was 
set to 100 rpm in accordance with the UPS 1 apparatus set up. The temperature of the 
water bath was set to 11°C. 380ml of buffer 3.0 added to each of the five vessels. 
Timer was set to 15 minutes. The beads were then placed into their assigned mesh 
baskets and submerged into the respective vessel to begin the test. According to 
FIP/AAPS guidelines, the submergence of the rotating basket in the dissolution 
medium is necessary. Test started within approximately 30 minutes of alginate bead 
production.  
 After 15 minutes of the test start time, the tester was paused and 1 ml of dissolution 
media was pipetted out into an eppendorf tube for analysis later. The baskets were 
 then lifted out of the vessels and washed with DI water to get rid of excess buffer 
media that might be present on the mesh. The beakers were washed and reloaded with 
380 ml of buffer 8.6. The baskets containing the same sample of beads was now 
submerged in the new dissolution media and the test was started once again.  
 
 
 
 
 
 
 
Figure 3-7: The test was paused fifteen minutes after the starting point in order to 
replace media; KPH/HCl (Potassium hydrogen phthalate/hydrochloric acid) was 
used to represent acidic medium present in the stomach while Glycine/NaOH 
represented alkaline conditions present along the intestinal tract of Salmon 
 
Test was paused at five minute intervals in order to collect samples – 1ml each time - 
in eppendorff tubes. With each sample removal an equivalent amount of media was 
replaced back into each vessel so as to keep total volume constant throughout the test. 
A total of twelve sampling points were used for sample collection - from 0 to 55 
minutes. The test conditions were set as summarised in table 3-15.   
100 µl aliquots were taken from collected samples to prepare a 96 well polystyrene 
well plate. An endpoint assay was carried out using the microplate reader. 
 
 
KPH/HCl 
pH 3.0 
Buffer replacement 15 min after the start of test 
Glycine/NaOH 
pH 8.6 
 Parameters 
 
Alginate Type Manugel GMB, GHB, DMB, 
Scogin LDH, MV 
Dissolution media 1 KPH-HCl 
pH 3.0 and 8.6 
Sampling time point (mins) 15 
Total number of sampling point (s) 1 
Dissolution media 2 Glycine-NaOH 
pH 8.6 
Sampling time points (mins) 0, 5, 10, 15, 20, 25, 30....55 
Total number of sampling points 12 
Volume of media (ml) 380 
Sample volume (ml) 1.0 
Temperature (℃) 11 
Rotation speed (rpm) 100  
Apparatus UPS 1 
Number of vessels 5 
Table 3-15: Conditions set for the in vitro dissolution tests carried out using UPS 
Apparatus 1 
 
3.2.5.3 Standardised in vitro test strategy  
The United States Pharmacopoeia (USP) have set out numerous standardised 
dissolution apparatus; USP apparatus 1 also known as the ‘stirred beaker method’ 
positions the test sample and a fixed volume of fluid in a vessel while stirring acts as 
 mechanical agitation. USP apparatus 2 is the ‘rotating basket and paddle’ whereas 
apparatus 3 is the ‘reciprocating cylinder’. USP apparatus 4 is the ‘flow through cell’ 
where the sample is placed in a column that is flushed with fluid continuously. USP 
apparatus 5 is ‘paddle-over-disk’ while apparatus 6 is a cylinder and apparatus 7 
consists of ‘reciprocating holders’ (Siewert, Dressman et al. 2003).   
It should be noted that the chosen test method may not necessarily be able to 
completely imitate the in vivo environment as long as it is able to test the pivotal 
performance indicators of the test formulation. As far as ODTs (orally disintegrating 
tablets) are concerned, apparatus 1 and 2 are the test method of choice. The rotating 
basket and paddle devices are robust yet simple and are therefore supported widely for 
experimental use. However, it should be noted that due to the single container nature 
of apparatus 2, change in pH or any kind of test medium leads to experimental 
difficulties. Even though the USP 1 set up may cause the formulation to clog the screen 
this apparatus offers the ability to change pH through media addition/replacement (US 
Pharmacopeia., 2011).     
The in vitro dissolution test in this study was carried out in quintuplicates following 
the method described in Section 3.2.5.2. Conditions set for the in vitro dissolution test 
are summarised in Table 3-15. The reasoning behind dissolution test parameters being 
set as such is detailed in the following sections. 
3.2.5.4 Temperature 
The temperature of the water bath was carefully monitored at 11°C since Atlantic 
salmon is exposed to a temperature range of 4 – 18°C (Jensen, Wahli et al. 2015). It 
has been previously reported that low temperatures tend to have an adverse effect on 
 both cellular and humoral specific immune response. Moreover, 4°C has been 
established as the non-permissive lower water temperature in salmonids (Szalai, Bly 
et al. 1992). Therefore, an optimum temperature between 4 and 18°C was deemed 
ideal to assess dissolution rates - a point where salmonids are best able to induce an 
immune response.   
3.2.5.5 pH 
The pH conditions found in A.Salmon stomach are acidic. The major digestive 
components in the stomach happen to be pepsin and HCl (Volkoff, 2010). The 
optimum pH for pepsin is 3.0. After being processed in the stomach, the mixture of 
dissolved nutrients and partially digested feed pass into the pyloric caeca. This is 
where trypsin, chymotrypsin and aminopeptidase complete peptide hydrolysis 
(Krogdahl and Bakke-McKellep, 2005). When the acidic chyme reaches the proximal 
intestine it becomes rapidly neutralised by bicarbonate (HCO3) in bile and pancreatic 
juice. Before feed intake the average pH through entire intestinal section is 8.2, after 
feed intake it decreases to 7.5 and the pH increases again during the period after 
feeding and can be slightly above 8.5 along the intestinal tract (Bucking and Wood, 
2009).    
For the microbeads to mimic a reasonably accurate passage through the A.Salmon GI 
tract, the dissolution medium needs to be kept acidic for the first fifteen minutes, so as 
to simulate gastric conditions. Following which, the dissolution medium then needs to 
be replaced with alkaline media to simulate the intestinal conditions present in 
A.Salmon. Additionally, for gastrointestinal formulations where one pH level is not 
capable of producing bio pharmaceutically relevant results, a change of pH during the 
 dissolution test is rendered appropriate. Therefore, buffer pH 3.0 (KPH and HCl) and 
buffer pH 8.6 (Glycine and NaOH) were used as the dissolution media.  
Almost all alginate dissolution test studies have been carried out under conditions 
viable for the human digestive system. The only data available for the dissolution of 
alginate microbeads under simulated A. Salmon digestive conditions (Goran, 2015) 
used the following buffers; pH 3.0 and pH 8.6 
3.2.5.6 Agitation rate  
In accordance with USP apparatus test method 1 and 2, agitation should be obtained 
in the basket and paddle device is by stirring at 50 to 100 rpm and should not exceed 
150 rpm. The agitation rate for the entire length of the test was set at 100 rpm.  
3.2.5.7 Sampling points  
Selecting dissolution test time points is based upon the type of formulation being 
tested. For delayed release formulations, dissolution requirements consist of at least 
three points, where the first sample is taken after 1 – 2 hours and the third sample is 
taken when the API is completely released. On the other hand, immediate release 
SODF’s will have a test time of approximately 30 minutes to an hour. 
Samples were taken at intervals of five minutes for an overall test duration of fifty-
five minutes. The first sampling point 0 was taken 15 minutes after the test was started. 
1 ml was pipetted out of each vessel and replaced by another 1 ml of the original 
dissolution media to keep total volume constant. After sampling point 0, every 
 following sampling point was after five minute intervals. All the samples were 
collected in 1.5 ml eppendorf tubes for analysis later.  
3.2.5.8 Dissolution media  
Each vessel was filled with volume of 380 ml buffer 3.0 at the start of the test. After 
sample 0 was taken at 15 minutes, the test media was then changed to pH 8.6, in order 
to keep in accordance with the simulated environment of A.Salmon’s digestive 
system.   
At the end of the test, aliquots of 100 µl were taken from the epindorffs to prepare the 
96-well plate for microplate reader analysis. An endpoint assay was performed using 
the BioTek microplate reader at 630 nm at 27 ºC 
 
 
 
 
 
 
 
 
 
 
 
 
 3.2.6 Encapsulation Efficiency (EE) 
The Bio-tek Absorbance Plate reader with Gen5 Data collection and Analysis software 
was used to detect absorbance in order to produce a standard curve. The in vitro tests 
used Blue Dextran (BD) – a water soluble model macromolecular drug with an average 
molecular weight of 2,000,000 as a suitable model API.   
 
 
 
Figure 3-8: Test strategy for the encapsulation efficiency experiment. Five sets of 
1.5ml batches were produced for each type of alginate tested 
 
 1.5 ml of alginate and BD solution were used to produce microbeads in 25 ml of CaCl2 
which played the role of a cross-linker in this test. Beads were then filtered to remove 
the cross-linker and washed with DI water in order to get rid of excess cross-linker. 
Beads were then added to a beaker filled with 200ml saturated NaHCO3. After a period 
of 24 hours when the beads were completely dissolved, 180ml of DI water is added to 
the beaker for dilution – this is done to avoid crystallisation and hence the need for 
further filtration. An aliquot of 100 µl is finally taken from the beaker and placed into 
an eppendorf tube to be prepared for the plate reader. Absorbance of BD was measured 
at 630 nm and 24℃. All measurements for this test were replicated five times and 
averaged.  
 
Process parameters  
Flow rate (ml/hr) 50 
Volume (ml) 1.5 
Diameter (µm) 23.2 
Distance between exit orifice and collector (cm) 10 
Table 3-16: Microbead fabrication process variables for encapsulation efficiency 
testing for all five types of alginates 
 
 
3.2.7 Viscosity Testing 
Discovery Hybrid Rheometer series 3 was used for this experiment. The rheometer 
consisted of cone and plate set up with measuring geometry as follows; 60 mm cone, 
angle of 1º and a 27 µm gap – which was used along with the TRIOS software to 
 obtain viscosity measurements of all samples. Five different types of alginate products 
provided by FMC polymers were measured at the following constant parameters; 
 
Process parameters  
Solution concentration (w/v %) 2 
Temperature (℃  ) 25 
Volume of solution tested (ml) 5 
Shear rate (1/s) 101 
Alginate type Manugel GMB, Scogin MV, Scogin 
LDH, Manugel GHB, Manugel DMB  
Table 3-17: Process variables used for the viscosity measurements of all five alginate 
types 
 
 
Each sample was placed on the bottom plate with the help of a syringe. The experiment 
was carried out in quintuplicates with the plates cleaned by a dry napkin carefully 
before a new sample was loaded for testing. For each sample, the strain was measured 
as the sample itself was subjected to a stress gradually increasing from 0 to almost 180 
Pa for the time duration of 2 minutes/sample.  
 
 
 
 
 
 3.2.8 Trial 
3.2.8.1 Production of encapsulated IPNV microbeads  
 
The following process parameters were set for the encapsulation process; 
Process parameters 
Alginate type Protanal 10/60FT 
Concentration (%) 2 
Pressure (bar) 3.0 
Flow rate (ml/hr) 60.5 
Distance between exit orifice and collector (cm) 10 
Table 3-18: Process parameters used for IPNV antigen encapsulation using AAJ 
 
Two sets of microbeads were produced; empty alginate beads to act as the control 
group and the experimental group which consisted of IPNV antigen encapsulated 
microbeads 
 
 
3.2.8.2 qPCR 
Real-time PCR is currently the most accurate and sensitive detection/quantification 
method for nucleic acids (Dorak 2007). Quantitative PCR was performed by using the 
SYBR green RT-PCR Kit (Qiagen) and the LightCycler 490 system (Roche).  
Quantitative polymerase chain reaction (qPCR) also known as real-time PCR is a 
molecular biology technique based on the polymerase chain reaction (PCR). PCR is 
driven by a thermostable polymerase enzyme which will synthesize a complementary 
 sequence of bases to any single strand of DNA. This means that a specific gene can be 
chosen which the polymerase will amplify in a mixed DNA sample through the 
addition of DNA complimentary to the gene of interest. Small pieces of DNA called 
‘primers’ prime the DNA sample at the right location in order for the polymerase to 
bind and copy only the gene of interest. The binding of primers is highly specific but 
the activity of the polymerase is controlled through temperature.  
 The same principle of amplification is employed during a real-time quantitative PCR 
(qPCR) reaction, where the amplification of a targeted DNA molecule is quantified in 
real-time, and not at the end as the conventional PCR, which reduces accuracy of 
quantification. Since qPCR allows for the reaction to be witnessed while it takes place 
(in real life), the acquired measurements are much more accurate, and qPCR therefore 
has become the workhorse of targeted quantitative analysis of gene expression.  
For the qPCR test carried out in this research, the SYBRgreen® dye was used as the 
real-time detection technology. It is the most commonly used intercalating fluorescent 
dye, which in the presence of a double stranded DNA will bind to the DNA helix. This 
ends up altering the structure of the dye hence activating its fluorescence. Every time 
a PCR reaction results in the double stranded DNA, the SYBRgreen® dye will bind 
to it and emit fluorescent signal which will be read off in real-time by the instrument 
as seen in figure 3 - 9. SYBRgreen® absorbs light at 497nm and is able to emit light 
at 520nm (Dorak 2007).  
During the denaturation phase of the DNA, the SYBRgreen® dye is present in the 
mixture but these molecules have less affinity towards single-stranded DNA. Once 
annealing or polymerisation takes place, the level of fluorescence increases. This is 
because as more and more DNA is created by PCR, more dye is able to bind with the 
 DNA double helix thus increasing the fluorescence intensity. When the two separate 
genes of interest have been produced, the DNA present in the mixture becomes 
double-stranded and SYBRgreen molecules bind to this dsDNA. Figure 3-9 offers a 
schematic description of the process.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-9: Highlights the process where SYBRgreen dye binds to the dsDNA product 
resulting in fluorescence 
 
The samples were all subjected to qPCR and the individual Ct values were determined. 
Ct data was then normalised for the expression of the house-keeping gene. House-
keeping genes are control genes used in qPCR as they are constitutive genes vital for 
the maintenance of basic cellular function and are expressed in all cells of an organism 
under normal and also patho-physiological conditions (Eisenberg and Levanon 2003). 
Denaturation  
Polymerisation  
Extension 
Forward primer 
Reverse primer 
 Once normalised, they are then processed by the Delta Delta Ct method as described 
previously by (Livak and Schmittgen 2001). Final results are presented as delta delta 
Ct values, and expression of each gene in control fish (not exposed to beads or antigen) 
was set to zero.   
For each gene, 50 ng of RNA was used as a template in a mixture of primers – 250 μm 
and SYBR Green RT-PCR master mix giving a total volume of 20 μl. The mixtures 
were incubated at 50 °C for ten minutes, followed by 95 °C for five minutes after 
which forty amplification cycles took place.  
 
3.2.8.3 ELISA (Enzyme-linked immunosorbent assay)     
 
The enzyme linked immunosorbent assay (ELISA) is a detecting/quantifying 
technique normally used to measure substances such as proteins, antibodies, peptides 
and hormones. This immunological assay technique is considered to be strongly 
specific and highly sensitive (Xiao and Isaacs 2012).  
Prior to sampling, the fish were anaesthetised with tricain mesilate (100 mg/l). Blood 
was collected from the caudal artery with a heparinised blood collection tube (V = 4 
ml) fitted with 0.8×38 mm disposable needles. The pooled blood samples were 
centrifuged at 4000 rpm for 10 min immediately after sampling. The plasma was then 
removed and kept frozen at -80oC prior to ELISA test.  
ELISA was performed following the method previously described by (Munang'andu 
et al. 2012) with minor modifications.  
 ELISA plate wells were coated with 100 µl polyclonal anti-IPNV diluted 1:2000 in 
coating buffer pH 9.6 (0.1M Carbonate buffer) and then incubated overnight at 4oC. 
The plates were washed before the incubation of 200 µl of 5% dry milk per well for 
the duration of 2 hours at room temperature. The washing steps were done in triplicate 
with 200 µl PBST/well, the dilutions were carried out with 1% dry milk. Once washed, 
the wells were incubated for 2 hours with 100 µl of IPNV supernatant 108 TCID50/ml. 
After another wash, the serum samples were diluted 1:40, added to the wells and 
incubated at 4oC overnight. Following another wash, 100 µl of mouse antibody against 
rainbow trout IgM diluted in 1:5000 was incubated for 2 hours. After this 100 µl of 
1:1000 dilution of peroxidase conjugated antimouse Ig (DAKO, Denmark) was 
incubated in each well for 1 hour. After washing 100 µl of O-phenylenediamine 
dihydrochloride substrate diluted in water was added to each well. The reaction was 
incubated for a duration of 15 minutes, after which the recation was stopped by adding 
50 µl of 1 M H2SO4 per well. An ELISA plate reader (TECAN, Genios) was used to 
analyse the samples at 492 nm.   
 
 
 
 
 
 4.  Fabrication, optimization & 
characterisation  
 
 
4.1 Introduction and aims  
The mechanism of drug delivery has a significant effect on both the likelihood for 
commercialization of the drug as well as its efficacy. This is why more effective 
methods for drug delivery need to be explored and analysed. Ideal drug delivery 
systems need to administer the correct amount of a specific therapeutic agent at the 
appropriate time, at the right location in a way that not only boosts compliance but 
simultaneously reduces side effects. Microbeads are one such mechanism that offer 
controlled drug release for extended periods of time. These microbeads provide 
protection for the drug itself and have the ability to offer controlled release which also 
increases patient comfort (Kim and Pack 2006). Moreover, the vaccine formulation 
itself should be stable with respect to carrier size, size distribution and surface 
morphology throughout the process of fabrication, storage as well as administration 
(Oyewumi et al., 2011).   
The bioactive compound itself is encapsulated into a polymeric matrix so as to protect 
it from degradation; proteolytic or acidic. The main aim of the first results chapter is 
to assess two novel microbead fabrication methodologies; Electrospraying and 
Aerodynamically assisted jetting. In order to initiate the optimisation of both ES and 
AAJ, firstly, polymeric parameters such as concentration of the alginate solution were 
 assessed. Following which, the governing process parameters such as flow rate, 
applied voltage, pressure and collecting distance were also studied.  
As there are a wide variety (especially in terms of size range) of feed pellets available, 
a similarly appropriate range of microbeads is also needed in order to fit into the pellet 
pores. The next objective was to carry out an extensive sizing study - for microbeads 
produced using both fabrication methodologies – in order to produce operational size 
maps for appropriate combinations of flow rate and applied voltage/pressure. 
Since these encapsulated microbeads are vacuum packed into industrially available 
functionalized feed pellets ready to be orally fed to the fish, it is imperative to gain a 
clearer understanding of the porous nature of these feed pellets. Hence, another aim of 
this research chapter was to analyse their surface morphology through SEM.  
Since biological compounds are neither cheap nor readily available, a secondary 
objective of this study was to gauge the effects of encapsulation on the sizes of alginate 
microbeads fabricated using ES and AAJ. TiO2 particles were used as a stand-in for 
potential API’s in this sizing study.  
Hydrogel microbeads used for drug delivery can be highly deformable specially the 
ones ranging from 1 µm to 100 µm. It is the mechanical properties of these microbeads 
that will determine whether they will be able to withstand the stress and shear forces 
applied upon them in the microenvironment they may be exposed to (Thanos, Bintz, 
and Emerich 2007) such as the feed coating stage or in capillaries in vivo, once inside 
the body. The maintenance of microbead integrity is also crucial in order to prevent 
immune response, dose dumping and achieving successful optimal performance (Kim 
et al. 2009).  Hence, the final aim of this chapter was to study their mechanical 
 stability, specifically; the effect of polymer concentration, varying cross-linking 
agents and fabrication methodologies on the strength of alginate microbeads.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4.2 Optimal Size distribution 
Smaller sized particles promote stability in blood circulation, as they possess the 
ability to permeate through biological barriers more efficiently by passing through 
capillaries following injection (Manfordini and Veronese., 1998) suggesting that 
nanoparticles tend to be a superior choice when it comes to targeted drug delivery.  On 
the other hand, larger sized particles are deemed preferential when it comes to vaccine 
delivery as they produce stronger and more lasting immune responses (Mody et al., 
2017). 
Once, polymeric microbeads are fabricated the next step is to incorporate them within 
fish feed pellets for successful oral delivery. There are two methods currently in use 
for the addition of microbeads into extruded feed pellets; through the pre-extrusion 
addition with water and meal mix or through vacuum infusion coating, which is the 
post-extrusion addition with oil. The former method requires a typically high 
temperature, which can put the biological compound at risk of denaturing, whereas the 
latter requires low temperatures. Even though, the temperature requirement for 
vacuum infusion is rather suitable, the process can only be effectively carried out if 
the microbead is able to fit into the pores present in the feed pellet. 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 4-1: SEM micrographs showing the superficial irregular porous nature of a 
typical fish feed pellet. The scale bar represents 20 µm. Magnification x 10 (A and B), 
x 100 (C and D)  
 
 
As seen in Figure 4-1, the pores present in feed pellets are not necessarily uniform. 
The idea is to fit as many microbeads in these pores as possible in order to attain 
maximum packing efficiency. Depending on the type, size and stage of growth span 
the fish is in, it will be fed using a specific feed pellet. Thus, depending upon the size 
of pellet being fed, the size of alginate microbeads able to fit into the irregularly shaped 
pores will change too. 
The functionalised feed pellets consumed in the IPNV trial study are the Commercial 
Starter feed produced by EWOS. These pellets have a uniform size distribution, 
roughly 1.3 mm in size. SEM carried out on these feed pellets highlights their porous 
morphology (Figure 4-1) it was also seen that the sizes of pores present on these pellets 
ranged from 22 – 47 µm approximately (Figure 4-2).  Due to this, it was noted that 
A. B. 
C. D. 
 successful vacuum packing of microbeads would only be possible if the microbeads 
themselves are less than 47 µm in size. 
 
Figure 4-2: SEM micrographs showing a closer look into the morphology of a 1.3 mm 
fish feed pellet used in the IPNV fish trials. The scale bar represents 5 µm. 
Magnification x 10 (A and B), x 100 (C and D)  
 
 
 
 
 
 
 
 
 
 
 4.2.1 Effect of polymer concentration on microbeads produced through 
electrospraying and aerodynamically assisted jetting  
 
Concentration (%) Microscopic Images Observations 
0.5 
 
Irregular structures that tend to 
take a more 
elongated/cylindrical shape 
1 
 
Slightly more spherical beads 
with tails  
1.5 
 
Spherical beads with smaller 
tails 
2 
 
Spherical beads with no tails  
 
Table 4-1: Comparison of four different alginate concentrations – 0.5, 1, 1.5 and 2%, 
the corresponding visual representation of microbeads produced (magnification x 8, 
Leica MZ10F) via ES and observations noted. Scale bar represents 50 µm 
 
 The difference in morphology for microbeads produced using 0.5% concentration is 
quite visibly different to the sample produced using 2%. This observation is in 
accordance to previous research where polymer concentration was highlighted as one 
of the main parameters as far as morphology of electrosprayed particles was concerned 
(Wu, Kennedy, and Clark 2009). 
Two main mechanisms that control the morphology of electrosprayed beads are; 
‘polymer diffusion’ during evaporation and ‘solvent evaporation’ from droplets when 
they move from the needle tip to the collector (Almeria et al. 2010). The polymer 
solution, namely its molecular weight and concentration, will dictate both these 
mechanisms. A flattened irregular structure was seen for microbeads produced using 
0.5% concentration suggesting that a lower polymer concentration favours the 
production of flat particles rather than take a spherical morphology as shown for 
microbeads produced using 2% concentration. This can be a direct effect of incomplete 
solvent evaporation as the solvent contents are comparatively higher for the decreased 
polymer contents in samples produced using a lower polymer concentration. Hence, 
particles produced using a lower polymer concentration are moderately dissolved and 
not completely dried when they touch the collector therefore leading to irregular or 
semi-solid, flat particles that solidify fully only after deposition (Bock et al. 2011).  
Moreover, chain entanglements also have an effect on the physical properties of 
particles produced. Solutions with lower concentrations contain less entanglement 
possibilities for polymer chains. However, at higher solution concentrations, the same 
available hydrodynamic volume will contain more polymer chains thus increasing 
chain entanglements. It has been shown previously that if the evaporating droplets 
have an adequately entangled network before reaching Rayleigh’s limit, the particles 
produced will be spherical in nature and also monodispersed. Since the entangled 
 network will help stabilise the droplet against rupture therefore also reducing the 
possibility of smaller and more irregular offspring particles being produced (Almeria 
et al. 2010). 
A similar trend was witnessed for microbeads produced using AAJ. Particles produced 
with 0.5% and 1% concentration solution took the form of irregular structures. 
Whereas, particles produced using 1.5% and 2% concentration solution started taking 
up a spherical shape. This again can be explained using the aforementioned 
mechanisms; polymer diffusion during evaporation, solvent evaporation during 
droplet moving from exit orifice to the collector and finally the number of chain 
entanglements increasing with increasing polymer concentration. Hence, spherical 
particles are generated when a sufficiently entangled network is present before the 
Rayleigh’s limit is achieved by the droplets (Almeria et al. 2010). Another observation 
that was noted during the use of 0.5% and 1% alginate concentration was the consistent 
spitting at the exit orifice. This suggested that the jet produced was not stable as the 
entangled network was not adequate enough to stabilise the droplet against rupture 
due to the applied pressure force, hence giving rise to many secondary (offspring) 
particles, too. Research by Xie and Wang (2007) also concluded that the morphology 
of particles tends to become worse with a decrease in polymer solution concentration. 
The results gained through this experiment as highlighted in Table 4-2, supported this 
research as the standard deviation for samples produced using 2% (w/v) concentration 
was the smallest, suggesting that this sample produced was in fact the most 
homogenous and monodispersed. Due to this, it was decided to produce the 
operational maps for microbead sizes (Section 4.2.2) using this concentration. 
 
 Concentration (%) Microscopic Images Observations 
0.5 
 
Constant spitting observed at 
the exit orifice. Multiple 
jetting witnessed and 
irregular shaped structures 
produced  
1 
 
Unstable aerodynamic 
conditions such as constant 
spitting at the exit orifice. 
Irregular shaped structures 
produced  
1.5 
 
Beads take a slightly more 
spherical shape but possess 
tails  
2 
 
Beads much more spherical 
in shape however some 
beads with tails still present  
 
Table 4-2: Comparison of microbeads produced using four different alginate 
concentrations – 0,5, 1, 1.5 and 2%. The corresponding visual representation of 
microbeads produced (magnification x40, Leica MZ10F) via AAJ and observations 
noted. Scale bar represents 40 µm 
 
 
 4.2.2 Effect of process parameters on the size of microbeads produced 
using electrospraying and aerodynamically assisted jetting 
The first and main process parameter analysed was flow rate. For both processing 
methodologies it was seen that an increase in flow rate showed an increase in the 
microbead size, too (Figure 4-3 and 4-4). This can be owed to the fact that at lower 
flow rates, a smaller volume of solution is ejected from the needle tip and therefore 
electrohydrodynamic forces have insufficient solution to act on (Pancholi, Stride, and 
Edirisinghe 2008). It was also seen that with a gradual increase in the flow rate at a 
constant voltage, only a slight increase in microbead size is seen due to the electric 
field strength not being capable of breaking the jet formed by the constantly increasing 
ejected solution as there is an insufficient amount of charged ions present (Zargham 
et al. 2012). 
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 Figure 4-3: The effect of flow rate (ml/hr) on the mean diameter (µm) of beads 
produced using ES (n=5). While flow rate was varied from the range 10 – 60 ml/hr, 
the voltage was kept constant at 4 kV 
                               
                                                   
Figure 4-4: A visual representation of microbeads produced using AAJ at the 
following parameters A) flow rate: 60ml/hr, pressure: 0.1 bar B) flow rate: 60ml/hr, 
pressure: 0.5bar C) flow rate: 20ml/hr, pressure: 0.1 bar D) flow rate: 20ml/hr, 
pressure: 0.5bar (n=5). Images taken using optical microscopy (MZ10 F, Leica 
microsystems) at magnification x 80  
 
  
Figure 4-5: Graph showing the effect of flow rate (ml/hr) on the mean diameter (µm) 
of beads produced using AAJ (n=5). Flow rate varied from the range 10 – 60 ml/hr 
while the pressure was kept constant at 0.8bar  
 
 
As clear from the trend witnessed in Figure 4-5, flow rate had the same effect on 
microbeads fabricated using AAJ as it did on ES fabricated ones. An increase in flow 
rate showed an increase in the mean size of microbeads. This is because for the same 
amount of aerodynamic forces, there is now more solution present. Hence, the same 
mechanism that applies for electrospraying and flow rate, can be applied here too. This 
trend is supported by previous research (Xie, Marijnissen, and Wang 2006) which also 
suggests that the solution flow rate is one of the dominant factors which contribute to 
particle size, and also observed the trend of particle size decreasing with decreasing 
flow rate.   
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 It was also noted that below 10 ml/hr, backflow was observed. Due to the low flow 
rate, the corresponding low applied pressure did not allow for jetting to take place. 
The pressure instead gave rise to the formation of bubbles in the silicone tubing 
holding the flow of the polymer media thus resulting in back flow.             
On the other hand, the second process parameter affecting microbead size for 
electrospraying; ‘applied voltage’ had the opposite effect on size of microbeads 
fabricated. The microbead size decreased with an increase in voltage (kV) as seen in 
Figure 4-6. The effect of applied voltage on the flowing liquid is the induction of 
charge on the surface of the droplet generated. The charge is accelerated towards the 
apex of the droplet which helps the formation of a jet which eventually (depending on 
the level of voltage applied) breaks up into main, secondary and/or satellite droplets 
(Gomez and Tang 1994).  Hence, as the voltage increases the meniscus formed at the 
needle tip elongates further due to the electrostatic forces present, causing smaller 
droplets to detach from the meniscus.   
 
Figure 4-6: The effect of voltage (kV) on the mean diameter (µm) of beads produced 
using electrospraying (n=5). Voltage varied from the range 2 – 12 kV while flow rate 
kept constant at 40 ml/hr 
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Figure 4-7: The effect of pressure (bar) on the mean diameter (µm) of beads produced 
using aerodynamically assisted jetting (n=5). Applied pressure varied from the 
range0.1 – 1bar while flow rate was kept constant at 40 ml/hr  
 
The second process parameter known to have an effect on microbead size produced 
using AAJ is applied pressure. It was seen that an increase in applied pressure also 
showed a decrease in the size of microbeads produced. Hence, for a constant flow rate 
but an increasing external applied pressure, the pressure gradient becomes higher 
which eventually breaks the jet up into smaller and smaller droplets. Once the liquid 
jet leaves the exit orifice, the pressure gradient - which at this point is acting as the 
main accelerating force in the axial direction - will vanish and the jet evolves under 
the influence of the viscous shear stresses exerted by the gas flow on the jet surface 
and the capillary stress (Ganan-Calvo and Barrero 1999). The standard deviation seen 
in figure 4 -7 is due to the pressure gradient not being enough to break the jet up into 
monodispersed particles, which means more offspring particles are present now due 
 to the liquid being jetted under unstable conditions. Arumuganathar et al. (2007) 
concluded that for a constant flow rate, if the pressure was too low, the medium 
flowing through the needle will be drawn out but not be jetted under stable conditions 
due to varied aerodynamic force flows. This tends to give rise to a more polydispersed 
sample with unwanted residues as seen in Figure 4-8. 
 
 
Figure 4-8: Microscopic images (A – B) showing samples produced using a constant 
flow rate of 40 ml/hr but varying applied pressure A) pressure: 0.1 bar B) 0.4 bar. 
Graph showing the relationship between pressure and standard deviation of samples 
produced. The standard deviation very clearly decreases with an increase in pressure 
showing the formation of a more monodispersed sample (n=5). The flow rate was kept 
constant at 40 ml/hr while the pressure varied from 0.1 – 3 bar  
 
 Lastly, the effect of collecting distance was assessed to see if it had any consequences 
on the size of microbeads produced. It was seen that an increase in distance also 
increased the particle size. This can be owed to the decreased strength of the electric 
field at larger distances. The strength of electric field is dependent upon the applied 
voltage divided by the distance of collection. Therefore, at these smaller distances the 
role of solvent evaporation becomes negligible when compared with that of the electric 
field. However, it was also noticed that with an increase in distance, the morphology 
of particles started changing too. As seen in figure 4-9 below, the particles started 
becoming less and less spherical. This can be attributed to solvent evaporation before 
the droplet reaches the collector plate.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
                                                              
  
 
 
 
 
 
 
 
 
 
Figure 4-9: Optical images of samples produced using ES with collecting distance A) 
8 cm B) 18 cm, and AAJ with collecting distance C) 8 cm D) 18 cm D) AAJ. The scale 
bar represents 200 μm. Graphs E and F showing the relationship between mean size 
and distance between needle and collector - ES and AAJ respectively). Both the 
graph’s show a positive correlation as an increase in distance also increases the mean 
diameter of microbeads produced (n=5) 
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 4.3 Operational size maps  
An intensive sizing study was carried out and operational maps were created which 
will be able to highlight alginate microbead size produced for every appropriate 
combination of flow rate (ml/hr) and applied voltage (kV)/applied pressure (bar). 
 
Figure 4-3: Operational size map of 2% alginate microbead sizes (μm) produced 
using ES, created for each appropriate combination of flow rate (ml/hr) and applied 
voltage (kV)(n = 5) 
 
 Parameter selection was carefully carried out. For the ES process, it was not deemed 
suitable to go further than 60 ml/hr since beyond that, microbeads with tails were being 
generated which are not suitable for vacuum packing in the crevices of feed pellets. 
Voltage was not assessed beyond 12 kV simply because characteristics of discharge 
became apparent through electric sparking. This was due to a sufficiently high electric 
field being created. Electric field being a function of voltage and distance; 
 
𝐸 =  𝑉 𝑑⁄  
 
where E is the electric field, V is the applied voltage and d is the distance between the 
two electrodes. This could not have been avoided since it was critical to keep all other 
parameters constant e.g. distance between needle and electrode and distance between 
needle and collector while only altering the flow rate and voltage. 
 
  
Figure 4-4: Operational size map of 2% alginate microbead sizes (μm) produced 
using AAJ, created for every appropriate combination of flow rate (ml/hr) and applied 
pressure (bar) (n = 5) 
 
 
The parameter selection of the operational map created for microbeads produced using 
AAJ was as follows; flow rate was assessed till 60 ml/hr to keep in accordance with 
the ES operational map. Pressure was not assessed beyond 3 bar as beads sized 10 µm 
were achieved at that point and most pore sizes in industrial feed pellets range from 
10 µm to 500 µm (Klaric, 2015).  
 The range of microbead sizes produced through ES using the chosen parameters was 
250 – 2500 µm (Figure 4-3). Whereas microbeads produced using AAJ ranged from 
20 – 80 µm (Figure 4-4). This is not to say that ES and AAJ can only produce alginate 
microbeads within these specified size ranges as this range is solely specific for the 
chosen parameters in this study.   
 
 
Figure 4-5: Bar chart comparing the mean sizes of microbeads produced using ES 
and AAJ at a given flow rate (ml/hr) (n=3) 
 
4.3.1 Inclusion of TiO2 in microbeads to act as a stand in for potential 
API’s  
The operational maps shown in Figure 4 - 3 and 4 - 4 were of empty alginate 
microbeads. The final objective of this project however is to have biological 
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 components (mainly vaccines) encapsulated within these microbeads. Since vaccines 
are quite an expensive biological component, it was deemed suitable to use an 
appropriate marker that would perhaps act as a stand in for a vaccine in order to see if 
and how the encapsulation of a material may affect the size of microbeads produced 
using the two fabrication methodologies; ES and AAJ.  
TiO2 is an inert and indigestible marker that has been used in various studies to assess 
the digestibility of diets, mostly in ruminants (Titgemeyer et al. 2001). In order for 
encapsulation to successfully occur, the marker had to be smaller than the micron 
range. TiO2 particles were sized using Transmission Electron Microscopy (TEM) and 
as seen in Figure 4-6 the particles were found to be in the nano range.     
 
 
 
 
 
Figure 4-6: TEM images obtained of TiO2 particles showed that their sizes ranged 
from 50nm – 200 nm (Magnification x 100,000). Scale bars represent 200 nm 
 
Different concentrations of TiO2 in 2% alginate were then assessed; 0.5%, 1%, 1.5% 
and 2%. It was seen that stable jetting was only achieved with the use of 2% TiO2 in 
2% alginate. Stable jetting is significant since it allows for a monodispersed sample to 
be produced. Hence, the use of 2% TiO2 in 2% alginate was seen appropriate for the 
production of microbead size operational maps. The same parameters that were used 
A. B. C. 
 for only 2% alginate microbeads were used for the TiO2 inclusive maps, too. Since 
TiO2 was in powdered form, a concern was the onset of ‘sedimentation’ once 
incorporated into alginate solution. However, a sedimentation test was carried out 
where 2% alginate solution + 2% TiO2 was observed for 48 hours. No visible 
sedimentation of TiO2 particles was observed during this period of time. 
 
 
 
Figure 4-7: Operational map of 2% alginate and 2% TiO2 microbead sizes(μm)  
produced using ES, created for each combination of flow rate (ml/hr) and applied 
voltage (kV) (n=5) 
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Figure 4-8: Operational map of 2% alginate and 2% TiO2 microbead sizes (μm) 
produced using AAJ, created for each combination of flow rate (ml/hr) and applied 
pressure (bar) (n=5) 
 
A slight increase in microbead size ranges was witnessed for beads produced using 
both fabrication methodologies as seen in Figures 4 - 7 and 4 - 8. However, the effects 
of process parameters followed the same trend. An increase in flow rate increased the 
size of microbeads produced (at constant applied voltage or pressure) while an 
increase in either voltage or pressure decreased the size of microbeads produced (at a 
constant flow rate). 
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Figure 4-9: 2% Alginate + TiO2 microbead samples fabricated through AAJ using 
flow rate: 60 ml/hr at varying pressures A) Pressure: 0.1 bar B) 3 bar. It can clearly 
be seen that bead size drastically decreased with increasing pressure. Further 
supported by microbead sizing which revealed the mean diameter of sample A) 1232 
µm and B) 334 µm. Both images taken at x10 magnification (n=5). Scale bar 
represents 250 (μm) 
 
 
 
 
Figure 4-10: 2% Alginate + TiO2 microbead samples fabricated through ES using 
flow rate 20 ml/hr at varying voltages A) Voltage: 4 kV B) 8 kV. It can clearly be seen 
that bead size drastically decreased with increasing voltage. Further supported by 
microbead sizing which revealed the mean diameter of sample A) 1232 µm and B) 334 
µm. Both images taken at x10 magnification (n=5). Scale bar represents 250 (μm) 
 
These results will be further supported by data gained in Section 6.2.1 where 2% 
alginate + TiO2 microbead sizes will be compared with 2% alginate + IPNV antigen, 
 to see whether the changes in size ranges remain constant to support the use of TiO2 
as a cheap and readily available stand in for vaccine for size distribution studies.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4.4 Morphological characterisation  
As mentioned earlier, irregular shapes have been associated with protrusion of any 
type of encapsulated component. Therefore, the ideal shape of microbeads needs to be 
spherical. Optical microscopic images of alginate microbeads generated using four 
different fabrication methodologies were obtained. Even though the microbead shapes 
were quite clearly etched out, and showed a perfectly spherical shape - as can be seen 
in Figure 4-11 - the optical microscopy technology offers a fairly low resolution along 
with a smaller depth of field. 
 
 
 
 
Figure 4-11: Optical microscopic images of 2% alginate microbeads fabricated using 
A) ES B) Manual deposition C) AAJ D) ES in combination with AAJ. Microbeads were 
seen to be spherical in shape regardless of the processing methodology used. Scale 
bar represents 200μm 
 
 The most commonly used technologies to assess the morphological characteristics of 
particles are AFM and SEM. However, both come with their own drawbacks.  
Atomic Force Microscopy (AFM) is a technology that is known to image almost any 
type of surface, both conducting and semiconducting. This is done by using a 
cantilever with a sharp probe (diamond or gold coated tip) that scans the sample’s 
surface. However, since the cantilever drags across the sample surface in order to 
operate, it is not a viable option to assess alginate microbeads that are gel-like and 
therefore extremely vulnerable to damage and rupture.   
Scanning Electron Microscopy (SEM) is another commonly used process to obtain 
insight on surface morphology. However, this technology requires surface stain 
coating (usually with an ultrathin coating of an electrically conducting material, 
normally gold) in order to avoid scanning faults and image artefacts. Therefore, SEM 
is limited to solid, inorganic samples which are capable of handling vacuum pressure 
(Anderson., 2012). Surface coating of alginate microbeads is hence not a possibility 
since that process will undeniably alter the bead’s surface morphology. Since alginate 
is a hydrogel, its hydrophilic structure means they have the capability of holding large 
amounts of water in their three-dimensional networks (Ahmed 2015).   
This means that taking a microbead out of the cross-linking solution for a long period 
of time for the surface morphology assessment procedure (including coating) may 
cause distortions such as shrinkage. Freeze-drying is a process that helps reduce 
shrinkage which occurs when a wet specimen dries through evaporation. This is 
because freeze-drying causes fast sublimation of frozen water from the alginate matrix 
thus resulting in the production of pores in areas where ice crystals were formally 
situated, without any time for shrinkage. This was observed when SEM was carried 
 out on electrosprayed alginate microbeads. The samples were clearly not able to 
withstand the vacuum pressure present as the microbeads severely dried out as seen in 
figure 4 - 2.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4-12: SEM images of 2% alginate microbeads produced using electrospraying 
Scale bar represents A) 10 µm and B) 100 µm 
 
However, non-conducting samples can be imaged without coating using specialised 
SEM instrumentation known as the ‘Environmental SEM’ which operates at a much 
lower vacuum. 
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Figure 4-13: ESEM images of 2% alginate microbeads produced using A) ES B) 
Manual deposition C) AAJ D) ES in combination with AAJ. Each microbead was 
mounted onto a stub, individually and observed under ESEM operated at 10kV.  2 
different magnifications used; x160 (A and C) x125 (B and D) 
 
Due to constant shrinking of the specimen and also desiccation and rupture in some 
cases, it wasn’t possible to obtain absolutely accurate images of the original surface 
morphology of the microbeads using ESEM and a wrinkled morphology was observed 
on the surface of all specimen. However, it is clear that ESEM images show similar 
topographical variations present on each specimen’s surface. The same irregular 
surface morphology for all four microbeads was observed even though they were 
produced using four different fabrication methodologies. Hence, it can be suggested 
that microbeads produced using ES and AAJ had the same morphological traits as 
those produced through manual deposition. 
A. B. 
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 4.5 Mechanical Testing 
Alginate gels are known to degrade slowly as the mechanical properties of these gels 
are altered with time (Langer et al., 2006). Tablets, beads and capsules are usually 
assessed for strength/deformation through a compression test, as illustrated in figure 
4-14, this test determines the behaviour of a material under a crushing load.  Therefore, 
it was deemed feasible to define mechanical stability of microbeads through two 
parameters; strength and elasticity. The strength will be measured by quantifying the 
force required to compress a microbead while elasticity being dependent upon the time 
required to compress the specific bead to a set value. The combination of these values 
will be able to determine the success or failure of these microbeads in vivo. 
 
 
 
 
 
Figure 4-14: The geometry of a sample tends to change as friction is produced at the 
test interface. During the compression test a sample will get crushed/squashed in one 
direction while remaining unrestrained in the other two directions 
 
Previous research states that both strength and elasticity are significant factors for the 
functional survival of cells as far as in vivo application is concerned (Stabler et al. 
2001). According to (Morch et al. 2006) the mechanical stability of beads is 
determined by alginate concentration and the type of gelling cation applied. Hence the 
sample 
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 mechanical testing study was divided into three main objectives; to assess the effect 
of alginate concentration on the strength of microbeads, to see the effect of varying 
cross-linking agents and lastly to determine the effect of microbead fabrication 
methodologies on the strength of these microbeads. 
Microbeads tested were all spherical in shape since irregular shapes have been 
associated with protrusion, which is unsuitable for cell encapsulation for 
immunoprotection (DeVos et al. 1996). This can be applied to other biological 
compounds as well such as vaccines in this particular case. 
 
4.5.1 Effect of alginate concentration on mechanical stability 
Results gained in this study show that compression is influenced by the concentration 
of alginate solution used. Figure 4-15 (A) shows a positive correlation between 
solution concentration and force applied. This means that a microbead produced using 
a more concentrated solution e.g. 2% will also need a higher amount of force to be 
applied for the microbead to reach 60% deformation i.e. 10.7g as compared to a bead 
produced using 0.6% alginate solution which will require less than half the force i.e. 
3.7g to reach the same level of deformation. The time required to compress the 
microbeads was also seen to increase linearly with the concentration of alginate used 
to produce the microbead. For example, 0.6% concentration solution reached the 60% 
deformation limit at 63 seconds while a bead produced using 2% alginate solution 
reached the same amount of deformation in 121 seconds. Hence suggesting that a 
microbead produced with a more concentrated solution is more mechanically stable. 
  
 
Figure 4-15: Graph presenting the relationship between alginate concentration (%) 
and  A) the force required to compress the microbead till it reaches 60% deformation 
and B) time required to compress the microbead to 60% deformation. Size of 
microbead and time of gelation were kept constant throughout (n=5) 
 
 
The viscosity of an alginate solution increases with higher concentrations of alginate 
(Chan et al. 2009). A more concentrated and viscous bead will contain more polymer 
chain entanglements within itself, which will therefore require a higher amount of 
force to overcome in order to reach a given level of deformation. These results were 
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 also supported by previous research, namely Devi et al. (2010) who also reported an 
increase in bead strength with increased concentration of alginate solution. This trend 
was observed for alginate microbeads cross-linked using SrCl2 and BaCl2, as well. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-16: Representation of raw data acquired using the TA.XT Plus Texture 
analyser software version 6.0. Force (g) against time (sec) graph. The 2 sets of data 
represent the mechanical strength of microbeads produced using 0.6% alginate and 
1.6% alginate (n=5) 
 
 
To make sure it was only the varying concentration affecting the strength of 
microbeads and not other variables, it was made sure that all the microbeads produced 
were kept at a consistent size and also kept in the cross-linking solution for a set time, 
each. Research suggests that both these factors will otherwise have an effect on the 
mechanical stability of beads (Vaithilingam et al. 2011). While the effect of size will 
0.6% alg 1.6% alg 
 be discussed later in this thesis, the consequence of altering the time an alginate 
microbead is kept in contact with cross-linking solution (also referred to as gelling 
time) can be explained as follows; alginate creates junction zones when it comes in 
contact with a cross-linking agent, an increase in gelling time will also increase the 
number of junction zones until a saturation point is achieved. Since unzipping these 
junction zones is a co-operative process, when gelling time increases, more and more 
cations take part in the formation of junction zones. This also increases the 
susceptibility for uncoupling in the junction zones (Zhang, Daubert, and Foegeding 
2007). Bhujbal et al. (2014) also supported this mechanism by reporting that an 
increase in gelling time decreases the mechanical strength of beads. 
 
4.5.2 Effect of varying cross-linking agent on mechanical stability 
Since alginate has an affinity towards positive cations, cross-linking agents usually 
used in order to form alginate gel’s are; CaCl2, SrCl2 and BaCl2. Figure 4-17 showed 
that microbeads cross-linked using BaCl2 required the most amount of force to 
compress (average force = 25g), while SrCl2 required the least (average force = 10g). 
However, the time required to compress SrCl2 beads was found to be a little higher 
(average time = 125 seconds) compared to the beads cross-linked with calcium 
(average time = 115 seconds) or barium (average time = 110 seconds). Therefore, 
microbeads cross-linked with BaCl2 appeared to be stronger with decreased elasticity 
while one’s cross-linked with SrCl2 showed the highest elasticity with a decrease in 
strength. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-17: Bar chart showing relationship between the type of cross-linking 
solution used and A) the force required to compress beads to 60% deformation 
(***p<0.001, *p<0.05, n = 5) and B) the time it takes for the beads to reach 60% 
deformation once compression is applied (n = 5). Time for gelling with cross-linking 
solution as well as the size of microbead was kept constant. Microbeads fabricated 
manually and average bead size was 2 mm 
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 These results show that mechanical stability of microbeads is in fact affected by the 
kind of cross-linking solution used. In the case of divalent cations, the ‘egg box’ model 
shows that the cations bond with the blocks of alginate polymers in a two-dimensional 
planar fashion. The extent of binding increases with an increasing ionic radius. It has 
been reported that Ba2+ cations with larger ionic radius can form a tighter structure 
compared to Ca2+ cations with a smaller ionic radius since Ba2+ cations are expected 
to take up a larger space between the blocks of alginate polymers resulting in a tighter 
arrangement of cross-linked alginate polymers (Kaklamani et al. 2014).   
The minimum length of G-G blocks needed for cross-linking decreases with 
increasing affinity of cations for alginate. As mentioned before, Sr2+ binds to G-G 
blocks only, Ba2+ binds to G-G and M-M blocks while Ca2+ binds to G-G and M-G 
blocks. This binding pattern lets Ca2+ and Ba2+ cross-linked beads form two times as 
many junctions as compared to Sr2+. 
The stability of beads is heavily dependent upon the type of cation applied for cross-
linking. This effect is caused by the varying chemical properties of the applied cations 
such as their atomic number, association constant, ionic radius, ionic strength and 
chemical affinity towards alginate (Juarez et al., 2014). This probability and specificity 
of binding patterns explains why it takes less force to compress Sr2+ cross-linked 
beads. However, the time required to compress these beads till they reached 60% 
deformation was slightly more for Sr2+ cross-linked microbeads which shows the 
elastic nature of Sr2+ beads while highlighting the more brittle nature of Ba2+ 
microbeads.   
 
 
 4.5.3 Effect of microbeads fabrication methodologies on their strength 
Figure 4 - 18 shows that beads deposited manually were the most mechanically stable 
since they required the highest amount of force to reach 60% deformation (mean force 
applied = 10g). While beads fabricated through AAJ required the least amount of force 
to reach the same level of deformation (mean force applied = 3.8g). It also took 
manually deposited beads the longest to reach 60% deformation (average time = 115 
seconds) while it took beads produced using AAJ and also those fabricated using both 
ES and AAJ in combination the shortest amount of time to reach the desired level of 
deformation (average time = 64 seconds). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-18: Bar chart showing A) force required to achieve 60% deformation (*p 
<0.05, n = 5) and B) time required to reach the same level of deformation for 
microbeads fabricated using four different fabrication methodologies; manual 
deposition, ES, AAJ and finally ES in combination with AAJ (**p<0.01, n = 5). 
Average bead size was 2 mm 
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 An explanation for these findings is that even though the gelling time with cross-
linking agent was kept constant, the sizes of microbeads produced using the four 
methodologies varied as highlighted in figure 4-19. The same trend in mechanical 
stability was observed when the cross-linking agent was changed from CaCl2 to SrCl2 
and BaCl2. Since the range of microbead sizes produced using AAJ can be almost ten 
times smaller than those produced through electrospraying, it was challenging to keep 
all the sizes at one constant range. Since the beads needed to be sized before they could 
be tested for mechanical properties it was deemed suitable to produce a sample with 
its homogeneity kept intact. The particles were kept as close in size as possible, for 
this reason only the offspring particles fabricated using AAJ were collected as they 
tend to be larger in size and could therefore be easily compared to the particles 
fabricated using ES.   
 
 
Figure 4-19: Bar chart highlighting the difference in microbead sizes produced using 
the four different methodologies assessed. (*p < 0.05, n = 5). Average bead size was 
2 mm 
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 Research shows that increasing the size of bead will also increase the stability of that 
bead. Since the volume of a bead is a function of its (radius)3, if the radius is halved 
the volume will be decreased to an eighth. Therefore, an increase in bead size will also 
increase both the force and time required to reach a certain level of deformation during 
a compression test (Bhujbal et al. 2014). As can be seen in figure 4-18, an increased 
microbead size shows an increase in both force and time required, too. An increased 
microbead size means an increase in the divalent ions that will eventually cross-link 
the alginate bead core therefore increasing the overall mechanical stability. Therefore, 
the decreased mechanical stability exhibited by microbeads produced through AAJ 
and ES in combination with AAJ is a function of their smaller radii as compared to 
manually deposited or electrosprayed microbeads that were in fact bigger in size.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4.6 Summary 
As stated in Section 4.1 the main aim of this chapter was to assess and optimise both 
ES and AAJ for their ability to fabricate alginate microbeads. An increase in polymer 
concentration was shown to create more homogenous beads that were also more 
spherical in shape. Effects of the governing process parameters on the mean bead 
diameters was also studied. It was concluded that for both fabrication methodologies 
- an increase in flow rate contributed to an increase in microbead size, too. Whereas, 
an increase in applied voltage considerably decreased microbead size. As far as 
applied pressure was concerned, an increase caused a substantial decrease in 
microbead size for beads fabricated using AAJ.     
Operational size maps were produced using MATLAB as seen in figures 4 - 3 and 4 - 
4. It was seen that ES possessed the ability to produce microbeads ranging from 250 
– 2500 µm while AAJ produced beads ranging from 25 – 60 µm for 2% alginate 
solution. Moreover, ES and AAJ were seen to produce microbeads ranging from 250 
– 2250 µm and 30 – 80 µm respectively, for 2% Alginate and 2% TiO2 – used as a 
vaccine stand in for this sizing study.  
As the final aim of this chapter, the mechanical stability of microbeads fabricated 
using ES and AAJ were studied. As seen in Figure 4 – 15, a positive correlation was 
witnessed between alginate concentration and force applied. 2% alginate solution 
required a higher amount of force – 10.7g – to reach 60% deformation as compared to 
beads produced using 0.6% alginate solution, which was seen to require only 3.7g 
applied force to reach the same exact level of deformation.    
 It was also seen that microbeads cross-linked with BaCl2 required the most amount of 
force (average force = 25g) to compress while SrCl2 (average size = 10g) required the 
least. However, the time required to compress SrCl2 beads (average time = 125 
seconds) was found to be slightly higher than that for both BaCl2 and CaCl2 (average 
time = 110 and 115 seconds, respectively). Therefore, it can be concluded that 
microbeads cross-linked with BaCl2 were stronger with decreased elasticity while 
SrCl2 showed the highest elasticity with decreased strength. Fabrication 
methodologies had negligible influence on microbead mechanical properties.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5.  Dissolution testing – observational and 
in vitro analysis  
 
 
5.1 Introduction and aims  
In order to gain a clearer understanding of the behaviour of a solid dosage form 
throughout the dissolution test, one of the primary objectives of this chapter was to 
analyse the dissolution process using optical microscopy as a tool for direct visual 
observation. The effects of polymer concentration, type of cross-linking solution and 
fabrication methodologies on microbead dissolution were studied.  
Following which the encapsulation ability of alginate microbeads was assessed by 
analysing their encapsulation efficiencies and dissolution properties. As the principal 
aim of this research was to characterise alginate microbeads as antigen delivery 
systems, it was deemed suitable for them to undergo in vitro dissolution testing. This 
furthers the development of an orally deliverable alginate system possessing the ability 
to deliver antigens to the distal intestine of A.Salmon while keeping their own integrity 
intact since successful oral delivery is only possible if the encapsulated antigen is 
protected from acidic and proteolytic degradation in the gastrointestinal tract of the 
fish.  
Moreover, in order for the encapsulated antigen to elicit an immune response, the 
antigen must first be able to release from the fabricated microbeads. Therefore, another 
primary objective of this chapter was to assess the release profiles of BD (Blue 
dextran) - model antigen - from alginate microbeads through a specifically tailored 
 dissolution test representative of the environmental conditions faced by A.Salmon 
particularly temperature as well as intestinal conditions such as pH.  
To further the understanding of the link between varying levels of encapsulation 
efficiencies and therefore release profiles, it was deemed appropriate to analyse the 
viscosities and molecular weights of the various types of alginates used in this section 
of the research.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5.2 Dissolution testing - Observational  
 
Dissolution is a process where mass transfer from a solid surface to the liquid phase 
occurs. Drug dissolution tests are routinely carried out in the pharmaceutical industry 
in order to provide significant information about drug release, clinical performance 
and bioavailability. It is employed throughout all phases of product release and 
stability testing. This is critical for drug release profiles as well as quality control 
purposes (Lee, Chan et al. 2006). A polymer’s behaviour during the process of 
dissolution can prove to be vital since an ideal drug delivery system will only provide 
the drug when and where it is needed and also just the minimum dose level required 
to produce the desired therapeutic effects (Miller-Chou and Koenig 2003).  
In order to protect the drug from harmful conditions in the body, it can be dispersed 
within a polymeric matrix. This system should be able to provide a programmable 
concentration – time profile that shows optimum therapeutic responses. Research has 
also shown that not only are polymeric drug carrier systems able to protect otherwise 
unstable drugs but also help increase residence time at the application site while 
enhancing the activity duration of drugs with a short half-life. This means that with 
the help of an ideal polymeric delivery system, compounds that would have otherwise 
been discarded and deemed useless can now be rendered effective (Miller-Chou and 
Koenig 2003).  
Polymer dissolution involves two transport processes; solvent diffusion and chain 
disentanglement. When an un-crosslinked amorphous polymer comes into contact 
with a thermodynamically stable compatible solvent, the solvent itself will diffuse into 
the polymer. This forms a gel like swollen layer, which is witnessed in the initial 
 moments of the dissolution process. After some time, the polymer will dissolve. There 
have also been reported cases where no gel layer is formed instead the polymer cracks 
(Miller-Chou and Koenig 2003).  Mass is lost through ion exchange of calcium which 
is then followed by the detachment of individual chains, this also results in a loss of 
mechanical stiffness over time (Augst, Kong et al. 2006). A cross-linked polymer on 
the other hand comprises of a structure joined in a three-dimensional lattice of 
polymeric materials through covalent or secondary bonding. The idea behind this 
approach is to induce the formation of a lattice surrounding drug molecules hence 
encapsulating them in a matrix (Hoffman 2012). As far as cross-linked matrix systems 
are concerned, drug release is governed by the process of degradation or swelling.  
Noyes and Whitney (1897) were the first to conduct and publish dissolution 
experiments. They set up glass cylinders submerged in vessels containing water and 
these cylinders were rotated at constant speed and temperature. In spite of the 
development of the in vitro dissolution process, the concept was not extensively used 
until early 1950s. Until then the in vivo availability of the drug was solely assessed 
through the disintegration of the tablet neglecting the dissolution process. In 1934, the 
Pharmacopeia Helvetica published the first official disintegration test for tablets. Even 
though this test was carried out using water at 37 ℃ as the medium and also 
incorporated periodical shaking, it was still quite modest in terms of procedural 
elements. A much more sophisticated method of testing was carried out in 1948 
(Filleborn 1948) where an artificial stomach was stimulated through in vivo conditions 
which included peristalsis, pH and the presence of food.  
The relationship between oral administration and drug dissolution was first explored 
by (Edwards 1951) it was suggested that if the drug absorption process from the GI 
tract was rapid then its appearance in the body can be attributed to the rate of 
 dissolution of the drug - aspirin - itself. Following this, (Nelson 1957) successfully 
related blood levels of orally administered theophylline salts to their in vitro 
dissolution rates. It was then realised that varying product formulations caused 
differences in the intensity, speed and duration of the drug response. Thus suggesting 
that drug bioavailability – the degree to which a dose of drug will reach circulation - 
is affected by the drugs dissolution behaviour. One study that supported this cause-
effect relationship was where various Digoxin formulations yielded up to sevenfold 
differences in serum digoxin levels (Lindenbaum, Mellow et al. 1971). This specific 
study motivated the FDA to implement comprehensive dissolution studies on various 
batches of digoxin tablets available in North America during 1972. The studies showed 
astounding differences in dissolution profiles of the varying digoxin products and 
concluded that the difference in bioequivalence stemmed from the varying dissolution 
rates. Similar situations like these lead to the initiation of developing official 
dissolution tests.  
The first USP (United States Pharmacopeia) apparatus 1 (consisting of the basket 
stirred flask test) was officially accepted as the dissolution test in 1970 - other 
apparatus’ have been developed since then and will be discussed in detail later in the 
chapter. However, the official guidelines for dissolution testing of solid oral dosage 
forms were first published in 1981 by the FIP (International Pharmaceutical 
Federation). These guidelines put forward an established approach to test an API 
(active pharmaceutical ingredient).  
The main aim in mind while designing an orally administered release formulation is 
for the gastrointestinal environment to have little or no effect on drug release rate. This 
happens to be quite challenging since the formulation will need to pass through quite 
a vast array of contrasting mediums throughout the gastro intestine. For example, the 
 optimum pH for digestive enzymes in the intestine of A. salmon has been reported to 
be 7.5 – 8.5 (Bucking and Wood 2009), while chyme pH ranges from 6.7 – 7.8 (Usher, 
Talbot et al. 1990). Even though commercial production of Atlantic salmon has been 
on-going for the past forty years, gaps regarding the physiological and biochemical 
characteristics of digestive processes in the intestine still exist (Krogdahl, Sundby et 
al. 2015). 
Observational analysis of the dissolution process helps detect any physical changes in 
an API. This can help guide the optimization of design and processing conditions as 
well as drug release from formulations.  
Over the years, various experimental techniques have been utilized to characterize 
polymer dissolution behaviour. Such techniques include gravimetry, interferometry, 
FT-IR imaging and optical microscopy. All these techniques have their own set of 
advantages and disadvantages. For example, gravimetry shows highly accurate 
frequency measurements but the variable viscoelastic properties exhibited by 
polymers can produce unwanted distortions. FT-IR imaging is able to produce real-
time analysis of the dissolution process but since no apertures are used in the set-up, 
the diffraction effects that normally affect resolution will not come into play using this 
methodology.  
Optical microscopy on the other hand, allows direct visual observation of the 
dissolution process. Moreover, when a slice of polymer is sandwiched between two 
glass slides, information about various stages of dissolution (solvent, gel and polymer 
layers) can also be received (Miller-Chou and Koenig 2003). Even though this method 
is limited to the micrometre scale, it does not prove as a hindrance in this study since 
the microbeads assessed here are all in the micrometre range, too. Since optical 
 microscopy has the ability to provide significant information into the behaviour of 
polymers in contact with solvents, this methodology was chosen for the assessment of 
empty alginate microbeads.  
The rate of dissolution is dependent on various factors such as; the nature of solvent 
and solute, particle size, temperature and/or mixing. Therefore, the dissolution study 
carried out in this part of the research - based around observational findings - was 
divided into three main objectives; the effect of solution concentration on dissolution 
rate, the effect of cross-linking agent on dissolution rate, the effect of fabrication 
methodologies of beads on dissolution.   
 
5.2.1 Effect of solution concentration on microbead dissolution  
Increase in the concentration of alginate solution means an increase in the mass of 
alginate and a decrease in the volume of water present in the solution. The gradual 
absence of water whilst increasing the mass of polymer in the solution suggests an 
apparent increase in the viscosity of the solution as well as the overall molecular 
weight of the bead produced using that solution. For example, 1.6% final concentration 
of alginate solution will be more viscous than 0.2% due to the increase in mass of 
alginate in the former solution.   
As seen in Figure 5-1 it can clearly be observed that there is a positive correlation 
between dissolution time and concentration since an increase in concentration of 
alginate solution increases the dissolution time too. Hence, the higher the mass of 
alginate possessed by the microbead, an increased interaction takes place between the 
cross-linking agent and more bonds are formed. This ends up increasing the overall 
dissolution time as it takes longer to break the increased amount of bonds present.  
  
Figure 5-1: Effect of alginate concentration (%) on dissolution time (mins). Ten 
different concentrations were assessed; 0.2, 0.4, 0.6, 0.8, 1, 1.2, 1.4, 1.6, 1.8 and 2% 
(n=5). Microbeads fabricated manually, average size 2 mm 
 
Figure 5-2 shows that within a set time period i.e. 10 minutes in this case, the bead 
produced using 0.2% solution completely dissolved. However, within the same time 
period it was seen that the bead produced using 2% solution was only able to dissolve 
partially. The complete dissolution of this particular bead took 26 minutes. The same 
trend was witnessed for microbeads cross-linked using SrCl2 in order to assess whether 
the trend witnessed was not just constricted to the CaCl2 cross-linker.  
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Figure 5-2: Time lapse images of the dissolution of microbeads produced using A) 
0.2% solution and B) 2% polymer solution over the duration of ten minutes, using 
optical microscopy. Microbeads fabricated manually, average size 2 mm. Scale bar 
represents 200 μm 
 
This trend is supported by previous research (Parsonage, Peppas et al. 1987) which 
suggests that dissolution is a process dictated by chain disentanglement dependent 
upon polymer molecular weight. Hence, larger molecular weights yield higher levels 
of disentanglement, which is why it takes a longer time for the dissolution of highly 
concentrated solutions to occur. Ueberrieter’s early work also supported this 
phenomenon as he also reported a decrease in dissolution rate with increased polymer 
molecular weight (Ueberrieter., 1968).  
Tapia, Ormazabal et al. (2007) analysed the erosion, swelling and dissolution 
behaviour of diltiazem hydrochloride release matrices based on alginate-gelatin 
mixtures. It was found that tablets produced using 20% polymer solution (gelatin-
alginate) had lower rates of swelling and the disruption of these tablets occurred fairly 
A. 
B. 
t = 2 mins t = 6 mins t = 10 mins 
t = 2 mins t = 6 mins t = 10 mins 
 quickly too, when compared to tablets produced using 50% polymer solution. These 
tablets ended up demonstrating a noticeable increase in the degree of swelling. 
However, the erosion process for these tablets was quite fast too. The high ion 
concentration present in a 50% polymer solution is responsible for increased water 
flow into the gel due to osmosis which then results in an increase in swelling. 
Moreover, research (Brondsted and Kopecek 1992) has suggested another important 
factor affects gel swelling behaviour: the repulsion of charges present along the 
polymer chain.  
However, as far as using alginate beads as drug carrier systems is concerned, it should 
be noted that according to previous research, the concentration of both the alginate 
solution used along with the concentration of the cross-linking agent have an effect on 
drug release rate. Mandal, Bostanian et al. (2001) concluded that drug release is 
directly proportional to the polymer concentration used to prepare the bead and an 
increase in CaCl2 (used as the cross-linking agent) concentration decreased the rate of 
drug release. Rajinikanth, Sankar et al. (2003) suggested that the rate at which the drug 
diffuses from the alginate matrix decreases as the concentration of CaCl2 solution 
increases, since there is greater cross-linking that tends to take place with the alginate. 
 
 
5.2.2 Effect of cross-linking agent on dissolution  
One of the most important features of alginate is its ability to efficiently bind with 
divalent cations leading to eventual hydrogel formation. Research suggests that the 
 affinity of alginate towards various divalent ions tends to decrease in the following 
order; Pb > Cd > Ba > Sr > Ca > Co.  
This effect of enhanced aggregation of alginate structure with divalent cations can be 
attributed to a mechanism known as ‘gel bridging’. In the presence of these cations, 
alginate will undergo bridging as they form gels. The integrity and efficiency of the 
gel formed will be dependent on the type of divalent cation present. The divalent cation 
for which alginate has a higher affinity, will form the gel faster and also allow for 
enhanced aggregation on a higher level (Chen, Mylon et al. 2007). In order to assess 
whether the cross-linking agent was the only variable affecting the dissolution rate of 
microbeads in this study, it was made sure that the gelling time (time spent in contact 
with cross-linking agent by microbead) was kept constant throughout. This is because 
during gel formation uronic molecules in alginate will bind to cations and the 
constitutive uronic molecules in alginate will create junction zones within the gel (Thu, 
Bruheim et al. 1996). With an increase in gelling time, the number of junction zones 
present in the gel will increase, too, until saturation of the gel is achieved (Zhang, 
Daubert et al. 2007).   
Results obtained from this study, supported the proposed order to affinity as it was 
seen that microbeads tend to show complete dissolution when cross-linked with CaCl2, 
only partial dissolution with SrCl2 and no dissolution at all when cross-linked with 
BaCl2. As seen in Figure 5-3 it took 25 minutes for a microbead cross-linked using 
CaCl2 to completely dissolve, but in that same time period the microbead cross-linked 
using SrCl2 was only able to partially dissolve. Whereas, the microbead cross-linked 
with BaCl2 showed no dissolution in that time period at all. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-3: Optical microscopy time lapse images showing microbeads produced 
using 2% w/v alginate solution and cross-linked with A) CaCl2, B) SrCl2 and C) BaCl2. 
Images acquired over time points t = 5, 10 and 25 mins. While it took 25 minutes for 
the microbead cross-linked with CaCl2 to fully dissolve, the microbead cross-linked 
using SrCl2 was only able to partially dissolve in that time whereas the one cross-
linked with BaCl2 showed no dissolution at all. Microbeads fabricated manually, 
average size 2 mm. Scale bar represents 500 μm 
 
Binding studies (Morch, Donati et al. 2006) reveal that different block structures in 
alginate will bind the ions to different extents; Ca2+ binds to G- and MG- blocks, Sr2+ 
binds to G blocks solely and Ba2+ binds to G – and M- blocks.   
(Smidsrod 1973) used both light scattering and viscosity studies to conclude that the 
stiffness of the chain blocks increased in order of MG<MM<GG. Therefore, it takes 
longer for beads cross-linked using Ba2+ since it binds to both M and G blocks forming 
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 the most stable alginate structure. But Ca2+ only tends to bind with G and MG blocks 
in the entire alginate chemical structure, which is a fairly less efficient junction and 
therefore can be broken in a much shorter period of time. Since the type of alginate 
being used will alter the composition and ratio of M:G blocks present and therefore 
also have an effect on the dissolution rate, it was made sure that only one type of 
alginate (Protanal LF 10/60, food grade, BioPolymer, AS, Norway) was used 
throughout this study, in order for the results gained to be consistent and only in 
response to the type of cross-linking ion used.   
The results showed that none of the microbeads assessed using BaCl2 as the cross-
linking agent showed any dissolution at all. To confirm the eventual time it might take 
for an alginate bead cross-linked with BaCl2 to dissolve, a sample was kept under 
observation for 24 hours. Figure 5 - 4 shows no visible dissolution during the 24 hour 
time period either, hence supporting research that suggests Barium ions form the 
strongest gels with alginate. Therefore, it can be said, that the results gained from this 
study support the theoretical sequence of alginate affinity towards divalent ions i.e. Ba 
> Sr > Ca.   
 
 
 
 
 
Figure 5-4: Optical microscopy time lapse images of microbead produced using 2% 
w/v alginate solution, cross-linked with BaCl2, showed no dissolution over the 0 – 24 
hour observation time period. Microbead fabricated manually, average size 2 mm. 
Scale bar represents 500 μm 
 5.2.3 Effect of microbead fabrication methodologies on dissolution  
The final objective set for this observational dissolution study was to assess whether 
the process employed for the fabrication of the microbead will play a part in its 
dissolution rate. As seen in Figure 5 - 5, beads fabricated using AAJ and also the ones 
produced using ES in combination with AAJ had a shorter dissolution time as 
compared to the other two methodologies used. This can be contributed to the fact that 
these particular microbeads were also much smaller in size. Microbeads produced 
were kept at this particular size specifically in order to keep the homogeneity of the 
sample intact as well as for clear and concise visual dissolution observation. 
As seen in the scatter graph (Figure 5-5) below, the purple and red clusters 
representing samples fabricated using AAJ, and ES in combination with AAJ 
respectively, are very tight and spread closely. In comparison, beads fabricated 
manually and through ES were larger in size (almost double) and also had a wider 
spread. This can be contributed to the dissolution times of the beads and are not 
necessarily related to the size distribution. For manual and ES fabricated beads the 
range of dissolution times was larger due to their smaller surface area. It’s important 
to note that the overall dissolution range remains the same for both groups – 
ES/manual and AAJ/ES in combination with AAJ, hence suggesting that dissolution 
was in relation to particle size and not necessarily the fabrication methodology used.      
  
Figure 5-5: Scatter graph comparing microbeads produced using the four different 
types of fabrication methodologies, their respective dissolution times (mins) and sizes 
(µm) (n=5) 
 
The dissolution times of beads produced using ES in combination with AAJ and the 
one’s produced using AAJ on its own were much shorter in comparison to the 
microbeads produced using the other two methods. This is due to the fact that beads 
produced using these methodologies were in fact much smaller - almost half in size. 
This means that there is almost half the amount of polymer present for the same 
amount of cross-linking agent to act upon and create disentanglements with. Due to 
this, it takes less time for the dissolving agent to break the disentanglements formed, 
hence the shorter dissolution times.  
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 Figure 5-6 shows an electrosprayed bead and a manually deposited one. Both had a 
similar size range and therefore dissolution time. Whereas Figure 5-7 shows 
microbeads produced using AAJ followed by ES and AAJ in combination. Both beads 
were close to each other in size and also dissolution rate. To clearly see the relationship 
between bead size and dissolution time a bar graph was produced (Figure 5-8). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-6: Optical microscopy time lapse images of microbeads (2% w/v alginate) 
fabricated through A) manual deposition (D = 1290 µm) and B) electrospraying, (D 
= 1203 µm). Images acquired over time points t = 0, 10 and 25 mins. Scale bar 
represents 200 μm 
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 Figure 5-7: Optical microscopy time lapse images of alginate microbeads (2% w/v) 
fabricated through A) AAJ and B) ES in combination with AAJ. Scale bar represents 
200 μm 
 
 
 
Figure 5-8: Bar graph highlighting the relationship between microbead size (µm) and 
dissolution time (mins). It can be seen that with an increase in bead size, the 
dissolution time increased too (*p < 0.05, n = 5) 
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 The results did not show any substantial difference in dissolution rates for microbeads 
produced using the four different methodologies assessed in this study. The higher 
dissolution times for beads produced using electrospraying and manual deposition can 
be contributed to the fact that these beads were in fact larger in size, too. Suggesting 
that size is the most critical factor affecting dissolution rates.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5.3 Viscosity and Molecular weight 
To assess and analyse the difference between the molecular properties of different 
types of alginates, their corresponding viscosities and molecular weights followed by 
their encapsulation efficiencies as well as their release profiles were studied.  
Alginate viscosity is reported to play a role in influencing drug release pattern from 
alginate matrices (Liew, Chan et al. 2006), their size and also their encapsulation 
efficiency (Lee, Chan et al. 2006).   
Microbeads were produced using five leading grades of sodium alginates; Scogin 
LDH, MV, Manugel GHB, GMB and DMB – all FDA approved as pharmaceutical 
excipients. The test was carried out as described in Section 3.2.7 (Chapter 3). The 
obtained dynamic viscosity values were summarised in the histogram below.   
 
Figure 5-9: Histogram highlighting the average dynamic viscosity (Pa.s) of all five 
types of alginates at constant shear rate 101 1/s, with Scogin MV being the most 
viscous while Scogin LDH being the least (n=5) 
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Since the name codes of the alginate types themselves do not signify their viscosity 
grade, the measurements observed here can help classify them. It was seen that the 
experimental viscosities reported here correlated with the suggested viscosity trends 
on the product specification summaries provided by FMC biopolymers; where Scogin 
MV possesses the highest viscosity followed by Manugel DMB > GMB > GHB > 
Scogin LDH. These five samples reflect a range of varied viscosities with Scogin MV 
and Manugel DMB easily placed into the high/medium viscosity grades while 
Manugel GMB/GHB and Scogin LDH fall into lower viscosity grades.  
The extreme difference between viscosity levels found between Scogin MV - 1.1 Pa.s 
- and Scogin LDH - 0.21 Pa.s - highlights the fact that M:G ratio is perhaps not the 
only factor affecting viscosity, since both Scogin MV and LDH have an equal 61:39 
M:G ratio as seen in table 3-2 (Chapter 3). It should be noted that the solution’s 
viscosity is also heavily dependent upon its molecular weight (King 1994) while the 
alignment of M and G blocks present along with the polymer chain length contribute 
too  (Rustoen 2015). 
It was imperative to understand the differences in sample viscosities in order to 
interpret their encapsulation efficiencies. Therefore, it was deemed suitable to analyse 
their molecular weights. Alginate’s that possess similar M:G ratios have been found 
to have significantly different molecular weights (Lee, Chan et al. 2006). Once the 
dynamic viscosity of the samples was acquired using a rheometer, those values were 
converted to relative viscosity using;  
 
                                                    η𝑟 =  
η
  η0
                                                     (1) 
  
where ηr is the relative viscosity, η is the viscosity of the polymer solution and η0 is 
the viscosity of the pure solvent. The intrinsic viscosity can then be determined using 
the following equation (Haug and Smidsrod 1962);  
 
                                           [η𝑖𝑛𝑡𝑟] ≡  lim𝑐 → 0
(η𝑟−1)
𝐶
≡  lim
𝑐 → 0
ln
η𝑟
𝐶
                                      (2) 
 
where ηr is the viscosity of the solution which is relative to the solvent (and ηr -1 being 
equal to the intrinsic viscosity) and C is the concentration in g (100 mL)-1. Once these 
values were obtained for all samples, (ln η)/C values were plotted against 
concentration. From this plot, the data was extrapolated to zero concentration and the 
intrinsic viscosity of the solution was estimated.  
An estimate of alginate’s respective molecular weights (Mwt) – approximated to the 
nearest thousand - were then obtained using the following equation (Smidsrod and 
Haug 1968) (Smidsrod 1970) (Matsumoto and Mashiko 1990); 
 
                                              [η] =  2.0 𝑥 10−5 Mwt                                                  (3) 
  
It should be noted that the relationship between intrinsic viscosity and molecular 
weight acts as an estimation of the degree of polymerisation since it does not take into 
account the M:G ratio or block structure of the alginate (Johnson, Craig et al. 1997).  
 Another reason why it was significant to obtain the molecular weights of these 
alginates, is for the simple reason that sodium alginate undergoes cross-linking to form 
insoluble calcium alginate microbeads and for this reason their viscosities should have 
no direct effect on drug release (Lee, Chan et al. 2006). The influence of viscosity 
comes into play as far as microbead morphology and/or their sizes are concerned.      
Given the structural complexity of alginates, it is quite conducive to obtain information 
on viscosities and molecular weights that can be helpful for characterisation and 
comparison between the encapsulation efficiencies and release profiles of the five 
different sample sets, in order to understand their functionalities as leading products 
available in industry currently.  
 
Table 5-1: Summary of the values obtained for dynamic, relative and instrinsic 
viscosity of samples along with their respective estimated molecular weights (Mwt). 
The Mwt values can only be regarded as comparative due to the given approximate 
nature of the method. 
 
Alginate type Scogin MV Scogin 
LDH 
Manugel 
GHB 
Manugel 
GMB 
Manugel 
DMB 
Dynamic viscosity 
(Pa.s) 
1.1 0.21 0.35 0.45 0.86 
Relative viscosity 3.60 2.70 3.0 3.0 3.40 
Intrinsic viscosity 
(100 ml g-1) (dL/g) 
7.20 5.50 5.50 5.70 6.30 
Mol. Weight 
(g/mol) (Da) 
360,000 280,000 280,000 290,000 320,000 
 The Mw values obtained here fell into the range specified for the various types of 
commercially available sodium alginates, which can lie between the range 32,000 - 
400,000 g/mol (Lee and Mooney 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5.4 Encapsulation Efficiency  
Drug entrapment/encapsulation efficiency acts as a significant index for drug delivery 
systems. The ability of a drug delivery system to encapsulate an ample amount of a 
specific therapeutic agent is one of their most sought after properties (Nii and Ishii 
2005). Encapsulation efficiency (EE) of a microparticle depends upon various factors. 
Formulation factors such as calcium cross-linker concentration, alginate type 
(mannuronic and guluronic acid content) and concentration, drying time and drug to 
polymer ratio (Acarturk and Takka 1999).   
To assess the ability of alginate microbeads to encapsulate proteins, Blue dextran (BD) 
was used as a suitable API and the encapsulation efficiencies of various types of 
alginates was studied. EE was calculated based upon data obtained from a microplate 
reader. The following equation was used to calculate EE; 
 
EE (%) =      
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐵𝐷 𝑝𝑟𝑒𝑠𝑒𝑛𝑡 
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐵𝐷 𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙
 × 100   
 
where the total amount of BD present in microbeads is the amount of BD entrapped 
in the polymeric microbead while the total amount of BD loaded is the known 
theoretical BD content added to the microbead. Values were expressed as a 
percentage. EE was calculated through reference to a standard calibration curve, which 
was produced for all five alginate types. Values for the coefficient of determination 
(R2) were ≥ 0.9856 (Appendix 2).  
 Standard curves were generated by plotting BD concentrations of nine two-fold serial 
dilutions (1.0 mg ml-1) against absorbance. All five calibration curves produced were 
found to be highly reproducible and linear. The full test methodology carried out is 
highlighted in section 3.2.6 and a schematic representation of the test strategy is 
highlighted in figure 3-8 (Chapter3).    
 
 
 
 
 
 
 
 
Figure 5-10: Box plot summarising the encapsulation efficiencies in terms of 
percentage of the five types of alginates. Error bars represent the SD values. Summary 
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Scogin MV 91.60 
Scogin LDH 93.50 
Manugel GHB 92.40 
Manugel GMB 87 
Manugel DMB 84.5 
 of the EE% values reported for all five types of test alginates. Test was carried out in 
quintuplicates and values were averaged 
 
The EE% values were observed to be high for all five types of alginates, ranging from 
84.5(± 1.66) % to 93.50(± 1.19) %. These high EE% values obtained can be explained 
by the microbead fabrication technique used involving cross-linking. As the surface 
of the polymer and BD solution comes into contact with CaCl2, the divalent cations 
Ca2+ interact with the alginate’s gluronic residues giving rise to spherical gel 
microbeads instantaneously, while promoting BD to become acutely entrapped into 
the three-dimensional matrix of the ionically cross-linked alginate (Lee, Chan et al. 
2006). Other authors have also reported high EE% of BD in alginate beads (Kim and 
Lee 1992). The duration of this test can also be held responsible for the high levels of 
EE% values obtained. The microbeads were left to dissolve over a period of 24 hours 
which helped assess whether the microbeads are capable of releasing 100% of the 
encapsulated agent over time.  
It was observed that Scogin types tend to have a comparatively higher EE% as 
compared to Manugels. This could be attributed to Scogin types being rich in 
mannuronic acid residues which tend to produce softer and less porous microbeads 
possessing the ability to disintegrate with time eventually. Therefore, lower levels of 
porosity allow the matrix to hold a higher amount of drug within them. However, on 
the other hand, alginates that are rich in guluronic acid residues have a higher porosity 
which can contribute to a lower drug entrapment efficiency as drug leakage into the 
cross-linking solution can occur (Sankalia, Mashru et al. 2005).      
The molecular weight of Scogin MV was found to be 360,000 while Scogin LDH was 
lower at 280,000. This is paralleled by their EE% as Scogin MV at a higher Mw has a 
 lower EE% whereas Scogin LDH at a lower Mw has a higher EE%. The same trend 
was witnessed for Manugels as well where GHB possessed the lowest Mw and the 
highest EE% while DMB possessed the highest Mw and the lowest EE% suggesting 
that an increase in molecular weight contributes to a decrease in EE%. Furthermore, 
it is also to be noted that even though both Scogin LDH and Manugel GHB had 
varying M:G ratios, their molecular weights happened to be the same and therefore 
EE% were also found to be quite similar – 93.50% and 92.40% respectively.     
These findings were also supported by previous research by (Fu, Ping et al. 2005) who 
found that molecular weight of the polymer itself also had an effect on the 
encapsulation efficiency. They concluded that the EE% of PLGA microspheres 
produced using PLGA 15000, 20000 and 30000 were 62.75, 27.52 and 16.3% 
respectively. Thus suggesting that an increase in molecular weight leads to a decrease 
in EE%.  
These results happen to be interconnected with both the viscosity and size of the 
samples as well. An increase in alginate molecular weight can extend the total number 
of cross-linking sites between the guluronic acid units and Ca2+ therefore increasing 
the viscosity and also microbead size (Lemoine, Wauters et al. 1998).   
Other factors have also known to contribute to the EE% of microbeads. (Jeyanthi, 
Mehta et al. 1997) reported that an increase of polymer concentration contributed to 
an increased level of EE too. An increase in concentration from 20 to 32.5% caused 
the EE to increase from 53.1 to 70.9%. This can be explained by the fact that when the 
polymer exists at a high concentration, it precipitates faster on a superficial level hence 
stopping drug diffusion (Rafati, Coombes et al. 1997). In addition to this, this 
phenomenon can also be contributed to the increasing viscosity of the solution which 
 helps delay drug diffusion within the polymer (Bodmeier and McGinity 1988). 
Interaction which takes place between the polymer and protein is also reported to make 
a contribution towards an increased EE value (Boury, Marchais et al. 1997).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5.5 Dissolution testing – In vitro 
It was deemed significant to carry out in vitro dissolution testing since it is a vital 
analytical test that helps identify physical changes in an API (Technical Brief Particles 
Sciences 2010). The in vitro dissolution test is the only standardised method to analyse 
and measure how an API is withdrawn out of a solidified dosage form. Data gained 
from a standardised in vitro dissolution test can help confirm quality control, validate 
the fabrication process, and ensure that the dosage form does not fail (rupture) during 
transit and that the API is released in a predicted way.   
A suitably accurate dissolution test will not only speed up drug development, but will 
also curtail the need for avoidable in vivo human/animal tests (Technical Brief 
Particles Sciences 2010). In vivo drug release in the human body can be measured 
through testing the urine or plasma concentrations, however, this is clearly not a 
practical technique that can be employed routinely. The FDA also recommends in vitro 
dissolution testing as a means to regulate in vitro-in vivo correlation levels 
(Kytariolos, Dokoumetzidis et al. 2010).   
In vitro drug release studies help give an insight into the characteristics of not only the 
API but the drug delivery mechanism as well. Alginate is non-toxic when administered 
orally and also offers protection to the mucous membranes of the upper GI tract (Koji, 
Chiaki et al. 1982). Alginate microbeads are also known to re-swell once dried hence 
possessing the ability to act as a controlled release system. Such controlled drug 
delivery systems have the capacity to control the rate of drug delivery, sustain the 
duration of therapeutic activity and targeting the delivery of drug to a tissue (Utreja, 
 Jain et al. 2010). A controlled release system will have to deliver a constant supply of 
the API through continuous release over a certain time period.   
 In order to take full advantage of what in vitro dissolution testing has to offer, 
selection of appropriate experimental conditions is deemed crucial. To draw 
imperative conclusions, in vivo conditions need to be imitated. Therefore, designing a 
suitable test method will take into account the most significantly appropriate 
parameters that will eventually help mimic certain in vivo conditions for e.g. 
temperature, pH, dissolution medium, agitation rate, sampling time points etc.  
Cumulative dissolution profiles offer a look into the amount of total drug dissolved 
from the formulation over time. The amount of volume lost during sample collection 
is replaced by the same amount throughout so as to avoid a change in total volume 
present in the vessel and to keep the accuracy of the final release profile intact.    
 
5.5.1 In vitro BD release  
BD encapsulated microbeads were prepared as described in Section 3.2.5.2 (Table 
3.16). BD concentrations of nine two-fold serial dilutions (1.0 mg ml-1) against 
absorbance were plotted to generate standard curves. All five calibration curves 
produced were put together in one graph, the co-efficient of determination for all five 
sets of samples suggested linear and reproducible results. Values for the coefficient of 
determination (R2) were ≥ 0.9992 (Appendix 3).  
 
 
  
Figure 5-11: In vitro cumulative BD release profiles shown as mean percentage over 
time (minutes). Error bars represent standard deviation (SD) (n = 5 for each time 
point). Average bead size ranged from 3217.5 – 3308.9µm 
 
The results as shown in Figure 5-10 suggest that the types of alginate used to fabricate 
microbeads had a significant effect on the release kinetics of BD. While alginate 
composition (M:G ratio) contributes to the observed trend in a considerable way, their 
encapsulation efficiency, viscosity and molecular weight - while all interconnected - 
play a role, too.  
Out of the five types tested, for the given time period Manugel DMB showed the least 
amount of BD release - 66.9% - it is also important to note that DMB also had the 
lowest encapsulation efficiency - 84.5%. Since the EE for DMB microbeads was quite 
low to begin with, this correlated with the BD release values as well. On the other 
hand, the highest BD release was seen for Scogin MV and LDH – 99.2% and 99.0%, 
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 respectively. Akin to their release values, their EE% were also quite similar – 91.60 
and 93.50% respectively.  
Polymer molecular weight affects polymer degradation and drug release (Kim and 
Pack 2006). Therefore the trend for BD release can also be explained using their 
molecular weight values values. A comparatively higher particle porosity suggests a 
higher quantity of the associated entrapped drug release. This was seen in the 
increasing BD release values which followed the trend Manugel GHB > GMB > DMB 
while their increasing Mw’s followed the inverse trend DMB> GMB > GHB 
suggesting that polymers with lower Mw produce more porous particles which in turn 
causes higher diffusivity and an increased amount of BD release. 
It should be noted that the higher the molecular weight, the more increased number of 
crosslinking points (Kikuchi, Yamada et al. 1996) between the guluronic acid units 
and calcium are present. Furthermore, a higher molecular weight can also produce 
microspheres with an increased density (Pepeljnjak, Filipovicgrcic et al. 1994). A 
microbead produced using a higher molecular weight may also contribute to a slight 
increase in size as well due to which it may take comparatively longer for alginate 
microbead erosion to occur. Previous research (Murata, Inose et al. 1993) also found 
that the release rate of BD from alginate beads fabricated using lower molecular 
weight happened to be faster as compared to those fabricated using an alginate of a 
higher molecular weight.  
The increased BD release observed for Scogin types in comparison to Manugel types 
can be explained by their composition; M:G ratio (Table 3 - 2). Scogins are rich in M-
type blocks whereas Manugels are high-G type. As far as Manugels are concerned, 
their guluronic acid conformation helps produce a high degree of coordination of 
 calcium which gives rise to more rigid gels due to being more calcium ion reactive. 
Due to this rigidity, they become less prone to erosion. With an increase in the 
mannuronic content the gel formed will become more elastic and softer in nature and 
also tend to dissolve more easily (Tonnesen and Karlsen 2002). This is observed in 
the behaviour of Scogin alginates as they release a higher amount of BD for the same 
test duration as compared to samples prepared using Manugel alginates. These results 
show that the M:G composition present in the hydrogel acts as the primary driving 
force behind microbead dissolution. This is because even though both Scogins; MV 
and LDH have substantially varying viscosities i.e. 1.1 and 0.21 Pa.s respectively, their 
release profiles are almost identical, with MV releasing 99.2% and LDH releasing 
99.0% for the given test duration. Whereas, Manugel GHB and GMB have a closer 
viscosity to Scogin LDH – 0.35 and 0.45 Pa.s, their BD release is lower in comparison 
at 94.2% and 82.9% respectively.  
Since BD is dispersed inside the biodegradable alginate matrix, when these 
encapsulated systems are exposed to a dissolution medium, the drug release is driven 
by diffusion through matrix swelling and dissolution/erosion at the periphery of the 
polymeric matrix  (Takka, Ocak et al. 1998). As the matrix is composed of both the 
polymer and drug molecule, the swelling effect is a uniform volume expansion of the 
bulk polymeric material which causes the pores present throughout the structure of the 
matrix to open up (Stevenson, Santini et al. 2012).   
Since this system was based on sodium alginate cross-linked with calcium chloride, 
the osmotic pressure gradient existing between the alginate gel and the environment 
plays a significant role in the swelling process. In the stomach i.e. acidic conditions, 
the swelling of calcium alginate beads is almost negligible, release is more likely to 
occur through the insoluble matrix by diffusion. In the intestine i.e. neutral conditions, 
 the beads will tend to swell and the drug release will be dependent upon the processes 
of swelling and erosion. The porous nature of these alginate beads allows for diffusion 
and penetration of water hence promoting its hydrolytic degradation followed by the 
ensuing release of dye (Schliecker, Schmidt et al. 2003).          
The cumulative release profiles developed from this dissolution study highlight that 
diffusion of the API occurs in two phases; first phase dictated by diffusion while the 
second phase driven by erosion of the polymeric matrix itself. During the first fifteen 
minutes of the test in alkaline media, Scogin MV, LDH and Manugel GHB released 
around 50% of their payload. All three types also encapsulated the highest amount of 
BD as seen in Table 5 - 9.     
The initial rapid release of BD from the beads can be explained by the large surface 
area of these particles (Soppomath et al., 2001). Moreover, it can also be suggested 
that the incorporated BD was present close to the particle’s surface and hence was 
solubilized immediately from the particles into the test media. The porous network of 
the polymer microbead presents itself as a channel where penetration of the dissolution 
media can occur.    
 
 
 
 
 
 
 
 5.6 Summary 
Initially, dissolution characteristics of microbeads were analysed through microscopic 
observation. Effects of solution concentration (0.2% - 2%), type of cross-linking agent 
(CaCl2, SrCl2 and BaCl2) and fabrication methodology (manual deposition, ES, AAJ 
and ES in combination with AAJ) were assessed. It was seen that increasing solution 
concentration also increased the microbead dissolution rate. This rate was also seen to 
be dependent on the type of cross-linking agent used, which decreased in the following 
order; Ba2+ > Sr2+ > Ca2+. The fabrication methodologies used for microbeads did not 
show any substantial difference on their dissolution rates. 
Through the analysis of release profiles it was observed that alginates containing high 
mannuronic content - Scogin LDH and MV -  tend to dissolve more easily therefore 
releasing a higher amount of BD over the given test duration while guluronic acid-rich 
alginates – Manugel GMB, GHB and DMB – are more rigid and therefore less prone 
to erosion. This leads to a lower release of BD from the microbeads over the same 
time duration.  In conclusion, the composition of alginate plays a central role in the 
release of BD from microbeads. Additionally, an array of factors including the 
alginate’s viscosity, molecular weight and encapsulation efficiency have an impact 
too. It is also important to note that the spherical shape of all microbead samples 
remained intact throughout the test duration and no bead rupture was observed. This 
suggests that the methodology applied, successfully fabricated polymeric microbeads 
which possessed the ability to withstand potential in vivo environmental conditions in 
A. salmon.   
 This study lays the platform to study the release of various types of vaccines from 
microbeads fabricated using ES and how these systems would potentially perform in 
in vivo studies with Atlantic Salmon. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6. Study of immune response to IPNV 
antigen in Atlantic salmon 
 
 
6.1 Introduction and aims  
 
The final objective of this research was to assess and analyse the ability of orally 
administered IPNV antigen encapsulated into alginate microbeads (fabricated using 
aerodynamically assisted jetting) to immunise Atlantic salmon. Two sets of samples 
were produced for the trial; the control sample consisted of alginate beads while the 
experimental group consisted of IPNV antigen-alginate encapsulated beads. The effect 
of orally administered IPNV antigen-alginate microbeads was estimated by measuring 
the level of IPNV specific antibodies in plasma after the treatment, and was 
complemented by profiling the expression of fifteen genes at three time points (day 0, 
21 and 57) post the vaccination/immunization treatment. A number of fish exposed to 
encapsulated viral antigen in their feed showed slightly higher level of IPN-specific 
antibodies in plasma, measured by ELISA in comparison to the control group that 
received only alginate. This finding was complemented by qPCR profiling of 
expression of a number of immune genes in the head kidney, namely those encoding 
transcription factors; FoxP3, GATA3 and Tbet, T-cell receptor (CD4 and TCRy) and 
intracellular signalling (STAT6) molecules, cytokines (IL 17A, TGFb, IFNa), antiviral 
effector proteins of the interferon system (Mx) and antibody effector molecules (IgM 
and IgT). Results gained from this research suggest that the IPNV encapsulated 
 alginate microbeads represent a promising venue for further exploration of oral 
vaccination against IPN in A. salmon.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6.2 Trial specifications 
 
6.2.1   IPNV antigen encapsulation in microbeads  
IPN is a disease that usually affects young salmonids, and the pelleted feed was 
produced in accordance with the small size of fish used in this study. Therefore, the 
crevices present in the feed pellet were also comparatively smaller. Due to this, an 
average microbead size of 15 – 25 µm was set to be produced, for successful vacuum 
packing and eventual oral delivery. The production methodology of IPNV 
encapsulated alginate microbeads was highlighted in Section 3.2.8.1 (Chapter 3).  
The encapsulated antigen (IPNV Ag) was produced by growing a recombinant Sp 
strain of IPNV, rNVI-15PTA - as previously reported (Chen et al. 2014). Sizes of 
samples that were produced are recorded in Table 6-1. 
 
Sample batch 
No. 
Mean Diameter (µm) Standard 
deviation 
1 
2 
3 
15 
16 
20 
7 
7 
8 
Table 6-1: The average size of IPNV antigen encapsulated microbeads for all three 
batches of samples prepared using aerodynamically assisted jetting 
 
 Figure 6-1 shows an image taken from one of the experimental sample batches 
prepared for the trial. All three batches were contained in 1000ml of CaCl2 cross-
linking solution – each – and refrigerated until feed preparation.  
 
 
Figure 6-1: Optical Microscopic image of IPNV encapsulated microbeads (batch 2) 
taken at x80 magnification. Scale bar represents 10 μm  
 
6.2.2   Feeding plan  
Diets were divided into three different groups. Diet 0 was based on the EWOS Start 1 
recipe and it contained neither antigen nor polymer. Diet 1/Ca-alginate contained 
EWOS Start 1 and empty calcium alginate beads while Diet 2/IPNV Ag consisted of 
EWOS Start 1 loaded with IPNV antigen encapsulated alginate microbeads. It should 
be noted that for result analysis (Section 6.2) Diet 0 was used as a control for gene 
expression data comparison; it was set to 0 on the qPCR data graphs while results from 
Diet 1 and 2 groups were expressed relative to it. All upregulations and 
downregulations shown on qPCR graphs were thus relative to the control Diet 0 that 
contained no beads. The average antigen dose was 109 TCID50/ml (Chen., 2015).  
 6.2.3   Trial design  
The trial was conducted in the subsequent order of events highlighted in Figure 6-2 
below.  
 
 
 
 
 
 
 
 
 
Figure 6-2: The time line highlighting the fish size and time course of the trial: period 
of acclimation (7 weeks), first sampling, oral vaccination interval (one week), immune 
induction (7 weeks) with second sampling in week 21 and third sampling in week 26. 
The entire trial lasted for a duration of 26 weeks 
 
Starting point was chosen at week 11 as the fish were quite small prior to that and their 
immune system was given time to develop. This time point – week 11 – was when fish 
were moved to tanks in order to begin acclimatisation. Acclimatisation is the process 
where an organism adjusts to a change in its environment.    
Eighty fish were present in each tank and the weight of individual fish from each tank 
was recorded. Eight circular tanks of 0.2 m3 volume were used in the trial. This trial 
was conducted in fresh water supplied from an underground source in Dirdal, Norway. 
Fresh water was used in order to mimic their natural environment as during this life 
stage fish are normally present in fresh water. The average flow in each tank was 3 
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Week 
Sampling  
Day 0 
Sampling  
Day 21 
Sampling  
Day 57 
Oral vaccination - Diet 1 & 2  
Acclimation  Induction  
 l/h. The oxygen saturation in water happened to be 90% while the temperature was 
13.5 °C. Only three sampling points were chosen due to logistical constraints.    
 
Parameter Quantity 
No. of tanks 8 
No. of treatments 2 
No. of tanks per treatment 4 
No. of fish per tank – Start 100 
No. of fish per tank – Day 1 85 
No. of fish per tank – Day 21 80 
No. of fish per tank – Day 57 80 
No. of sampling points 3 
No. of fish – Sampling Day 0 5 
No. of fish per tank – Sampling Day 21 5 
No. of fish per tank – Sampling Day 57 10 
Table 6-2: Fish challenge trial parameters 
 
The vaccination interval took place during week 21. This is because the immune 
response of salmon can be significantly affected by smoltification. Vaccination should 
be avoided during this time to ensure maximum immune response. The interval lasted 
for a week as that is the typical length of exposure for IPNV oral vaccines.     
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 6-3: Sampling chart for the trial. For sampling Day 0, 15 fish were removed 
from each tank and placed in a new tank. Out of which 20 fish were then randomly 
chosen for sampling. For sampling Day 21, 5 fish were removed from each tank and 
placed in a separate tank, from which 20 fish were chosen for sampling. On Day 57, 
10 fish were removed from each tank out of which 20 were chosen for sampling      
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 6.3 Gene expression assessment through qPCR 
 
 
Gene expression profiling has proven itself as a useful tool when studying complex 
conditions in A. salmon (Skugor et al. 2008) (Johansen et al. 2016) (Alzaid, Martin, 
and Macqueen 2016). High-throughput approaches (microarray or RNA sequencing 
technology) are ideally suited for previously unexplored or poorly studied conditions 
while targeted profiling of a selected number of key genes (e.g. by qPCR) offers an 
alternative for situations where prior knowledge exists, that is, when one knows which 
genes are responsive. qPCR is also suitable for screening in pilot studies; it is typically 
used to help in the refinement of treatments, before resources are spent on more costly 
high-throughput transcriptomics approaches. In this study, targeted qPCR profiling of 
the expression of fifteen genes with key roles in immune responses was done on head 
kidney samples at 3 time points during the study period. This has helped shed more 
light on the type and dynamics of immune responses which followed upon the test oral 
vaccine/immunization treatment. As mentioned, targeted approach was suitable for 
this study as 1) target organ (head kidney) has been selected based on previously 
described essential roles of this organ in immunity and responses of head kidney T 
and B cells to vaccination  and 2) immune gene sequences exist in Atlantic study and 
validated primers for these genes are accessible in literature. The selection of head 
kidney tissue for qPCR screening was based on the fact that it performs key immune 
functions in fish, represents the systemic compartment as it is one of the main antigen 
trapping organs for blood-borne antigens in fish (Espenes et al. 1996) and finally, 
because IPNV has high tropism for head kidney (Munang'andu et al. 2013).   
 Special focus was given to T and B cell specific markers and other factors that regulate 
their behaviour. How a naïve T helper (Th) cell develops will largely determine the 
outcome of the overall immune response that ensues. In order to differentiate into a 
specialized Th cell, naive Th cell needs to receive cytokine signals from cells that got 
in contact with antigen and which also present the antigen to Th cells. Based on this 
stimulation through bound antigen-receptor complexes and cytokines, the Th cell will 
develop into one of the Th lineages and continue to orchestrate the immune response. 
Th cells are called helper cells because one of their main roles is to send signals to 
other types of immune cells. Th cells can be imagined as orchestrators of immune 
responses which send signals to other immune cell by cytokines. The surface of target 
cells (e.g. macrophages) express receptors to which these cytokines bind. When 
cytokine signal is transmitted via the surface receptor into cytoplasm and then by 
signalling cascade to the nucleus it results in the change of gene expression of the 
target cell so that its function changes according to Th cell cytokine-mediated 
instructions. Macrophages, B cells, neutrophils and other immune cells receive these 
cytokine inputs from Th cells and differentiate highly specialized functions, e.g. a B 
cell transforms into the antibody producing cell when it receives the cytokine cocktail 
signal from the Th cell of the Th2 lineage. Antibody-based immunity is based on 
appropriate signaling of Th2-specific cytokines that are needed for differentiation of 
B cells into antibody producing cells. More detail description of involved factors can 
be seen Figure 6-4 which shows cytokines, intracellular signalling cascade molecule  
and transcription factors involved in the development of naïve Th cell into one of the 
specific Th lineages (Th1, Th17, Th2, and Treg) (Skugor et al. 2008).  
 
  
 
 
Figure 6-4: All T helper (Th) cells including the naïve Th cell express CD4. The figure 
shows T cell pathways with their activator cytokines; Th1 specific (IFNy and IL12), 
Th17 specific (IL-17, and in some species TGFb), Th2 specific (IL-10 and IL-4/13, 
which is one gene in fish while in mammals there are two genes, IL-4 and IL-13), and 
Treg specific (TGFb and IL6), along with transducers of their signals (signalling 
cascade STAT molecules that transduce the cytokine signals from the surface of target 
cell to transcription factors with their regulatory factors such as transcription factors 
(T-bet, RORy, GATA3, FoxP3)  
 
Once the naïve Th0 cell has differentiated into the Th1 lineage, its function is to 
respond against intracellular microorganisms such as intracellular bacteria and viruses. 
Th2 cell lineage on the other hand deals with extracellular pathogens and multicellular 
parasites, and is required for the stimulation of antibody production by B cells. Th17 
is highly pro-inflammatory and deals with extracellular bacteria and fungal microbes; 
Th17 is also often implicated in autoimmunity (Bedoya et al. 2013). Finally, Treg cells 
 are anti-inflammatory and are down-regulating immune responses, which can be 
associated with immune tolerance, or unsuccessful immunization.  
Since salmonid fish have genes encoding activator cytokines, signal transducers and 
transcription factors characteristic of all four Th lineages, targeted analysis of these 
genes by qPCR allowed investigation of important early process expected to occur 
during development of an immune response to oral vaccination.   
Genes involved in effector functions have also been added to the analysis, including 
the transcript which encodes Mx protein. Phylogenetic analysis has revealed that Mx 
genes are present in almost all vertebrate genomes. They are usually active against 
RNA viruses. Atlantic salmon is known to encode multiple Mx proteins which have 
the ability to suppress viruses (Verhelst, Hulpiau, and Saelens 2013). IFN-a and b 
induce antiviral activity in cells forming an early line of defence against viral 
infections, they do so by inhibiting the process of IPNV replication. A correlation 
between the inhibition of IPNV and Mx protein expression has been observed by 
(Larsen, Rokenes, and Robertsen 2004). This finding adds to the already existing 
evidence suggesting that antiviral activity is a significant role of Mx proteins.  
The expression of Mx genes is controlled by interferons type I (IFNa) or III (IFNλ). 
Atlantic salmon IFN (Alpha/beta interferon) has been reported to have an antiviral 
effect against IPNV in salmon cells, therefore its expression was monitored in this 
research. Other genes included in the analysis are described in Table 6-3.  
 
 
 Gene symbol and 
name 
Gene function overview Author/Year 
T-bet Fundamental role in coordinating 
type I immune responses  
One of the key transcription factors 
that control the fate of both innate 
and adaptive immune cells 
(Kumari et al. 2015) 
GATA3 – Gata 
binding protein 3 
 
Transcription factor that is essential 
for the development of Th2 cell 
lineage  
(Kumari, Bogwald, 
and Dalmo 2009) 
IL-17A - Interleukin 
17A 
 
A pro-inflammatory cytokine 
involved in the development of the 
Th17 lineage and priming of 
neutrophils and macrophages 
around inflamed areas to fight 
extracellular microbes 
(Mutoloki et al. 2010) 
IL-4/13 - Interleukin 
4/13 
 
Interleukin 4/13 (IL-4/13) plays significant 
roles in supporting Th2 development 
through STAT6 signalling cascade and later 
in immune responses that lead to antibody 
production in B cells  
(Sequeida, Maisey, 
and Imarai 2017)  
STAT1 - Signal 
transducer and 
activator of 
transcription 1 
 
This signal cascade molecule 
transmits an interferon signalling 
(IFNy) and is involved in regulation 
of transcription required for Th1 
development 
 
(Sobhkhez et al. 
2014) 
 STAT6 - Signal 
transducer and 
activator of 
transcription 6 
 
This molecule belongs to the Th2 
cell signalling cascade that also has 
the ability to bind directly to DNA 
and regulate transcription  
  
(Goenka and Kaplan 
2011) 
TGFb - 
Transforming 
growth factor b 
 
This cytokine is an immune 
response regulator that controls the 
fate of multiple cell types including 
Treg cells 
 
(Li and Flavell 2008)  
CD4 - T helper cells 
 
This receptor is expressed on naïve 
T cells and Th cells and is involved 
in assisting in the communication 
with antigen-presenting cells   
Evidence has been gathered over 
years that supports the existence of 
at least four CD4 T-cell subsets in 
fish; Th1, Th2, Th17 and Treg cells    
(Zhu and Paul 2008) 
IFNa - Interferon 
type I 
 
IFNa plays a vital role in host 
defense against viral pathogens, part 
of Th1 responses 
(Skjesol et al. 2010)  
Mx 
 
Anti-viral effector protein induced 
by IFN I, known to provide 
protection against IPNV infections   
(Das et al. 2007) 
MHCII - 
Histocompatibility 
complex class II 
 
Surface marker of antigen-
presenting cells that first come in 
contact with the antigen and present 
it in the groove of the MHC proteins 
to Th cells 
(Holling, Schooten, 
and van Den Elsen 
2004) 
 TCRy - T cell 
receptor 
 
This receptor is expressed on T cells 
and is involved in recognition of 
fragments of antigen peptides bound 
to MHC molecules. Each T cell 
expresses TCR receptors which 
specifically bind antigen/MHC 
complex during physical contact 
between T cell and antigen-
presenting cell 
(Yazawa et al. 2008)  
IgM - 
Immunoglobulin M 
 
Effector antibody molecule, subtype 
M is the major systemic antibody in 
teleost fish 
(Hordvik 2015)  
IgT - 
Immunoglobulin T 
Effector antibody molecule, subtype 
T is produced in mucosal surfaces in 
fish  
(Tadiso, Lie, and 
Hordvik 2011) 
FOXP3  T-cell specific transcription factor. 
Plays a significant role in the 
immune regulatory process and the 
development of Treg cells 
(Zhang et al. 2011) 
Table 6-3: An overview of genes assessed via qPCR, along with their function 
 
 
6.3.1 Gene expression results  
The qPCR data on day 0, day 21 and day 57 are presented in Figures 6-4, 6-5 and 6-6, 
respectively. Expression of fifteen genes was profiled on Day 0 in order to assess the 
immune status in head kidney prior to exposure to test diets (all fish were exposed to 
Diet 0 at day 0 for seven weeks (acclimatisation period) but tanks that were later 
 assigned to test diets were labelled) (Figure 6 - 7). All genes showed regulation within 
the +1 and -1 ddCt values, which translates to 2-fold up- and down-regulation. Only 2 
genes, both with previously described roles in Th2 responses, GATA3 and STAT6, 
showed significant up-regulation in fish assigned to tanks that would later receive the 
test diet with alginate and no antigen. At the same time, Th17-specific cytokine IL17A 
showed down-regulation of approximately 2-fold; however, it was not statistically 
significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 6-5: Gene expression using qPCR at sampling Day 0. A differential pattern of 
up and down-regulation of fifteen genes sampled from A.Salmon head kidney is 
presented. Mean values of Ca-alg group (Diet 1) and IPNV-alg group (Diet 2) relative 
to control group (Diet 0) are recorded (n = 20, p <0.05) 
 
Quite a few genes showed significant upregulation in at least one of the test groups on 
day 21. At this time point, T-bet induction was highest among all measured genes. The 
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 levels of the transcript encoding T-bet were significantly higher in both test feeds 
group in comparison to the control diet. Suggesting the onset of Th1 differentiation.  
Although differences between test feeds were not large, somewhat higher levels of 
transcripts were seen for all Th1/17 genes (T-bet, STAT1, IFNa and IL-17A) except 
for Mx that showed higher level in the alginate-IPNV test group. Of the two measured 
T cell receptors (CD4 and TCRy) only TCRy was induced by the IPNV antigen test 
feed; however, this regulation was not significant. In contrast, significant down-
regulation of CD4 was observed in the group exposed to IPNV-alg feed. The main 
mechanism of alginate encapsulated antigens has been proposed to be biased towards 
the Th2 response.    
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-6: Gene expression using qPCR at sampling Day 21. A differential pattern 
of up and down-regulation of fifteen genes sampled from A.Salmon head kidney is 
presented. Mean values of Ca-alg group (Diet 1) and IPNV-alg group (Diet 2) relative 
to control group (Diet 0) are recorded (n = 20, p <0.05) 
 
 
-2.50
-2.00
-1.50
-1.00
-0.50
0.00
0.50
1.00
1.50
2.00
CD4 TCRy FoxP3 GATA3 IL4/13 TGFb MHC2 STAT6 IgT IgM
d
d
C
t
Day 21 Ca-alg
IPNV-alg
*
*
*
*
*
*
-2.00
-1.00
0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
Tbet STAT1 IFNa IL17A MX
d
d
C
t
Day 21 Ca-alg
IPNV-alg
*
*
*
*
 The regulatory transcription factor FOXP3 (usually found in thymus) showed 
significant downregulation at day 21 only in the group exposed to the antigen. The 
expression levels of Th2 transcription factor GATA3 and cytokine IL4/13 were also 
downregulated in this group while STAT6 also implicated in Th2 responses, showed 
opposite regulation. Increased expression level of around 2-fold of the gene encoding 
mucosal immunoglobulin IgT was not statistically significant.  
Most genes were down-regulated on day 57 in both groups, while differences between 
the two test diets were negligible. T-bet remained up-regulated, however, there was a 
drop in the expression of T-bet in comparison to day 21. T cell receptor TCRy was 
significantly affected in both groups, as were TGFb, STAT6 and IgT. The transcript 
encoding IgT was found to be most down-regulated at day 57 with an almost 8-fold 
lower levels in comparison to the control group. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-7: Gene expression using qPCR at sampling Day 57. A differential pattern 
of up and down-regulation of fifteen genes sampled from A.Salmon head kidney is 
presented. Mean values of Ca-alg group (Diet 1) and IPNV-alg group (Diet 2) relative 
to control group (Diet 0) are recorded (n = 20, p <0.05) 
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 6.4 Assessment of immune responses through ELISA 
 
Immunoglobulin (Ig) (also referred to as antibody) is part of the humoral defence 
which plays a critical role in parasitic, bacterial and viral infections (Choudhury and 
Prasad 2011). As mentioned earlier, IgM is the major systemic antibody found in 
teleost fish, including salmonids (Hordvik., 2015). IgM was the first immunoglobulin 
to appear in evolution (Magnadottir 1998). IgM levels have previously been used as 
an indicator of fish health and ELISA is widely used as the principal technique for the 
quantification of IgM in the serum of fish (Choudhury and Prasad 2011). The 
methodology followed for ELISA analysis is described in Section 3.2.8.3 (Chapter 3).  
The ELISA assay in the present study quantified IgM that specifically binds to the 
IPNV antigen used for oral vaccination.   
The assay revealed slightly higher values in fish that received antigen with alginate in 
their diet (blue), irrespective of the OD used (Figure 6-8). It is recommended that the 
output of the ELISA assay developed for the IPNV antigen-specific IgM is measured 
at two OD values (Branas and Estepa 1994). Absorption spectrum at two maxima: 450 
and 490 nm offers a higher assay sensitivity i.e. boosting the ability to detect 
differences present. Both measurements showed high correlation at the individual 
sample level.  
It could be noted that this mostly occurred in tanks 1 and 6 (Figure 6-8). The result 
was, however, not significant. Differences related to the plate were minor, while all 
fish that exhibited higher IgM level belonged to the group which consisted of large 
fish (Figure 6-9).  
 
  
Figure 6-8: ELISA results of IPNV antigen-specific immunoglobulin IgM in plasma 
of A. salmon at day 57 post oral vaccination. Values of two OD measurements (450 
and 490 nm) in relation to the eight tanks shown. The ELISA samples were n = 8 per 
tank, are represented by shapes, with the smaller circles denoting smaller fish while 
bigger circles denote bigger fish. Red shapes represented the unencapsulated sample 
while blue represented IPNV encapsulated samples 
 
It would be fair to suggest that the IPN antigen encapsulated in polymeric microbeads 
survived through the encapsulation/feed preparation process as higher IgM levels can 
generally be detected in tanks containing IPNV-alg feed.   
  
Figure 6-9: ELISA results of IPNV antigen-specific immunoglobulin IgM in plasma 
of A. salmon at day 57 post oral vaccination. Values of two OD measurements (450 
and 490 nm) are shown (n = 16 per diet) 
 
 
 
 
 
 
 6.5 Discussion  
 
6.5.1 Gene expression data through qPCR 
Sampling at Day 0 was carried out to assess whether there were any significant 
differences between the fish in tanks that would be assigned to test treatments. Not too 
many substantial differences were observed – they were mainly below +1 and -1 ddCt. 
However, as judged by the profiled genes in this particular study, it could be said that 
there was a slightly higher level of genes implicated in Th2 immunity in the group 
later assigned to the alginate only diet.  
At day 21, the effect of dietary treatments was evident in both groups. Judged by the 
similarity of observed responses in two dietary groups, it could be concluded that any 
prior activation of Th2 immune responses in the group which received only alginate 
did not play a major role in responses that occurred at day 21. The marker of Th cells 
CD4 was found down-regulated while the TCR-γ showed higher expression in 
vaccinated fish (although not significant). Together, this could mean that the 
population of T cells in head kidneys of vaccinated fish contained more cytotoxic T-
cells expressing TCR-γ (Goodman and Lefrancois 1988) than CD4 positive T cells.   
The expression profile of T-bet suggested that alginate by itself influences expression 
of immune related genes, and possibly skews immunity towards Th1 responses. 
Addition of IPNV antigen and alginate in the diet slightly increased induction of T-
bet compared to the alginate only group. An additional proof for more pronounced 
Th1 responses in the vaccinated antigen-alginate group was the expression profile of 
the anti-viral cytokine IFNa, which was significantly induced in comparison to the 
 control feed. Master regulator FoxP3 that is required for the development of Treg cells 
in mammals (Weaver et al. 2007) and very likely in fish too, showed lower expression 
profile in the vaccinated fish. Treg cells are immunosuppressive towards pro-
inflammatory Th-mediated responses, which suggested that vaccinated fish had an 
improved chance of mounting the immune response. Furthermore, T-bet is known to 
inhibit development of the Th2 lineage by suppressing the production of Th2 cytokines 
and GATA3 in mammals (Weaver et al. 2007) which were indeed more markedly 
downregulated in the vaccinated group.  
Thus, the low expression profile of both GATA3 and IL4/13 could be an evidence that 
the vaccinated group at day 21 showed more pronounced anti-viral immune responses 
and somewhat downplayed Th2 responses. However, STAT6 that transduces Th2 
signals and transcript encoding IgT were also among the genes that showed higher 
expression profiles in vaccinated than in fish that received only alginate. Although 
considered a Th1 cytokine, T-bet has also been shown to be involved in improved 
antibody-mediated clearance of malaria in humans (Oakley et al, 2014), while Sun et 
al, 2011 showed that predominant expression of intraglomerular T-bet expression 
correlated with antibody-mediated rejection in humans. 
 
6.5.2 Immune response through ELISA 
ELISA analysis showed that a number of fish managed to produce IPNV antigen 
specific IgM antibodies.  
The responses were weak, but were seen to be tank specific as tank 1 and 6 showed 
higher IgM levels for both OD values analysed. The fish located in these tanks were 
 fed samples containing the IPNV antigen encapsulated microbeads. This could mean 
that one or more unknown factors present in tanks 1 and 6 and absent in tanks 2, 4 and 
8 greatly contribute to the effect of oral vaccination.    
Interestingly, it was also noted that fish bigger in size displayed the highest levels of 
IgM whereas smaller fish possessed half as much. Perhaps fish larger in size consumed 
more feed per fish weight as compared to smaller fish or were able to absorb the 
antigen more effectively, which resulted in a larger dose of the antigen in immune 
tissues resulting in the better response to oral vaccination.  
 The low levels of IgM detected (Figure 6-8) can certainly be contributed to a 
significant factor which was that samples were only exposed to a small dose of antigen 
and not a real virus following the process of immunisation. After coming into contact 
with the viral infection, the fish exposed to the IPN antigen would perhaps be quicker 
in mounting an increased immune response.  
The detection of IgM however suggests that the fish samples had been primed. The 
amount of circulating B cells was increased. These B cells then successfully produced 
IgM which possesses the ability to bind to the IPN antigen. In the case of exposure to 
the IPN virus in future, these fish samples will be able to produce IgM more rapidly 
which will neutralise the virus in the initial stages of onset.   
 
 
 
 
 6.4 Limitations 
 
 
Even though IPNV is known to have an increased tropism for head kidney, the spleen 
is another major organ that is acknowledged as the region where antibodies are 
produced. Viral antigens can also be detected in the liver and pancreas too. Hence, in 
a future challenge trial it would be ideal to include samples taken from the spleen, 
liver, pancreas and hindgut as well. 
Another critical limitation of this trial was the amount of time points considered 
throughout the duration of the experiment. Since samples were taken all of three times 
through a period of 57 days, the intervals were in fact quite long for sampling. It is 
therefore possible that many interesting dynamics regarding gene expression were 
overlooked. However, the reason why these time points were initially chosen were due 
to the fact that oral vaccine is not expected to show a quick response, specifically with 
regards to fish it takes approximately two weeks for adaptive immunity to kick in.       
 
 
 
 
 
 
 
 
 
 
 
 
 6.5 Summary  
 
 
The evolutionary relationship which exists between host immune defences and viral 
counter attacks are important to analyse since a better understanding only beneficially 
aids the aquaculture industry as a whole. An enhanced knowledge of host-pathogen 
synergy provides additional input for an improved viral infection survival rates during 
high susceptibility periods where farmed fish especially Atlantic salmon are 
concerned.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 7. Conclusions and Future work  
 
 
 
7.1 Summary and conclusions 
 
This chapter offers an overview of the principal conclusions established throughout 
this thesis. In Chapter 1, a series of objectives were set out in order to achieve the 
overall aim of this research study. These objectives followed a sequential order as 
outlined in Figure 7-1 below. 
The optimisation of two novel microbead fabrication techniques: ES and AAJ resulted 
in microbeads ranging from 25 – 2500 µm (Figure 4-10 and 4-11). This size range 
promotes the promising application of microbeads to serve as oral drug delivery 
mechanisms through the encapsulation of an API, since this size range is ideal for easy 
and effective incorporation within the feed pellet for oral intake. In terms of the wider 
implications of this work, the operational maps produced offer a distinct look into the 
size range of microbeads that can potentially be fabricated using ES and AAJ 
methodologies for every appropriate combination of flow rate and applied 
voltage/pressure possible for a given concentration of alginate. 
 
 
 
 
 Furthermore, mechanical testing revealed that fabrication methodologies had 
negligible influence on the microbeads’ mechanical properties. The mechanical 
properties of microbeads fabricated through ES and AAJ were also conclusively 
associated with polymer concentration and type of cross-linking solution. The novelty 
of these methodologies lies in the simplicity of control they have to offer since 
homogenous microbeads of a vast size range are produced through the adjustment of 
basic process parameters, which is a substantial drawback where other conventional 
synthesis techniques are concerned. 
An in vitro dissolution test methodology specifically tailored to mimic the in vivo 
environment of A. salmon was established. This study helps lay a platform for the 
analysis of biologically active compound release from the Ca-alg matrix. Furthermore, 
it provides an insight into the potential performance of these release systems in vivo.   
Since the primary aim of this research is to characterise alginate microbeads as antigen 
delivery systems, Chapter 4 was solely dedicated to the assessment and analysis of 
Ca-alg microbeads’ dissolution profiles and encapsulation efficiencies. The approach 
applied for the encapsulation of a potential API (BD) promises an efficient, continuous 
single-step process, possessing the ability to fabricate monodisperse BD encapsulated 
microbeads with high encapsulation efficiency (>84.5 – 93.50%) for all five types of 
commercially leading alginates tested. While the release profiles obtained concluded 
potential API release of up to 66.9 - 99% under simulated A. salmon in vivo 
conditions, for a test duration of 55 minutes under pH 3.0 and 8.0, as the antigen is 
significantly inclined to be released in the mid/distal intestine – consisting of an acidic 
environment leading to an alkaline one - where the antigen can be absorbed. 
 As the final principal aim of this research, the absorbed antigen is tested for its ability 
to induce a specific immune response in A. salmon. Results gained from an IPNV 
challenge trial indicated that the absorbed antigen was able to induce an immune 
response in A. salmon. ELISA analysis highlighted a slight increase in levels of IPN 
specific antibodies in the blood plasma of the experimental group exposed to 
encapsulated viral antigen in Ca-alg microbeads as compared to the control group fed 
un-encapsulated Ca-alg microbeads. Results gained from qPCR gene analysis 
supported these findings as upregulation in specific immune genes in the experimental 
group consisting of fish fed with encapsulated IPNV-alg microbeads was observed 
over the sampling time period.   
Additionally, another imperative observation established by the analysis of data 
gained through qPCR and ELISA was the stability of IPNV antigen through the 
challenge trial. Indication of the presence of IPNV antigen at the final stage of 
sampling (day 57) of the trial suggests its survival through the process of storage – 
highlighting long shelf-life, the process of feed production – highlighting robustness 
and finally the process of antigen incorporated pellet uptake by the A.Salmon – 
highlighting successful crossing through the epithelial layers present in the intestine.       
 
 
 
 
 
 
 
 
 
 7.2 Recommendations for future research 
 
 
Section 7.1 emphasized the outcomes achieved diligently through the course of this 
research. This section presents further suggestions for possible future work that can 
help build on the platform initiated at present through this thesis. Given the constraints 
in resources available in terms of variables such as risk, time and especially cost, 
further exploration of various areas of interest associated with this research were 
hindered. Some of the suggestions are as follows;  
 In Chapter 4, an additional operational size map study should be performed 
using a biologically active compound such as the IPNV antigen itself. This can 
offer a more specific outlook on the size range of microbeads that can be 
produced through ES and AAJ. Even though the stand in used in our studies 
consisted of particles small enough in size in comparison to alginate chains, 
the incorporation of an active macromolecule may make a contribution to the 
final fabricated microbeads’ size    
 Mechanical testing can be further branched out by performing compression 
testing on the same five alginate types as those used during dissolution testing 
so as to present a more comprehensive outlook into these specific types of 
alginates. This will also help further the understanding of the effect their 
chemical structures may have on their mechanical stability 
 The approach for optimisation of microbead fabrication methodologies; ES 
and AAJ can be extended towards the exploration of various other 
polymer/drug combinations 
  In chapter 5, the model API (BD) for in vitro dissolution testing can be replaced 
with the relevant antigen itself. This can perhaps offer a more definitive result 
of the effect of the encapsulated compound on the dissolution behaviour of Ca-
alg microbeads    
 In Chapter 6, the challenge trial carried out has the potential to be carried out 
more systematically with the addition of many more sampling points and 
collecting sample’s from more than one organ 
 Furthermore, in addition to the ELISA and qPCR techniques, the immune 
response can be analysed through protionics. Since qPCR is a more targeted 
approach, it might be useful to look into protein expression to gain a closer 
understating of the immune response 
 A challenge trial that assesses mortality rate could also prove useful. The trial 
carried out in this thesis analysed the effect of vaccination itself. The fish 
samples were exposed to a small dose of antigen. A new approach for a trial 
could expose the samples to a real virus after the process of immunisation and 
assess levels of success by looking at mortality rates  
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 Appendices 
 
 
 Manugel GMB Manugel GHB Manugel DMB 
Time (min) % BD 
release 
SD % BD 
release 
SD % BD 
release 
SD 
5 13.82 4.04 27.36 6.67 12.16 2.67 
10 23.03 5.05 39.52 8.67 12.16 2.67 
15 32.24 7.07 45.6 10 21.28 4.67 
20 32.24 7.07 54.72 12 30.40 6.67 
25 50.67 11.11 54.72 12 39.52 8.67 
30 50.67 11.11 66.88 14.67 48.64 10.67 
35 50.67 11.11 72.96 16 54.72 12 
40 55.27 12.12 85.12 18.67 63.84 14 
45 55.27 12.12 85.12 18.67 63.84 14 
50 82.91 18.18 94.24 20.67 66.88 14.67 
55 82.91 18.18 94.24 20.67 66.88 14.67 
 
 
 Scogin MV Scogin LDH 
Time 
(min) 
% BD 
release 
SD % BD 
release 
SD 
5 31.81 6.98 42.42 10.85 
10 42.42 9.30 49.49 10.85 
15 56.56 12.40 49.49 10.85 
20 74.23 16.28 70.70 15.50 
25 84.85 18.60 70.70 15.50 
30 84.85 18.60 81.30 17.83 
35 95.44 20.93 81.30 17.83 
40 98.98 21.71 98.98 21.71 
45 98.98 21.71 98.98 21.71 
50 99.18 21.75 98.98 21.71 
55 99.18 21.75 98.98 24.03 
 
Appendix 1: Average percentage BD release (mean) and standard deviation (SD) of 
all five different alginate types at 11 ºC, following USP test method 1 at 100 rpm 
agitation rate   
  
 
Alginate type Calibration curve R2 
Scogin MV y = 0.1427x + 0.0053 0.997 
Scogin LDH y = 0.1438x + 0.0051 0.9988 
Manugel DMB y = 0.1683x + 0.0042 0.9986 
Manugel GHB y = 0.1822x + 0.0073 0.9963 
Manugel GMB y = 0.1928x + 0.005 0.9988 
 
Appendix 2: Standard calibration curves along with equation and R2 values for the 
five types of alginates used, during the encapsulation efficiency test  
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Alginate type Calibration curve R2 
Scogin MV y = 0.208x + 0.0022 0.997 
Scogin LDH y = 0.2063x + 0.0301 0.9992 
Manugel DMB y = 0.2108x + 0.0024 0.9999 
Manugel GHB y = 0.2299x + 0.0043 0.9993 
Manugel GMB y = 0.2174x + 0.0047 0.999 
 
Appendix 3: Standard calibration curves along with equation and R2 values for the 
five types of alginates used, during the dissolution test  
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